Document:

EX-10.1

 Exhibit 10.1 

Settlement Agreement, dated August 9, 2022, among the parties to the Litigation 

SETTLEMENT AGREEMENT 

THIS SETTLEMENT AGREEMENT (the “Agreement) ” is made as of this 9th day of August, 2022 (the “Execution
Date”) by and among: 
  

	 	•	 	 Patrick J. Bartels, Eugene I. Davis, Raphael T. Wallander, Alan J. Carr, and William L. Transier (collectively,
the “Litigation Designees”); 

  

	 	•	 	 Sears Holdings Corporation, Kmart Holding Corporation, Kmart Operations LLC, Sears Operations LLC, Sears, Roebuck
and Co., ServiceLive Inc., SHC Licensed Business LLC, A&E Factory Service, LLC, A&E Home Delivery, LLC, A&E Lawn & Garden, LLC, A&E Signature Service, LLC, FBA Holdings Inc., Innovel Solutions, Inc., Kmart Corporation,
MaxServ, Inc., Private Brands, Ltd., Sears Development Co., Sears Holdings Management Corporation, Sears Home & Business Franchises, Inc., Sears Home Improvement Products, Inc., Sears Insurance Services, L.L.C., Sears Procurement Services,
Inc., Sears Protection Company, Sears Protection Company (PR) Inc., Sears Roebuck Acceptance Corp., SR – Rover de Puerto Rico, LLC (f/k/a Sears, Roebuck de Puerto Rico, Inc.), SYW Relay LLC, Wally Labs LLC, SHC Promotions LLC, Big Beaver of
Florida Development, LLC, California Builder Appliances, Inc., Florida Builder Appliances, Inc., KBL Holding Inc., KLC, Inc., Kmart of Michigan, Inc., Kmart of Washington LLC, Kmart Stores of Illinois LLC, Kmart Stores of Texas LLC, MyGofer LLC,
Rover Brands Business Unit, LLC (f/k/a Sears Brands Business Unit Corporation), Sears Holdings Publishing Company, LLC., Sears Protection Company (Florida), L.L.C., SHC Desert Springs, LLC, SOE, Inc., StarWest, LLC, STI Merchandising, Inc., Troy
Coolidge No. 13, LLC, BlueLight.com, Inc., Sears Brands, L.L.C., Sears Buying Services, Inc., Kmart.com LLC, Sears Brands Management Corporation, and SRe Holding Corporation (each, a “Debtor” and collectively, the
“Debtors”); 

  

	 	•	 	 The Restructuring Subcommittee, as defined below; 

 

	 	•	 	 The Official Committee of Unsecured Creditors appointed in the Bankruptcy Cases (as defined below) (the
“Committee”); 

  

	 	•	 	 Cushman & Wakefield, Inc., Duff & Phelps, LLC, Joseph Jordan, Lawrence Meerschaert, Dave
Rodney, Leena Munjal, Scott Huckins, Robert Riecker, Robert Schriesheim, William C. Kunkler, Ann N. Reese, Paul G. DePodesta, Benefit Street 2018, LLC, Cyrus 1740 Master Fund, LP, Cyrus Special Strategies Master Fund, LP, Cyrus Select Opportunities
Master Fund, Ltd., Canary SC Master Fund, LP, CRS Master Fund, LP, Cyrus Opportunities Master Fund II, Ltd., CMH VI, LP, CYR Fund, LP, Canary SC Fund, LP, Crescent 1, LP, Cyrus Capital Partners, LP, Cascade Investment, L.L.C., Bruce Berkowitz, CRK
Partners LLC, Cesar L. Alvarez, ESL Institutional Partners L.P., ESL Investments, Inc., ESL Investors, L.L.C., ESL Partners L.P., Fairholme Capital Management, L.L.C., Fairholme Funds, Inc., JPP II LLC, JPP LLC, Kunal S. Kamlani, Edward Scott
Lampert, 

  
 1 

 Steven Mnuchin, RBS Investment Management LLC, RBS Partners LP, SPE I Partners L.P., SPE
Master I L.P., Seritage GS Holding LLC, Seritage Growth Properties, Inc., Seritage Growth Properties, L.P., Seritage KMT Finance LLC, Seritage KMT Mezzanine Finance LLC, Seritage MS Holdings LLC, Seritage SPS Holdings LLC, Seritage SRC Finance LLC,
Seritage SRC Mezzanine Finance LLC, Thomas J. Tisch (collectively, the “Original Action Defendants”);  
  

	 	•	 	 The Participating Public Shareholder Defendants, as defined below and as identified in Exhibit 1 attached
hereto, as such Exhibit may be amended, modified or supplemented prior to the Settlement Approval Date (defined below) in accordance with the terms of this Agreement; 

 

	 	•	 	 The Administrative Expense Claims Representative, as defined below; and 

 

	 	•	 	 Transform Holdco LLC, Transform Leaseco LLC, Transform SR Holdings LLC (together, “Transform”
and together with the Litigation Designees, the Debtors, the Restructuring Subcommittee, the Committee, the Original Action Defendants, the Participating Public Shareholder Defendants, and the Administrative Expense Claims Representative, the
“Parties”; each of Transform, the Litigation Designees, the Debtors, the Restructuring Subcommittee, the Committee, the Original Action Defendants, the Participating Public Shareholder Defendants, and the Administrative Expense
Claims Representative, a “Party”). 

 RECITALS 

WHEREAS, beginning on October 15, 2018 and continuing thereafter, each of the Debtors filed a voluntary petition for relief under
chapter 11 of title 11 of the United States Code (such title, the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”), thereby commencing
bankruptcy cases that are jointly administered under Case No. 18-23538 (RDD) (the “Bankruptcy Cases”) and creating estates under section 541 of the Bankruptcy Code (the
“Estates”); and 
 WHEREAS, a subcommittee of the board of directors of Sears Holdings Corporation was formed (the
“Restructuring Subcommittee”), consisting of independent directors, to investigate potential claims and causes of action that the Debtors and their Estates might have as a result of transactions that occurred before October 15,
2018, involving persons or entities that were at the time affiliates of the Debtors, including the ESL Defendants (as defined below); and 

WHEREAS, on October 24, 2018, the United States Trustee appointed the Committee [ECF No. 276]1 in the Bankruptcy Cases; and 
 WHEREAS, on January 17, 2019, Transform Holdco
LLC and the Debtors entered into an asset purchase agreement and related agreements (collectively, as they may have been amended, modified or supplemented from time to time, the “Asset Purchase Agreement”), and on February 

 

	1 	 ECF references are to Case No. 18-23538 (the Bankruptcy Cases)
unless otherwise indicated. 

  
 2 

 8, 2019, the Bankruptcy Court entered the Order (I) Approving the
Asset Purchase Agreement Among Sellers and Buyer, (II) Authorizing the Sale of Certain of the Debtors’ Assets Free and Clear of Liens, Claims, Interests and Encumbrances, (III) Authorizing the Assumption
and Assignment of Certain Executory Contracts and Leases in Connection Therewith, and (IV) Granting Related Relief [ECF No. 2507] approving the Debtors’ entry into the Asset Purchase Agreement and the Debtors’
performance of their obligations thereunder (the “Sale Order”); and 
 WHEREAS, pursuant to the Asset Purchase
Agreement and the Sale Order, the Debtors sold to Transform Holdco LLC, and Transform Holdco LLC purchased from the Debtors, substantially all of the assets and businesses of the Debtors, subject to and in accordance with the terms of the Asset
Purchase Agreement and the Sale Order (the “Sale Transaction”); and 
 WHEREAS, the Sale Transaction closed on
February 11, 2019 at 12:01 a.m. Eastern Time; and 
 WHEREAS, on April 18, 2019, certain of the Debtors filed a complaint
(the “Original Complaint”), on their own behalf and on behalf of the Estates, against Edward S. Lampert, ESL Investments, Inc., RBS Partners LP, CRK Partners LLC, SPE Master I L.P., ESL Partners L.P., SPE I Partners L.P., RBS
Investment Management LLC, ESL Institutional Partners L.P., ESL Investors, L.L.C., JPP LLC, JPP II LLC, Fairholme Capital Management, L.L.C., Cesar L. Alvarez, Bruce Berkowitz, Alesia Haas, Kunal S. Kamlani, Steven Mnuchin, Thomas J. Tisch, Seritage
Growth Properties, Inc., Seritage Growth Properties, L.P., Seritage KMT Mezzanine Finance LLC, Seritage SRC Mezzanine Finance LLC, Seritage KMT Finance LLC, Seritage SRC Finance LLC, Seritage GS Holding LLC, Seritage SPS Holdings LLC, and Seritage
MS Holdings LLC, thereby initiating an adversary proceeding, Adv. Proc. No. 19-08250 (RDD) (the “Original Action”), in the Bankruptcy Court; and 

WHEREAS, on October 15, 2019, the Bankruptcy Court entered the Order (I) Confirming Modified Second Amended
Joint Chapter 11 Plan of Sears Holdings Corporation and Its Affiliated Debtors and (II) Granting Related Relief (ECF No. 5370) (the “Confirmation Order”), which confirmed the Debtors’ Modified
Second Amended Joint Chapter 11 Plan of Sears Holding Corporation and Its Affiliated Debtors [ECF No. 5293] (as amended, supplemented, or modified, the “Plan”);2 and 

WHEREAS, as of the Execution Date, the Plan has not yet gone effective; and 

WHEREAS, the Confirmation Order approved, among other things, the settlement and treatment of certain Administrative Expense Claims
against the Debtors pursuant to a settlement between and among the Debtors, the Committee, and an ad hoc group of administrative expense claims (the “Administrative Expense Claims Consent Program”); and 

 

	2 	 Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the
Plan or Confirmation Order, as applicable. 

  
 3 

 WHEREAS, the Administrative Expense Claims Consent Program and the Confirmation Order
provided for the appointment of a representative of holders of administrative expense claims (the “Administrative Expense Claims Representative”); and 

WHEREAS, the Confirmation Order also granted the Committee joint standing with the Debtors to investigate, commence, prosecute, settle
and otherwise dispose of the Jointly Asserted Causes of Action and provided for the immediate appointment of the Litigation Designees, comprising three individuals selected by the Committee and two individuals selected by the Debtors; and 

WHEREAS, the Confirmation Order granted the Litigation Designees the “exclusive right, authority, and discretion to determine and
to initiate, file, prosecute, enforce, abandon, settle, compromise, release, withdraw, or litigate to judgment any Jointly Asserted Causes of Action pursuant to the terms of the Liquidating Trust Agreement applicable to the Liquidating Trust Board
(including, for the avoidance of doubt, section 6.5(c) of the Liquidating Trust Agreement),” which Jointly Asserted Causes of Action include all claims and causes of action asserted in the Original Action, and any other claims or causes of
action ancillary thereto, including additional claims or causes of action related to the subject matter of the Original Action, see Confirmation Order ¶ 18; and 

WHEREAS, on November 25, 2019, the Committee, acting through the Litigation Designees and on behalf of the Debtors and their
Estates, filed the First Amended Complaint [Ad. Pro. No. 19-8250, ECF No. 52] (the “First Amended Complaint”) in the Original Action against the Original Action Defendants;
and 
 WHEREAS, the First Amended Complaint does not include any claims against Alesia Haas, one of the defendants named in the
Original Complaint, and Ms. Haas is no longer a party to the Original Action (and is not a party to the Public Shareholder Action (as defined below)); and 

WHEREAS, on February 21, 2020, the Original Action Defendants filed motions to dismiss several counts in the First Amended
Complaint and memoranda in support thereof (the “Motions to Dismiss”); and 
 WHEREAS, between April 30, 2020
and June 15, 2020, the plaintiffs in the Original Action and the Original Action Defendants submitted further briefs regarding the Motions to Dismiss; and 

WHEREAS, on August 19, 25, and 31, 2020, the Bankruptcy Court held oral argument on the Motions to Dismiss, which remain pending;
and 
 WHEREAS, on October 15, 2020, the Committee, acting though the Litigation Designees and on behalf of the Debtors and their
Estates, filed a complaint against certain defendants who were public shareholders of the Debtors at various times prior to the commencement of the Bankruptcy Cases (the “Public Shareholder Defendants”), Adv. Pro. No. 20-07007 (RDD) (the “Public Shareholder Action”); and 

  
 4 

 WHEREAS, on January 19, 2021, various Public Shareholder Defendants filed
motions to dismiss the Public Shareholder Action (the “Public Shareholder Motions to Dismiss”), and those Public Shareholder Defendants and the plaintiffs in the Public Shareholder Action subsequently completed briefing of the
Public Shareholder Motions to Dismiss; and 
 WHEREAS, on March 12, 2021, the Bankruptcy Court heard oral argument on the Public
Shareholder Motions to Dismiss, which remain pending; and 
 WHEREAS, on March 15, 2021, the Bankruptcy Court consolidated the
Original Action and the Public Shareholder Action (together, the “Actions) ” pursuant to Federal Rule of Bankruptcy Procedure 7042; and 

WHEREAS, as of the date of this Agreement, the Bankruptcy Court has not issued a decision with respect to any portion of the Motions to
Dismiss or the Public Shareholder Motions to Dismiss; and 
 WHEREAS, on April 6, 2022, the Bankruptcy Court entered an order
[Ad. Pro. No. 198250, ECF No. 270] (the “Mediation Order”) appointing the Hon. Shelley C. Chapman, the Hon. James M. Peck (Ret.), and Jed D. Melnick to serve as co-mediators
(collectively, the “Mediators”) to conduct a mediation (the “Mediation”) in connection with the Original Action; and 

WHEREAS, pursuant to the terms of the Mediation Order, the Mediation concluded on May 23, 2022, without an agreement to settle any
of the claims in the Original Action; and 
 WHEREAS, on May 24, 2022, the Mediators filed a report regarding the Mediation [Ad.
Pro. No. 19-8250, ECF No. 272]; and 
 WHEREAS, on May 31, 2022, the Bankruptcy
Court entered an order [Ad. Pro. No. 198250, ECF No. 275] extending the Mediation without interruption from and including May 23, 2022, through and including June 13, 2022; and 

WHEREAS, on June 14, 2022, the Mediators filed a notice [Ad. Pro. No. 19-8250, ECF
No. 276] that the Mediation would be extended through and including June 30, 2022, subject to potential further discretionary extensions; and 

WHEREAS, since June 30, 2022, the Mediation has continued; and 

WHEREAS, as a result of good faith negotiations that have occurred as part of the Mediation, the Parties have reached this Agreement,
under which they desire to settle and compromise certain disputes, including all disputes between and among them relating to the claims that were or could have been asserted in the Actions, on the terms and subject to the conditions set forth
herein, to avoid the cost and uncertainty of further litigation; and 
 WHEREAS, the Parties desire to fully and finally settle and
resolve all claims and other disputes that were brought or could have been brought in the Actions and certain other disputes related to the Bankruptcy Cases without any concession or admission of liability by any Party on the terms and conditions
set forth in this Agreement. 

  
 5 

 NOW, THEREFORE, for and in consideration of the promises and agreements set forth
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be bound, do promise and agree as follows: 

1. Definitions. As used in this Agreement (including the Exhibits hereto), the following capitalized terms shall have the meanings
specified below (in addition to the definitions of other capitalized terms appearing elsewhere in this Agreement): 
 “Final Approval
Date” means the first date on which the time to file a notice of appeal from the Settlement Approval Order has expired without the filing of such a notice (or, if such a notice is timely filed, the date on which the Settlement Approval
Order has been affirmed pursuant to an order that has become final and is no longer subject to further appeal or review), and the Settlement Approval Order is no longer subject to appeal or petition for review as a matter of law; provided,
however, that the Settlement Payment Parties/Entities (as defined below) may agree in writing on an earlier Final Approval Date, in which case the Final Approval Date shall be the earlier date agreed upon and set forth in that writing. 

“Related Parties” means, with respect to a Party, (i) each of, and in each case in its capacity as such, that
Party’s current and former affiliates, predecessors, successors, family members, and assigns, (ii) any advisory clients, funds, or other investment vehicles to which such Party (or any person or entity controlled by, or under common
control with, such Party) served as investment manager, manager, adviser, sub-adviser, general partner, or equivalent (collectively “Adviser”), or which were under common management or shared
a common Adviser with such Party, (iii) any recipients or subsequent transferees of any transfers that are alleged in one or both of the Actions to be avoidable and alleged to have been received by the Party, and (iv) with respect to such
Party and any persons and entities coming within any of clauses (i), (ii), and (iii), each of its and their representatives, employees, officers, directors, managers, members, shareholders, partners, parents, subsidiaries, agents, attorneys, and
other advisors, in each case in their capacity as such, and, solely with respect to the Sears D&O Defendants (as defined below), the Sears Insurers in their capacities as insurers for those defendants; provided, however, that for any
Participating Public Shareholder Defendant, the term “Related Parties” shall only include persons and entities coming within clause (ii) if the provided Certification (defined below) from that Participating Public Shareholder
Defendant encompasses securities received by the persons and entities coming within clause (ii). 
 “Releases” means the
releases set forth in Section 7 of this Agreement. 
 “Sears D&O Defendants” means the following individuals, each
of which was named as a defendant in the Original Action, in whole or in part, for acts or omissions in his or her capacity as a director or officer of one or more of the Debtors: Cesar L. Alvarez, Bruce Berkowitz, Paul G. DePodesta, Scott Huckins,
Kunal S. Kamlani, William C. Kunkler, Joseph Jordan, Edward S. Lampert, Lawrence Meerschaert, Steven Mnuchin, Leena Munjal, Ann N. Reese, Robert Riecker, Dave Rodney, Robert Schriesheim, and Thomas J. Tisch. 

  
 6 

 “Sears Insurers” means the insurers, listed in Exhibit 2 attached
hereto, but only in their capacities as insurers under the Sears Policies. 
 “Sears Policies” means the 2015-16 and 2017-24 insurance policies, listed in Exhibit 3 issued to Sears Holdings Corporation and its affiliates providing coverage for the Debtors’ directors
and officers, including the Sears D&O Defendants. 
 “Seritage Defendants” means Seritage GS Holding LLC, Seritage
Growth Properties, Seritage Growth Properties, L.P., Seritage KMT Finance LLC, Seritage KMT Mezzanine Finance LLC, Seritage MS Holdings LLC, Seritage SPS Holdings LLC, Seritage SRC Finance LLC, and Seritage SRC Mezzanine Finance LLC. 

“Settlement Approval Date” means the date of entry of the Settlement Approval Order. 

“Settlement Approval Order” means an order, in form and substance reasonably acceptable to the Parties, entered by the
Bankruptcy Court, pursuant to sections 105 and 363 of the Bankruptcy Code and Federal Rule of Bankruptcy Procedure 9019, approving this Agreement and including the Bar Order (as defined in Section 12 below). 

“Settlement Payment Parties/Entities” means the Sears Insurers, the Original Action Defendants making the Original Action
Defendants Payment (as defined in Section 3(c)(ii) below) and paying any Deficit (as defined below), and the Participating Public Shareholder Defendants. 

2. Dismissal of Actions. Within three (3) business days after Debtors’ receipt of the Settlement Amount as set forth in
Section 3 below, counsel for the Committee, acting through the Litigation Designees and on behalf of the Debtors, their Estates, and the Restructuring Subcommittee will cause to be filed stipulations of dismissal, with prejudice, signed by
counsel for all applicable Parties pursuant to Federal Rule of Civil Procedure 41(a), made applicable to the Actions by Federal Rule of Bankruptcy Procedure 7041, of (i) all claims against all Original Action Defendants in the Original Action,
(ii) all claims against the Participating Public Shareholder Defendants in the Public Shareholder Action, and (iii) all claims against any Related Parties of Original Action Defendants who were also named as defendants in the Public
Shareholder Action (which Related Parties are identified and set forth in Exhibit 4). 
 3. Settlement Payment. 

 a. In consideration for the other terms of this Agreement, including the dismissal of the Actions as and to the extent set forth in
Section 2 above and the Releases set forth in Section 7 below, the Settlement Payment Parties/Entities will collectively pay or cause to be paid $175,000,000 (the “Settlement Amount”) to the Debtors as set forth in the
subparagraphs below of this Section 3, which amount shall be distributed in accordance with the terms of the Settlement Approval Order and the Plan. 

  
 7 

 b. The Settlement Amount will be paid, in accordance with the payment instructions set forth
in Exhibit 5, no later than the first business day that is at least sixteen (16) calendar days after the Final Approval Date; provided, however, that each Participating Public Shareholder Defendant shall be required to pay its
Allocable Portion of the Public Shareholder Payment, as set forth in Sections 3(c)(iii) and 3(d) below and on Exhibit 1, to the Debtors no later than five calendar (5) days after the Settlement Approval Date, which payment shall be
returned by the Debtors to the applicable Participating Public Shareholder Defendant in the event that the Final Approval Date does not occur; and, provided, further, the Debtors shall, before the date by when payment is due, provide the
Settlement Payment Parties/Entities supporting tax information and other documentation reasonably necessary to make the Settlement Payment. 

c. Responsibility for the Settlement Amount shall be apportioned as follows: 

 

	 	i.	 The Sears Insurers shall pay a total of $125,625,000 (the “D&O Insurer Payment”) on behalf
of and as directed by the Sears D&O Defendants, with the amount of the D&O Insurer Payment to be paid by each of the Sears Insurers as agreed among those Sears Insurers and set forth in a separate agreement between and among the Sears
Insurers and the Sears D&O Defendants in which the Sears Insurers have obligated themselves to make the D&O Insurer Payment; 

  

	 	ii.	 Original Action Defendants sued, in whole or in part, on claims not covered by the Sears Policies shall pay a
total of $41,875,000 (the “Original Action Defendants Payment)”, with the amount of the Original Action Defendants Payment to be paid by each of those Original Action Defendants to be as agreed among them as specified in Exhibit
6 hereto; and 

  

	 	iii.	 Subject to Section 3(d) below, the Participating Public Shareholder Defendants shall pay a total of
$7,500,000 (the “Public Shareholder Payment”), with the amount of the Public Shareholder Payment to be paid by each Participating Public Shareholder Defendant to be as calculated in accordance with Section 3(d) below and as
specified on Exhibit 1. 

  

	 	iv.	 Other than as specified in sub-section (c)(ii) above and in sub-section (d) below, no Original Action Defendant shall have any obligation to pay the Settlement Amount or any portion thereof. 

d. The portion of the $7,500,000 Public Shareholder Payment allocated to each Participating Public Shareholder Defendant (the
“Allocable Portion”) is based on each such Participating Public Shareholder Defendant’s confidential certification of the total number of shares of stock in Lands’ End, Inc. and total number of Seritage Growth Properties
subscription rights that the Participating Public Shareholder Defendant or, as applicable, one or more of its Related Parties as set forth in such certification, received in connection with the transfers alleged in the Public Shareholder Action (the
“Certification”), as calculated in accordance with the formula set forth on Exhibit 7 hereto. As of the Execution Date, the aggregate 

  
 8 

 amount of the Public Shareholder Payment so allocated to Public Shareholder Defendants that
have become Parties to this Agreement and thus have become Participating Public Shareholder Defendants totals $4,035,712.51 (the “Already Committed Portion of the Public Shareholder Payment”), not the full $7,500,000. Any
additional Public Shareholder Defendant (an “Additional Public Shareholder Defendant”) may become a Participating Public Shareholder Defendant prior to the Settlement Approval Date, without the need for further
amendment of this Agreement (other than the amendment of Exhibit 1 to identify all Participating Public Shareholder Defendants, which amendment the Parties shall cause to be filed with the Bankruptcy Court), in accordance with the following
process: Any Additional Public Shareholder Defendant wishing to join and receive the benefits of this Agreement must execute, prior to the Settlement Approval Date, a joinder to this Agreement in the form set forth on Exhibit 8 hereto, which
joinder shall include a confidential Certification of the total number of shares of stock in Lands’ End, Inc. and the total number of Seritage Growth Properties subscription rights that the Additional Public Shareholder Defendant or, as
applicable, one or more of its Related Parties as set forth in such certification, as well as its Related Parties (if known), received in connection with the transfers that are alleged in the Public Shareholder Action to be avoidable. Counsel for a
majority (based on Allocable Portion) of those Public Shareholder Defendants that have become Participating Public Shareholder Defendants by the Execution Date and by counsel for the Original Action Defendants that are making the Original Action
Defendants Payment are entitled to review, confirm, and approve the Public Shareholder Defendant’s joinder. If such counsel approves in writing the joinder, then the Additional Public Shareholder Defendant, in order to become a Participating
Public Shareholder Defendant, must pay, within five (5) days after the Settlement Approval Date, its Allocable Portion of the $7,500,000 Public Shareholder Payment (the Allocable Portions of the Public Shareholder Payment allocated to and paid
by all such Additional Public Shareholder Defendants, the “Additional Portion of the Public Shareholder Payment”). The portion of the Public Shareholder Payment not allocated to Participating Public Shareholder Defendants in
accordance with the terms hereof shall be the Deficit, which shall be calculated by subtracting (i) the sum of (x) $4,035,712.51 (the Already Committed Portion of the Public Shareholder Payment) and (y) the total amount of the
Additional Portion of the Public Shareholder Payment from (ii) $7,500,000 (the Public Shareholder Payment). Notwithstanding anything to the contrary contained in this Agreement, any such Deficit shall be paid by the Sears Insurers and the Original
Action Defendants who are making the Original Action Defendants Payment, with the Sears D&O Defendants directing the Sears Insurers to pay 75% of the Deficit and the Original Action Defendants to pay 25% of the Deficit, and with each such
Original Action Defendant to pay that portion of such 25% in accordance with its percentage of the Original Action Defendants Payment as set forth on Exhibit 6 hereto. 

e. Each of the Settlement Payment Parties/Entities shall be liable severally for only that portion of the Settlement Payment specified in this
Agreement, including the Exhibits hereto (or, with respect to the Sears Insurers, as agreed by and among them), to be paid by it and shall not be jointly and severally liable for the full Settlement Payment. 

  
 9 

 4. Public Shareholder Action. Each Participating Public Shareholder Defendant
that pays its Allocable Portion of the Public Shareholder Payment in accordance with this Agreement shall be treated as Party to this Agreement and shall obtain the benefit of the Releases, as set forth in Section 7 below, and of the dismissal
of all claims in the Public Shareholder Action asserted against all Participating Public Shareholder Defendants, as set forth in Section 2 above. Each other Public Shareholder Defendant shall not be a Party to this Agreement, shall not receive
the benefit of the Releases set forth in Section 7, and shall not have the claims asserted against it in the Public Shareholder Action dismissed pursuant to this Agreement (except if and to the extent any such other Public Shareholder Defendant
is a Related Party of an Original Action Defendant as listed on Exhibit 4). 
 5. Bankruptcy Court Approval. Effectiveness of
this Agreement is conditioned on its approval by the Bankruptcy Court pursuant to a Settlement Approval Order and the occurrence of the Final Approval Date. By the motion seeking entry of the Settlement Approval Order, the Parties will request a
stay from the Bankruptcy Court of the Actions and of the motion by the Committee, acting through the Litigation Designees on behalf of the Debtors and their Estates, for approval of litigation funding [ECF No. 10407] pending in the Bankruptcy
Cases and a continuation of the Mediation, pending the Bankruptcy Court’s consideration of approval of this Agreement (and pending any related appellate proceedings) and the occurrence of the Final Approval Date. 

6. Cooperation and Further Assurances. The Parties agree to cooperate with each other to execute such further documents or
instruments or to take such other steps as may be reasonably necessary to: (i) obtain the Settlement Approval Order, and (ii) effectuate the terms, intent and conditions of this Agreement. 

7. Party Releases. The Parties acknowledge that this Agreement is intended to fully resolve any and all potential liability of
the Original Action Defendants and the Participating Public Shareholder Defendants based on, relating to, in connection with or in any manner arising out of any and all claims and causes of action that are or were asserted in the Actions, that could
have been asserted in the Actions, that relate to or arise out of any the transactions that are or were at any time at issue in the Actions and, except as otherwise expressly provided herein with respect to the Carve-Outs (as defined in
Section 8 below), that otherwise concern the Debtors or the Bankruptcy Case. Without limiting the foregoing, and except as expressly set forth in this Agreement with respect to the Carve-Outs (defined below), effective as of the Final Approval
Date and payment of the Settlement Amount: 
 a. The Debtors, the Restructuring Subcommittee and each of its members, the Committee and each
of its members, each of the Litigation Designees, and the Administrative Expense Claims Representative (collectively, the “Sears Parties”), on behalf of themselves and the Estates, forever release, acquit and discharge the Original
Action Defendants, the Participating Public Shareholder Defendants, the Sears Insurers, and Transform (collectively, the “Defendant Parties”), all Related Parties of each such Party and all Insured Persons as that term is defined in
the 

  
 10 

 D&O Policies, of and from any and all claims, causes of action, liabilities,
obligations, demands, suits, objections, counterclaims, defenses, debts, damages, sums of money due or owed, expenses, damages, attorneys’ fees, accounts, covenants, contracts, agreements, arrangements, promises, indemnities, warranties,
trespasses, torts, injuries or losses, of whatever kind or character, whether known or unknown, anticipated or unanticipated, foreseen or unforeseen, suspected or unsuspected, absolute, fixed, conditional or contingent, matured or unmatured,
liquidated or unliquidated, disputed or undisputed, assertable directly or derivatively, due or to become due, whether arising from contract, equity, tort or otherwise, and whether arising out of common law or pursuant to statute
(“Claims”), that the Sears Parties and the Estates have, ever had or may have, based on, relating to, in connection with, or in any manner arising out of any act or omission through and including the Execution Date, against the
Defendant Parties and their Related Parties, and such Insured Persons, based on, relating to, in connection with, or in any manner arising out of the Debtors, the Bankruptcy Cases, the Actions, the Asset Purchase Agreement, or the Sale Transaction,
including those Claims that were asserted, or could have been asserted, at any time in the Actions (including in the Original Complaint and the First Amended Complaint, as well as the complaint in the Public Shareholder Action), or that are based
on, relate to, are in connection with, or in any manner arise out of any act undertaken or omission by any Defendant Party or Related Party thereto or any transaction engaged in by or on behalf of any of the Debtors whether or not at issue at any
time in the Actions. 
 b. The Defendant Parties forever release, acquit and discharge the Sears Parties and their Related Parties of and
from all Claims that the Defendant Parties have, ever had, or may have, based on, relating to, in connection with, or in any manner arising out of any act or omission through and including the Execution Date, against the Sears Parties and their
Related Parties based on, relating to, in connection with, or in any manner arising out of the Debtors, the Bankruptcy Cases, the Actions, the Asset Purchase Agreement, or the Sale Transaction, including those Claims that were asserted, or could
have been asserted, at any time in the Actions, or that are based on, relate to, are in connection with, or in any manner arise out of any act undertaken or omission by any Sears Party or Related Party thereto or any transaction engaged in by or on
behalf the Debtors whether or not at issue at any time in the Actions. 
 c. Each of the Original Action Defendants and each of the
Participating Public Shareholder Defendants forever releases, acquits and discharges each of the other Original Action Defendants and the Related Parties of each such other Original Action Defendants, and each of the other Participating Public
Shareholder Defendants and the Related Parties of each such other Participating Public Shareholder Defendants, of and from all Claims based on, relating to, in connection with, or in any manner arising out of the Actions, including any Claims for
contribution, indemnification or reimbursement with respect to any portion of the Settlement Payment paid by an Original Action Defendant or Participating Public Shareholder Defendant and any defense costs incurred by any such Original Action
Defendant or Participating Public Shareholder Defendant in connection with the Actions. 

  
 11 

 8. Carve-Outs and Reservations of Rights. Notwithstanding anything to the contrary
contained in this Agreement, including the Releases, nothing in this Agreement shall release, discharge or otherwise impair or affect the Parties’ (or their Related Parties’) claims, rights and defenses based on, relating to, in connection
with, or otherwise arising in any manner out of the following matters (collectively, the “Carve-Outs”): 
 a. All rights,
claims and defenses of Transform (and its Related Parties), on the one hand, and the Debtors (and their Related Parties), on the other hand, with respect to the matters identified on Exhibit 9; provided, however, if and to the extent
such Exhibit provides for any such matters to be settled or otherwise resolved on the terms specified therein, such terms shall control. For the avoidance of doubt, nothing in this Agreement waives or otherwise releases Transforms’
indemnification obligations under section 9.2(e) of the Asset Purchase Agreement for taxes. 
 b. All rights and claims of Cyrus (as defined
in Section 9(b) below) as against the Debtors and the Estates with respect to the pending Section 507(b) Appeal (as defined in Section 9(a) below), all rights and claims of the Debtors and the Estates as against Cyrus with respect to
the pending Section 506(c) Appeal (as defined in Section 9(a) below), and all rights and claims that the Debtors and the Estates may have against Cyrus or any Related Party of Cyrus based on, relating to, in connection with or otherwise
arising in any manner out of the Bankruptcy Cases other than any claims that were asserted against Cyrus in the Original Action or that otherwise relate to any of the transactions that are or were the subject of the Original Action, as more fully
set forth in Section 9 below (any such rights and claims of the Debtors and the Estates, the “Cyrus Carved-Out Claims”).  

c. All rights and claims of any Original Action Defendant or Participating Public Shareholder Defendant (or of any Related Party of any
Original Action Defendant or any Participating Public Shareholder Defendant) to seek any contribution, indemnification, reimbursement or other funding from any of their respective investors, partners, funds or insurers with respect to any portion of
the Settlement Payment to be paid by such Original Action Defendant or Participating Public Shareholder Defendant (or by any Related Party of such Original Action Defendant or Participating Public Shareholder Defendant) or with respect to any
defense costs incurred by such Original Action Defendant or Participating Public Shareholder Defendant in connection with the Actions; provided, however, that (i) the Sears Insurers shall be responsible for the D&O Insurer Payment
and 75% of any Deficit as provided in this Agreement, and (ii) the Sears Insurers and the Sears D&O Defendants are entering into a separate agreement that will set forth the Sears Insurers’ ongoing responsibilities and obligations
under the Sears Policies and that will address specifically the obligations of the Sears Insurers with respect to the payment or reimbursement of outstanding defense costs incurred by the Sears D&O Defendants in connection with the Original
Action and provide releases among 

  
 12 

 those Parties on the terms set forth in that separate agreement; provided, further,
that no Original Action Defendant (and no Related Party of such an Original Action Defendant) shall seek contribution, indemnification, reimbursement or other funding for any portion of the Settlement Amount to be paid (or for any defense costs
incurred) by such Original Action Defendant (or a Related Party) from any Participating Public Shareholder Defendant or from any of its Related Parties to the extent that such Participating Public Shareholder Defendant (or Related Party) received
transfers that are the subject of the Actions directly in its own name (rather than as an investor or partner in the Original Action Defendant (or in its Related Party)), and no Participating Public Shareholder Defendant (and no Related Parties of
any Participating Public Shareholder Defendant) shall seek contribution, indemnification, reimbursement, or other funding for any portion of the Settlement Amount to be paid (or for any defense costs incurred) by such Participating Public
Shareholder Defendant (or a Related Party) from any Original Action Defendant or from any of its Related Parties to the extent that such Original Action Defendant (or Related Party) received transfers that are the subject of the Actions directly in
its own name (rather than as an investor or partner in the Participating Public Shareholder Defendant (or in its Related Party)). 
 d. Any pre-petition claims that any of the Original Action Defendants or Participating Public Shareholder Defendants (or that any Related Party of any Original Action Defendant or of any Participating Public Shareholder
Defendant) may have against the Debtors or their Estates in the Bankruptcy Cases and all rights appurtenant thereto, including all rights to share in distributions made to creditors from the Estates in the Bankruptcy Cases; provided, however,
in light of and subject to the Releases provided by the Sears Parties as set forth in Section 7 above, and except as provided in Sections 8(b) and 9(b) of this Agreement, the Original Action Defendants and the Participating Public
Shareholder Defendants agree that all such claims shall be treated as general unsecured claims (and not as secured or priority claims). 
 e.
All rights and claims of all Parties to enforce this Agreement or for damages for its breach. 
 9. Section 507(b) Appeal/Section 506(c)
Appeal Litigation.  
 a. ESL Investments, Inc., JPP, LLC, and JPP II, LLC (the “ESL Defendants”), all of which
are Original Action Defendants, are appellants in the appeals styled ESL Investments, Inc., et al. v. Sears Holding Corporation, Case Nos. 20-3343(L), 20-3346
(CON), and 20-3349 (CON), that are currently pending in the U.S. Court of Appeals for the Second Circuit (including any proceedings that may ensue if there is a remand or other proceedings relating to the
disputes at issue in these appeals, the “Section 507(b) Appeal”). The ESL Defendants shall, as soon as reasonably practicable after the Final Approval Date, either (i) withdraw the claims they have asserted
in the Section 507(b) Appeal; or (ii) at the Debtors’ election (subject to the consent of the Committee) assign any right to recovery on their disputed super-priority administrative expense claims that are the subject of the 

  
 13 

 507(b) Appeal to the Estates (which assignment shall be subject to all defenses, limitations
and similar such rights as may exist with respect to such claims as and when held by the ESL Defendants); provided, however, that if the Debtors, with the Committee’s consent, elect option (ii), then the assignment documentation shall be
reasonably acceptable to the ESL Defendants, the Debtors shall cover the reasonable legal expenses of the preparation of such documentation, and the Debtors and not the ESL Defendants shall substitute themselves for the ESL Defendants in any further
legal proceedings relating to the Section 507(b) Appeal and shall be responsible for all legal or other expenses that may need to be incurred in connection therewith; and provided, further, that the Debtors shall, as soon as reasonably
practicable after the Final Approval Date, withdraw their claims as against the ESL Defendants in the related appeal that is currently pending (but stayed) in the U.S. District Court for the Southern District of New York styled In re Sears
Holdings Corp., Case Nos. 19 Civ. 8002 (VB) & 19 Civ. 8237 (VB) (the “Section 506(c) Appeal”).  

b. Original Action Defendant Cyrus Capital Partners, L.P. (“Cyrus”) does not release its claims at issue in the
Section 507(b) Appeal. The Debtors and their Estates shall retain all defenses to the claims asserted in the Section 507(b) Appeal by Cyrus. In addition, the Debtors and their Estates shall retain, and shall not release under this
Agreement, their claims in the Section 506(c) Appeal as against Cyrus and all Cyrus Carved-Out Claims. 

10. No Admission of Liability. Each Party acknowledges that this Agreement is a compromise of disputed claims and defenses and
that the Settlement Payment provided hereunder shall not be construed as an admission with respect to the merits of the claims and defenses by any Party. 

11. Acknowledgement of Defendants’ Good Faith. The Debtors acknowledge that, notwithstanding the allegations made in the
Actions, (a) all of the Original Action Defendants and the Participating Public Shareholder Defendants, and all of the Related Parties of the Original Action Defendants and the Participating Public Shareholder Defendants, acted in good faith in
taking the actions they took (and in refraining from taking the actions they did not take) that are the subject of the Actions, and (b) without limiting the foregoing, the Debtors’ directors and officers (including those named as Original
Action Defendants) acted in good faith in what they believed to be the best interests of the Debtors after obtaining and reasonably relying on the advice of legal, financial and other professionals in effectuating and approving, on behalf of the
Debtors, the transactions at issue in the Actions. No Party shall publicly claim that it has prevailed or succeeded in the Actions or characterize the terms of this Agreement as such, and no Party shall publicly refer to the amount of the Settlement
Payment as evidence of the strength or viability or legitimacy of its claims or defenses; provided, however, that this shall not prevent any Party from referring to the actual terms of this Agreement in response to an inquiry about the
Agreement. For the avoidance of doubt, the acknowledgement set forth in the first sentence of this Section 11 is made by the Debtors (and not the Committee or the Litigation Designees); and provided, further, if the Final Approval Date
does not occur and the Settlement Amount is not paid, this acknowledgment will be of no force and effect and may not be cited, relied upon, or in any way used in connection with continued litigation of the Actions or otherwise. 

  
 14 

 12. Claim-Over Protections. As part of the Settlement Approval Order, the
Committee, acting through the Litigation Designees and on behalf of the Debtors and their Estates shall seek the entry by the Bankruptcy Court of, and this Agreement is conditioned upon the entry of, a standard and customary order, in form and
substance reasonably acceptable to the Parties, and effective as of the Final Approval Date, barring (a) any Public Shareholder Defendants that do not become Participating Public Shareholder Defendants and against whom the Public Shareholder
Action is not therefore dismissed and (b) any other person or entity that the Sears Parties (or any Related Parties of any Sears Parties) have sued or may sue, or against whom the Sears Parties (or any Related Parties of any Sears Parties) have
asserted or may otherwise assert a claim, and that is not a Party to this Agreement (each person or entity falling within clause (a) or clause (b), a “Non-Settling Party”), from asserting
any claim for contribution, reimbursement or indemnification against any of the Original Action Defendants, the Participating Public Shareholder Defendants or any of the foregoing’s Related Parties (collectively, a “Settling
Party”) arising out of, based on, in connection with or relating to any of the claims or allegations set forth in the Actions (a “Claim-Over”) and providing for the Sears Parties to reduce any judgment or other recovery
they may obtain against any such Non-Settling Party by the amount required under applicable law, calculated by reference to the proportionate share of fault attributable to the Settling Parties, to preclude
the Non-Settling Party from asserting a Claim-Over (a “Bar Order”); provided, however, the Bar Order shall not apply to (i) any claim for contribution, reimbursement or
indemnification that is based on a contract entered into by a Non-Settling Party with a Settling Party providing for such contribution, reimbursement or indemnification by the Settling Party; (ii) any
claim for which a court determines joint liability does not exist as a matter of law, equity or fact as between any Non-Settling Party and any Settling Party; or (iii) any claims for contribution,
reimbursement or indemnification asserted with respect to claims or causes of action that are brought by any person or entity other than the Sears Parties or any Related Parties of any Sears Parties. For the avoidance of doubt, this Agreement is not
and shall not be deemed or construed to be an admission or evidence that any Original Action Defendants or the Participating Public Shareholder Defendants, or any Related Parties of the foregoing, are joint tortfeasors with any Non-Settling Party or that any Original Action Defendants or Participating Public Shareholder Defendants share any liability with any Non-Settling Party. 

13. Additional Seritage Payment. As further consideration for the Releases set forth in Section 7(a) above, and in full
satisfaction and settlement of any and all claims or expenses arising from or relating in any way to the Seritage Defendants’ role as landlord to any of the Debtors as tenants, including, but not limited to, (1) any claims by the Debtors
relating to lease termination payments, including lease termination payments pursuant to that certain lease termination agreement, dated August 22, 2018, between Seritage SRC Finance LLC, Seritage KMT Finance LLC, and Sears Operations LLC and
Kmart Operations LLC, and (2) any pre-petition or post-petition expense reimbursement obligations owed by the Seritage Defendants to the Debtors with respect to any of the properties leased by the
Seritage Defendants to the Debtors, the Seritage Defendants will pay the Debtors $500,000 (the “Additional Seritage Payment”). For the avoidance of doubt, the Additional Seritage Payment shall be in addition to the payment of a
portion of the Settlement Amount that the Seritage Defendants are making pursuant to Section 3 above and Exhibit 6 hereto, and the Seritage Defendants shall make the Additional Seritage Payment at the same time as they pay their required
portion of the Settlement Amount. 

  
 15 

 14. Representations and Warranties by the Debtors, the Litigation Designees and
the Committee. Each of the Sears Parties represents and warrants that (a) it has all corporate or other power and authority necessary to enable it to enter into this Agreement and carry out the transactions contemplated by this Agreement
and to grant the releases and make the commitments specified in this Agreement; (b) all corporate or other actions necessary to authorize it to enter into this Agreement and to carry out the transactions contemplated by it have been taken and
that each person executing this Agreement on its behalf has the authority to execute this Agreement on its behalf and to bind it to the terms of this Agreement; (c) the execution and performance of this Agreement does not and shall not conflict
with or contravene any agreement, undertaking, commitment, or law or regulation by which it is bound or to which its assets or properties are subject; and (d) before executing this Agreement, (i) it has been fully informed of its terms,
contents, conditions, and effects; (ii) it has had a full and complete opportunity to discuss this settlement with its attorney or attorneys; (iii) it is not relying in any respect on any statement or representation made by any other
Party; and (iv) no promise or representation of any kind has been made to such Party separate and apart from what is expressly contained in this Agreement. 

15. Representations and Warranties by the Original Action Defendants, the Participating Public Shareholder Defendants, and
Transform. Each of the Original Action Defendants, Participating Public Shareholder Defendants, and Transform represents and warrants that (a) it has all corporate or other power and authority necessary to enable it to enter into this
Agreement and carry out the transactions contemplated by this Agreement and to grant the releases and make the commitments specified in this Agreement; (b) all corporate or other actions necessary to authorize it to enter into this Agreement
and to carry out the transactions contemplated by it have been taken and that each person executing this Agreement on its behalf has the authority to execute this Agreement on its behalf and to bind it to the terms of this Agreement; (c) the
execution and performance of this Agreement does not and shall not conflict with or contravene any agreement, undertaking, commitment, or law or regulation by which it is bound or to which its assets or properties are subject; and (d) before
executing this Agreement, (i) it has been fully informed of its terms, contents, conditions, and effects; (ii) it has had a full and complete opportunity to discuss this settlement with its attorney or attorneys; (iii) it is not
relying in any respect on any statement or representation made by any other Party; and (iv) no promise or representation of any kind has been made to such Party separate and apart from what is expressly contained in this Agreement. 

16. Governing Law. Except to the extent the Bankruptcy Code may control, this Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of New York without giving effect to the conflicts of laws rules of the State of New York. 

17. Forum. Each of the Parties hereto irrevocably consents to the exclusive jurisdiction of the state and federal courts
situated in the State of New York to interpret and enforce this Agreement and to resolve any disputes relating to or concerning this Agreement. The Parties further agree to submit any such dispute(s) to the Bankruptcy Court to the extent permitted
under law. 
 18. Entire Agreement; Amendment. This Agreement, including the Exhibits hereto which are an integral part of
this Agreement, constitutes the complete understanding between and among the Parties and any prior understandings and agreements with regard to subject matter of this Agreement, written or oral, are superseded in their entirety. This Agreement
cannot be altered, amended, or modified in any respect, except by a writing duly executed by all Parties. 

  
 16 

 19. Waiver. The failure of any of the Parties to enforce at any time any
provision of this Agreement shall not be construed to be a waiver of such provision, nor in any way affect the validity of this Agreement or any part thereof or any right of any person thereafter to enforce each and every provision. No waiver of any
breach of this Agreement shall be held to constitute a waiver of any other breach. 
 20. Nature of Releases. The Releases in
this Agreement include an express, informed, knowing, and voluntary waiver and relinquishment of claims to the fullest extent permitted by law. The Parties acknowledge that they may have sustained damages, losses, costs, or expenses that are
presently unknown and unsuspected and that such damages, losses, costs, or expenses as may have been sustained may give rise to additional damages, losses, costs, or expenses in the future. The Parties further acknowledge that they have negotiated
this Agreement taking into account presently unasserted, unsuspected, and unknown claims, counterclaims, causes of action, damages, losses, costs, and expenses, and the Parties voluntarily and with full knowledge of its significance, expressly waive
and relinquish any and all rights they may have under any state or federal statute, rule, regulation, or common law principle, in law or equity, relating to limitations on general release. Specifically, without suggesting that California law is
applicable, each Party expressly waives any rights it may have under California Civil Code Section 1542 (and other similar statutory provisions) which provides that: “A general release does not extend to claims that the creditor or
releasing party does not know or suspect to exist in his or her favor at the time of executing the release, and that if known by him or her would have materially affected his or her settlement with the debtor or released party.” 

21. Construction of Terms, Headings. When necessary herein, all terms used in the singular shall apply to the plural, and vice
versa, and all terms used in the masculine shall apply to the neuter and feminine genders, and vice versa. Unless the context of this Agreement clearly requires otherwise: (a) “or” has the inclusive meaning frequently identified with the
phrase “and/ or”; (b) “including” has the inclusive meaning frequently identified with the phrase “including but not limited to” or “including without limitation”; and (c) references to
“hereunder,” “herein,” “or “hereof” relate to this Agreement as a whole. The division of this Agreement into Sections and the insertion of headings are for convenience of reference only and shall not affect the
construction or interpretation of this Agreement. 
 22. Calculation of Days. In computing any period of time specified by the
terms of this Agreement, the term “days” (unless specified otherwise) shall be deemed to refer to calendar days. If the last day of any period described in this Agreement is a Saturday, Sunday, or legal holiday, the period is extended to
include the next day that is not a Saturday, Sunday, or legal holiday. 
 23. Costs and Fees. Each Party shall bear its own
attorneys’ fees and costs relating to the negotiation and execution of this Agreement (but subject to the rights of the Sears D&O Defendants to obtain payment or reimbursement of their fees and costs from the Sears Insurers under the Sears
Policies and subject to Section 8(c) above); provided, however, that nothing herein shall preclude any Estate professional, including any counsel or other professional for the Debtors, the Committee, or the Restructuring
Subcommittee, or the Administrative Expense Claims 

  
 17 

 Representative or any of his professionals, from being paid or reimbursed for its fees and costs from the
Debtors and the Estates pursuant to order of the Bankruptcy Court or, in the case of the Administrative Expense Claims Representative and his professionals, pursuant to ECF No. 7454. If any Party(ies) reasonably determines to file a motion or
to commence an action to enforce the terms of this Agreement, however, the prevailing Party(ies) shall be entitled to seek an award, in addition to any other claims or damages, of its (their) reasonable costs and expenses including reasonable
attorneys’ fees, incurred in connection with such enforcement motion or action. 
 24. Waiver of Jury Trial. The Parties hereby
waive any right to trial by jury in any action at law or in equity or in any other proceeding seeking to enforce or interpret the terms of this Agreement. 

25. Joint Preparation. The Parties jointly prepared this Agreement. Any rule of law or any other statute or legal decision or common
law principle that would require interpretation of any term or alleged ambiguity in this Agreement against the person or entity who drafted this Agreement is of no application and hereby is expressly waived and disclaimed and may not be utilized or
relied upon by any of the Parties. 
 26. Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of and
be enforceable by the Parties hereto and their respective successors, endorsees, transferees, heirs, beneficiaries, and assigns. 
 27.
Severability. If any provision of this Agreement is or may be held by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nonetheless survive and continue in full force and effect without
being impaired or invalidated in any way. 
 28. Counterparts. It is understood and agreed that this Agreement may be executed in
identical counterparts and may be transmitted by email or facsimile, each of which shall be deemed an original for all purposes. The Parties agree that electronic signatures shall have the same force and effect as original signatures. 

29. Notices. Any notices or communications relating to this Agreement shall be in writing and sent by electronic mail or overnight mail
to the Parties through their counsel, as listed below. Any Executing Party may change its address for notices and communications by supplying all Executing Parties with new contact information: 

 

	 	a.	 Litigation Designees and the Committee 

Ira S. Dizengoff (idizengoff@akingump.com) 

David M. Zensky (dzensky@akingump.com) 

Sara L. Brauner (sbrauner@akingump.com) 

Dean Chapman (dchapman@akingump.com) 

Akin Gump Strauss Hauer & Feld LLP 

One Bryant Park 
 New York, NY
10036 

  
 18 

 b. Debtors 

Ray C. Schrock, P.C. (Ray.Schrock@Weil.com) 

Garrett A. Fail (Garrett.Fail@Weil.com) 

Weil, Gotshal & Manges LLP 

767 Fifth Avenue 
 New York, NY
10153 
 c. The Restructuring Subcommittee 

Paul M. Basta (pbasta@paulweiss.com) 

Kelley A. Cornish (kcornish@paulweiss.com) 

Robert A. Britton (rbritton@paulweiss.com) 

Paul, Weiss, Rifkind, Wharton & Garrison LLP 

1285 Avenue of the Americas 

New York, NY 10019 
 d. Original
Action Defendants 
 Philip D. Anker (Philip.Anker@wilmerhale.com) 

Noah Levine (Noah.Levine@wilmerhale.com) 

Ryanne Perio (Ryanne.Perio@wilmerhale.com 

Wilmer Cutler Pickering Hale and Dorr LLP 

7 World Trade Center 
 250
Greenwich Street 
 New York, NY 10007 

Counsel for Edward Scott Lampert, ESL Institutional Partners L.P., ESL 

Investments, Inc., ESL Investors, L.L.C., ESL Partners L.P., JPP II LLC, 

and JPP LLC 
 Robert A. Sacks
(sacksr@sullcrom.com) 
 Brian D. Glueckstein (gluecksteinb@sullcrom.com) 

Sullivan & Cromwell LLP 

125 Broad Street 
 New York, New
York 10004 
 Counsel for Steven Mnuchin 

Sidney P. Levinson (slevinson@debevoise.com) 

Erica S. Weisgerber (eweisgerber@debevoise.com) 

Debevoise & Plimpton LLP 

919 Third Avenue 
 New York, NY
10022 
 Counsel for Cascade Investment, L.L.C. 

  
 19 

 Brad Scheler (Brad.eric.scheler@friedfrank.com) 

Scott Luftglass (Scott.luftglass@friedfrank.com) 

Michael Keats (Michael.keats@friedfrank.com) 

Fried, Frank, Harris, Shriver & Jacobson LLP 

One New York Plaza 
 New York,
NY 10004 
 Counsel for Seritage GS Holding LLC, Seritage Growth Properties, 

Seritage Growth Properties, L.P., Seritage KMT Finance LLC, Seritage 

KMT Mezzanine Finance LLC, Seritage MS Holdings LLC, Seritage SPS 

Holdings LLC, Seritage SRC Finance LLC, and Seritage SRC Mezzanine 

Finance LLC. 
 Evan R. Chesler
(echesler@cravath.com) 
 J. Wesley Earnhardt (wearnhardt@cravath.com) 

825 Eighth Avenue 
 New York, NY
10019 
 (212) 474-1000 

Counsel for Ann Reese, Paul DePodesta, and 

William Kunkler 
 Gregory P.
Joseph (gjoseph@jhany.com) 
 Rachel M. Cherington (rcherington@jhany.com) 

Courtney A. Solomon (csolomon@jhany.com) 

Joseph Hage Aaronson LLC 
 485
Lexington Avenue, 30th Floor 
 New York, NY 10017 

(212) 407-1210 

Counsel for Cesar L. Alvarez 

Andrew J. Frackman (afrackman@omm.com) 

Daniel S. Shamah (dshamah@omm.com) 

O’Melveny & Myers LLP 

7 Times Square 
 New York, NY
10036 
 (212) 326-2000 

Counsel for Thomas Tisch and Benefit Street 

2018, LLC 

  
 20 

 Mark J. Hyland (hyland@sewkis.com) 

Paul M. Miller (millerp@sewkis.com) 

Robert J. Gayda (gayda@sewkis.com) 

Thomas Ross Hooper (hooper@sewkis.com) 

Seward & Kissel LLP 

One Battery Park Plaza 
 New
York, New York 10004 
 (212) 574-1200 

Counsel for Bruce Berkowitz, Fairholme Capital Management, L.L.C., 

and Fairholme Funds, Inc. 

Michael S. Shuster (mshuster@hsgllp.com) 

Vincent Levy (vlevy@hgsllp.com) 

Matthew Gurgel (mgurgel@hsgllp.com) 

Holwell Shuster & Goldberg LLP 

425 Lexington Avenue 
 New York,
New York 10017 
 (646) 837-5151 

Counsel for Kunal S. Kamlani 

Chris Gair (cgair@gairlawgroup.com) 

Jeffrey S. Eberhard (jeberhard@gairlawgroup.com) 

Gair Eberhard Nelson Dedinas Ltd. 

1 E. Wacker Drive, Suite 2600 

Chicago, IL 60601 
 (312) 600-4900 
 Counsel for Robert Riecker, Robert Schriesheim, 

and Scott Huckins 
 Sawnie
McEntire (smcentire@pmmlaw.com) 
 Robert Rosen (rrosen@pmmlaw.com) 

Parsons McEntire McCleary 
 1700
Pacific Ave., Ste. 4400 
 Dallas, TX 75201 

(214) 237-4303 

Counsel for Cushman & Wakefield 

Elliot Moskowitz (elliot.moskowitz@davispolk.com) 

Davis Polk & Wardwell LLP 

450 Lexington Avenue 
 New York,
NY 10017 
 Counsel for Cushman & Wakefield 

  
 21 

 Andrew Devore (andrew.devore@ropesgray.com) 

Timothy Farrell (timothy.farrell@ropesgray.com) 

Ropes & Gray 
 800
Boylston Street 
 Boston, MA 02199 

Counsel for Duff & Phelps, LLC 

Eric R. Reimer (ereimer@milbank.com) 

Tom Kreller (tkreller@milbank.com) 

Andrew Leblanc (aleblanc@milbank.com) 

Milbank LLP 
 55 Hudson Yards

 New York, NY 10001 

Counsel for Cyrus 1740 Master Fund, LP, Cyrus Special Strategies Master 

Fund, LP, Cyrus Select Opportunities Master Fund, Ltd., Canary SC 

Master Fund, LP, CRS Master Fund, LP, Cyrus Opportunities Master 

Fund II, Ltd., CMH VI, LP, CYR Fund, LP, Canary SC Fund, LP, 

Crescent 1, LP, and Cyrus Capital Partners, LP 

Howard J. Kaplan (hkaplan@kaplanrice.com) 

Michelle Rice (mrice@kaplanrice.com) 

Kaplan Rice LLP 
 142 W 57th St,

 New York, NY 10019 

Counsel for Leena Munjal, Lawrence Meerschaert, and Joseph Jordan 

e. Participating Public Shareholder Defendants 

Julia Frost-Davies (Julia.Frost-Davies@morganlewis.com) 

John C. Goodchild, III (john.goodchild@morganlewis.com) 

Morgan, Lewis & Bockius LLP 

One Federal St. 
 Boston, MA
02110 
 Counsel for certain Participating Public Shareholder Defendants indicated 

on Exhibit 1 
 William H.
Gussman, Jr. (bill.gussman@srz.com) 
 Randall T. Adams (randall.adams@srz.com) 

Schulte Roth & Zabel LLP 

919 Third Avenue 
 New York, NY
10022 
 Counsel for Lockheed Martin Corporation Master Retirement, Mason 

Capital Management LLC, and S.A.C. Capital Associates, LLC (n/k/a 

Point72 Associates, LLC) 

  
 22 

 C. Lee Wilson (clwilson@jonesday.com) 

Jones Day 
 250 Vesey Street

 New York, New York 10281 

Counsel for QIC Limited as Trustee for the Queensland Investment Trust 

No. 2 (incorrectly named in the public shareholder action as “QIT2 IE 

DFA CORE MANDATE”) 
 John
B. Orenstein (JOrenstein@greeneespel.com) 
 Holley C.M. Horrell (hhorrell@greeneespel.com) 

Greene Espel PLLP 
 222 South
Ninth Street 
 Suite 2200 

Minneapolis, MN 55402 
 Counsel
for AQR Delta Fund, LP, AQR Delta Master Account, L.P., AQR 
 Delta Sapphire Fund, LP, and AQR Delta XN Fund, LP 

Daniel Guyder (Daniel.Guyder@AllenOvery.com) 

Justin Ormand (Justin.Ormand@AllenOvery.com) 

Allen & Overy LLP 

1221 Avenue of the Americas 

New York, NY 10020 
 Counsel for
certain Participating Public Shareholder Defendants, as 
 indicated on Exhibit 1 

Jack Yoskowitz (yoskowitz@sewkis.com) 

Paul Koepp (koepp@sewkis.com) 

Seward & Kissel LLP 

One Battery Park Plaza 
 New
York, NY 10004 
 Counsel for certain Participating Public Shareholder Defendants, as 

indicated on Exhibit 1 

Honeywell, Robert T. (Robert.Honeywell@klgates.com) 

K&L Gates LLP 
 599
Lexington Avenue 
 New York, New York 10022 

Counsel for certain Participating Public Shareholder Defendants, as 

indicated on Exhibit 1 
 Joseph
T. Kelleher (JKelleher@stradley.com) 
 Keith R. Dutill (kdutill@stradley.com) 

Stradley Ronon Stevens & Young, LLP 

2005 Market Street, Suite 2600 

Philadelphia, PA 19103 
 Counsel
for certain Participating Public Shareholder Defendants, as 
 indicated on Exhibit 1 

  
 23 

 James Miller (JDMiller@cahill.com) 

Joel H. Levitin (JLevitin@cahill.com) 

Michael J. Birnkrant (MBirnkrant@cahill.com) 

Cahill Gordon & Reindel LLP 

32 Old Slip 
 New York, NY 10005

 Counsel for certain Participating Public Shareholder Defendants, as 

indicated on Exhibit 1 
 f.
Administrative Expense Claims Representative 
 Erika L. Morabito (erikamorabito@quinnemanuel.com) 

Brittany J. Nelson (brittanynelson@quinnemanuel.com) 

Quinn Emanuel 
 1300 I Street

 Suite 900 
 Washington,
D.C. 20005 
 g. Transform 

Sean A. O’Neal (soneal@cgsh.com) 

Cleary Gottlieb Steen & Hamilton LLP 

One Liberty Plaza 
 New York, NY
10006 
 Such notices shall be deemed to have been served when received by the addressee. Any Party may give written notice of a change of address and,
after notice of such change has been received, any notice or request shall then be given to such Party as above provided at such changed address. 

[Signatures on Following Pages] 
  

  
 24 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date
first written above. 
  

			
	For Litigation Designees & Committee:
	
	AKIN GUMP STRAUSS HAUER & FELD LLP
		
	By:	 	
		 	 Ira S. Dizengoff

	
	Counsel for Litigation Designees & Committee
	
	For Debtors:
	
	WEIL, GOTSHAL & MANGES LLP
		
	By:	 	
		 	 Ray C. Schrock, P.C.

		 	Garrett A. Fail
	
	Counsel for Sears Holdings Corporation, et al., Debtors and Debtors in Possession
	
	For Restructuring Subcommittee:
	
	PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
		
	By:	 	
		 	 Robert A. Britton

	
	Counsel for the Restructuring Subcommittee

			
	For Edward Scott Lampert, ESL Institutional Partners L.P., ESL Investments, Inc., ESL Investors, L.L.C., ESL Partners L.P., JPP II LLC, and JPP LLC:
	
	WILMER CUTLER PICKERING HALE AND DORR LLP
		
	By:	 	
		 	 Philip D. Anker

	
	Counsel for Edward Scott Lampert, ESL Institutional Partners L.P., ESL Investments, Inc., ESL Investors, L.L.C., ESL Partners L.P., JPP II LLC, and JPP LLC
	
	For Steve Mnuchin:
	
	SULLIVAN AND CROMWELL LLP
		
	By:	 	
		 	 Robert A. Sacks

	
	Counsel for Steve Mnuchin
	
	For Cascade Investment, L.L.C.:
	
	DEBEVOISE & PLIMPTON LLP
		
	By:	 	
		 	 Sidney P. Levinson

	
	Counsel for Cascade Investment, L.L.C.

			
	For Seritage GS Holding LLC, Seritage Growth Properties, Seritage Growth Properties, L.P., Seritage KMT Finance LLC, Seritage KMT Mezzanine Finance LLC, Seritage MS Holdings LLC, Seritage SPS Holdings LLC, Seritage
SRC Finance LLC, and Seritage SRC Mezzanine Finance LLC:
	
	FRIED, FRANK, HARRIS, SHRIVER & JACOBSON LLP
		
	By:	 	
		 	 Michael C. Keats

	
	Counsel for Seritage GS Holding LLC, Seritage Growth Properties, Seritage Growth Properties, L.P., Seritage KMT Finance LLC, Seritage KMT Mezzanine Finance LLC, Seritage MS Holdings LLC, Seritage SPS Holdings LLC,
Seritage SRC Finance LLC, and Seritage SRC Mezzanine Finance LLC
	
	For Ann Reese, Paul DePodesta, and William Kunkler:
	
	CRAVATH, SWAINE & MOORE LLP
		
	By:	 	
		 	 J. Wesley Earnhardt

	Counsel for Ann Reese, Paul DePodesta, and William Kunkler

			
	For Cesar L. Alvarez:
	
	JOSEPH HAGE AARONSON LLC
		
	By:	 	
		 	 Gregory P. Joseph

	
	Counsel for Cesar L. Alvarez
	
	For Thomas Tisch and Benefit Street 2018, LLC:
	
	O’MELVENY & MYERS LLP
		
	By:	 	
		 	 Andrew J. Frackman

	
	Counsel for Thomas Tisch and Benefit Street 2018, LLC
	
	For Bruce Berkowitz, Fairholme Capital Management, L.L.C., and Fairholme Funds, Inc.:
	
	SEWARD & KISSEL LLP
		
	By:	 	
		 	 Mark J. Hyland

	
	Counsel for Bruce Berkowitz, Fairholme Capital Management, L.L.C., and Fairholme Funds, Inc.

			
	For Kunal S. Kamlani:
	
	HOLWELL SHUSTER & GOLDBERG LLP
		
	By:	 	
		 	 Matthew Gurgel

	
	Counsel for Kunal S. Kamlani
	
	For Robert Riecker, Robert Schriesheim, and Scott Huckins:
	
	GAIR EBERHARD NELSON DEDINAS LTD
		
	By:	 	
		 	 Chris Gair

	
	Counsel for Robert Riecker, Robert Schriesheim, and Scott Huckins

			
	For Cushman & Wakefield:
	
	DAVIS POLK & WARDWELL LLP
		
	By:	 	
		 	 Elliot Moskowitz

	
	Counsel for Cushman & Wakefield
	
	For Duff & Phelps, LLC:
	
	ROPES & GRAY LLP
		
	By:	 	
		 	 Timothy Farrell

	
	Counsel for Duff & Phelps, LLC
	
	For Cyrus 1740 Master Fund, LP, Cyrus Special Strategies Master Fund, LP, Cyrus Select Opportunities Master Fund, Ltd., Canary SC Master Fund, LP, CRS Master Fund, LP, Cyrus Opportunities Master Fund II, Ltd., CMH
VI, LP, CYR Fund, LP, Canary SC Fund, LP, Crescent 1, LP, and Cyrus Capital Partners, LP:
	
	MILBANK LLP
		
	By:	 	
		 	 Eric R. Reimer

	
	Counsel for Cyrus 1740 Master Fund, LP, Cyrus Special Strategies Master Fund, LP, Cyrus Select Opportunities Master Fund, Ltd., Canary SC Master Fund, LP, CRS Master Fund, LP, Cyrus Opportunities Master Fund II, Ltd.,
CMH VI, LP, CYR Fund, LP, Canary SC Fund, LP, Crescent 1, LP, and Cyrus Capital Partners, LP

			
	For Leena Munjal, Lawrence Meerschaert, and Joseph Jordan:
	
	KAPLAN RICE LLP
		
	By:	 	
		 	 Howard J. Kaplan

		 	Michelle Rice
	
	Counsel for Leena Munjal, Lawrence Meerschaert, and Joseph Jordan
	
	For Administrative Expense Claims Representative:
	
	QUINN EMANUEL URQUHART & SULLIVAN, LLP
		
	By:	 	
		 	 Erika L. Morabito

	
	Counsel for the Administrative Claims Representative
	
	For Transform:
	
	CLEARY GOTTLIEB STEEN & HAMILTON LLP
		
	By:	 	
		 	 Sean A. O’Neal

	
	Counsel for Transform

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	MORGAN, LEWIS & BOCKIUS LLP
		
	By:	 	  

		 	John C. Goodchild
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	SCHULTE ROTH & ZABEL LLP
		
	By:	 	  

		 	Randall T. Adams
	
	Counsel for Lockheed Martin Corporation Master Retirement, Mason Capital Management LLC, and S.A.C. Capital Associates, LLC (n/k/a Point72 Associates, LLC)

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	JONES DAY
		
	By:	 	  

		 	C. Lee Wilson
	
	Counsel for QIC Limited as Trustee for the Queensland Investment Trust No. 2 (incorrectly named in the public shareholder action as “QIT2 IE DFA CORE MANDATE”)

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	GREENE ESPEL PLLP
		
	By:	 	  

		 	John B. Orenstein
	
	Counsel for AQR Delta Fund, LP, AQR Delta Master Account, L.P., AQR Delta Sapphire Fund, LP, and AQR Delta XN Fund, LP

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	ALLEN & OVERY LLP
		
	By:	 	  

		 	Daniel Guyder
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	SEWARD & KISSEL LLP
		
	By:	 	  

		 	Jack Yoskowitz
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	K&L GATES LLP
		
	By:	 	  

		 	Robert T. Honeywell
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	STRADLEY RONON STEVENS & YOUNG, LLP
		
	By:	 	  

		 	Joseph T. Kelleher
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

			
	For certain Participating Public Shareholder Defendants (as indicated on Exhibit 1 to this Agreement):
	
	CAHILL GORDON & REINDEL LLP
		
	By:	 	  

		 	James Miller
	
	Counsel for certain Participating Public Shareholder Defendants, as indicated on Exhibit 1

 EXHIBIT 1 

List of Participating Public Shareholder Defendants 
  

							
	 Participating Public Shareholder Defendant
	  	Settlement
Payment Amount	 	  	Law Firm / Counsel
	 T. Rowe Price Associates, Inc.

(on behalf of T. Rowe Price High Yield Fund, T. Rowe Price Institutional High Yield Fund; T. Rowe Price Funds SICAV - Global High Yield Bond Fund; T. Rowe
Price U.S. Equities Trust; T. Rowe Price Total Equity Market Index Fund; and T. Rowe Price Extended Equity Market Index Fund)
	  	$	63,160.00	 	  	Morgan, Lewis &
Bockius LLP
	 Ori Uziel
	  	$	61,759.00	 	  	Morgan, Lewis &
Bockius LLP
	 Blackrock Asset Management Ireland Limited

BlackRock Inc.

The Bank of New York Mellon (International) Limited, as

Trustee of the Blackrock iShares UK Equity Index Fund (UK)
	  	$	488,325.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw All Country Global Alpha Extension Portfolios, L.L.C.
	  	$	809.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw All Country Global Alpha Plus Special Fund, L.P.
	  	$	2,371.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw Kalon Portfolios, L.L.C.
	  	$	20,104.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw Oculus Portfolios, L.L.C.
	  	$	46,928.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw U.S. Broad Market Core Alpha Extension Portfolios, L.L.C.
	  	$	8,538.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw U.S. Broad Market Core Alpha Extension Special Portfolios II (MA), L.L.C.
	  	$	2,374.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw U.S. Broad Market Core Alpha Plus Special Fund, L.P.
	  	$	10,671.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw U.S. Large Cap Core Alpha Extension Portfolios, L.L.C.
	  	$	1,187.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw Valence Portfolios, L.L.C.
	  	$	129,943.00	 	  	Morgan, Lewis &
Bockius LLP
	 D. E. Shaw World Alpha Extension

Portfolios, L.L.C.
	  	$	3,436.00	 	  	Morgan, Lewis &
Bockius LLP
	 Dekel Partners, L.P.

Fine Offshore Partners, L.P.

Fine Partners I, L.P.

Noga Partners, L.P.

Tapuz Partners, L.P.
	  	$	469,061.00	 	  	Morgan, Lewis &
Bockius LLP
	 Sculptor Domestic Partners II LP

Sculptor Domestic Partners, LP

Sculptor Capital Investments, LLC (aka Sculptor Group fdba

Och-Ziff Capital Management Group, LLC)

Sculptor Capital Management, Inc. (fdba Och-Ziff Capital

Management Group Inc., aka Oz Group)
	  	$	64,089.00	 	  	Morgan, Lewis &
Bockius LLP
	 Force Capital II LLC

Force Capital II Ltd

Force Capital Ltd

Force Select Ltd
	  	$	177,582.00	 	  	Morgan, Lewis &
Bockius LLP

							
	 The Vanguard Group, Inc., as Agent

Vanguard Balanced Index Fund

Vanguard Consumer Discretionary Index Fund

Vanguard Extended Market Index Fund

Vanguard Growth and Income Fund

Vanguard Institutional Total Stock Market Index Fund

Vanguard Large-Cap Index Fund

Vanguard Mid-Cap Index Fund

Vanguard Mid-Cap Index Portfolio

Vanguard Mid-Cap Value Index Fund

Vanguard Small-Cap Index Fund

Vanguard Small-Cap Value Index Fund

Vanguard Tax-Managed Capital Appreciation Fund

Vanguard Total Stock Market Index Fund

Vanguard Total Stock Market Index Trust

Vanguard Value Index Fund
	  	$	477,619.00	 	  	Morgan, Lewis &
Bockius LLP
	 MOST DIVERSIFIED PORTFOLIO SICAV - TOBAM ANTIBENCHMARK GLOBAL EQUITY FUND
	  	$	1,664.00	 	  	Morgan, Lewis &
Bockius LLP
	 MOST DIVERSIFIED PORTFOLIO SICAV - TOBAM ANTI-BENCHMARK US EQUITY FUND
	  	$	55,359.00	 	  	Morgan, Lewis &
Bockius LLP
	 MOST DIVERSIFIED PORTFOLIO SICAV - TOBAM ANTI-BENCHMARK WORLD EQUITY FUND
	  	$	24,441.00	 	  	Morgan, Lewis &
Bockius LLP
	 Omega Advisors Inc.

Omega Capital Investors, L.P.

Omega Capital Partners, L.P.

Omega Charitable Partnership, L.P.

Omega Equity Investors, L.P.

Omega Overseas Partners, Ltd
	  	$	107,288.00	 	  	Morgan, Lewis &
Bockius LLP
	 Karlin Holdings Limited Partnership
	  	$	154,829.00	 	  	Morgan, Lewis &
Bockius LLP
	 GSO Aiguille Des Grands Montets Fund I LP

GSO Aiguille Des Grands Montets Fund II LP

GSO Aiguille Des Grands Montets Fund III LP

GSO Cactus Credit Opportunities Fund LP

GSO Coastline Credit Partners LP

GSO Credit Alpha Trading (Cayman) LP

GSO Credit-A Partners LP

GSO Palmetto Opportunistic Investment Partners LP GSO

Special Situations Fund LP

GSO Special Situations Master Fund LP

GSO Special Situations Overseas Fund Ltd

Steamboat Credit Opportunities Master Fund LP
	  	$	419,624.00	 	  	Morgan, Lewis &
Bockius LLP
	 Barclays Capital Inc.

Barclays Capital Securities Limited

Barclays Capital Derivative Funding
	  	$	154,841.00	 	  	Morgan, Lewis &
Bockius LLP
	 Fiam LLC

Jonathan Chiel, as Trustee of the Fidelity Concord Street Trust
	  	$	72,403.00	 	  	Morgan, Lewis &
Bockius LLP
	 Gothic HSP Corporation
	  	$	57,588.00	 	  	Morgan, Lewis &
Bockius LLP
	 First Trust Consumer Discretionary
Alphadex® Fund
	  	$	40,661.00	 	  	Morgan, Lewis &
Bockius LLP
	 HBOS Final Salary Pension Scheme
	  	$	62,603.74	 	  	Allen & Overy
LLP
	 SAC Capital Associates, LLC (n/k/a Point72 Associates, LLC)
	  	$	259,842.75	 	  	Schulte Roth &
Zabel LLP

									
	 Lockheed Martin Corporation Master Retirement Trust
	  	$	7,895.37	 	  	 
	Schulte Roth & Zabel
LLP	 
 
	 MASON CAPITAL MGMT LLC
	  	$	82,899.15	 	  	 
	Schulte Roth & Zabel
LLP	 
 
	 Kenden Alfond
	  	$	1,901.33	 	  	 
	Seward & Kissel
LLP	 
 
	 AQR DELTA Fund, LP

AQR DELTA Master Account, L.P.

AQR DELTA Sapphire Fund, LP

AQR DELTA XN Fund, LP
	  	$	55,968.97	 	  	 	Greene Espel PLLP	 
	 Credit Suisse First Boston
	  	$	1,893.57	 	  	 
 
	Cahill Gordon &
 Reindel LLP
	 
  

	 Credit Suisse Funds AG
	  	$	531.71	 	  	 
 
	Cahill Gordon &
 Reindel LLP
	 
  

	 Horizon Spin-off and Corporate Restructuring Fund
	  	$	11,160.70	 	  	 	K&L Gates LLP	 
	 Kinetics Portfolio Trust
	  	$	142,275.67	 	  	 	K&L Gates LLP	 
	 Luma Capital S.A.—SPF
	  	$	121,272.57	 	  	 	K&L Gates LLP	 
	 Prescott Associates L.P.

Prescott General Partners LLC

Prescott International Partners L.P.

Prescott Investors, Inc.
	  	$	82,412.25	 	  	 	K&L Gates LLP	 
	 Global Targeted Value Fund, a subfund of Dimensional Funds plc
	  	$	4,168.67	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Targeted Value Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	1,325.78	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Core Equity 1 Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	22,730.91	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Core Equity 2 Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	33,445.69	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Sustainability Core 1 Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	1,025.09	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Social Core Equity 2 Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	906.10	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Large Cap Equity Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	555.25	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 VA U.S. Large Value Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	1,169.35	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 U.S. Vector Equity Portfolio, a series of DFA Investment Dimensions Group Inc.
	  	$	10,580.74	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 Dimensional U.S. Core Equity 2 ETF, a series of Dimensional ETF Trust (into which T.A. U.S. Core
Equity 2 Portfolio, a series of DFA Investment Dimensions Group Inc., was converted)
	  	$	9,032.20	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 Dimensional U.S. Targeted Value ETF, a series of Dimensional ETF Trust (into which Tax-Managed U.S. Targeted Value Portfolio, a series of DFA Investment Dimensions Group Inc., was converted)
	  	$	239.87	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 Dimensional U.S. Equity ETF, a series of Dimensional ETF Trust (into which Tax-Managed U.S. Equity Series, a series of DFA Investment Dimensions Group Inc., was converted)
	  	$	1,213.08	 	  	 

	Stradley Ronon
Stevens & Young,
LLP	 
 
 
	 QIC Limited as Trustee for the Queensland Investment Trust No. 2 (incorrectly named in the
public shareholder action as QIT2 IE DFA CORE MANDATE)
	  	$	2,008.00	 	  	 	Jones Day	 
	 Total Settlement Payment from Participating Public Shareholder Defendants
	  	$	4,035,712.51	 	  			

 EXHIBIT 2 

Sears Insurers 
  

	 	•	 	 XL Specialty Insurance Company 

 

	 	•	 	 QBE Insurance Corporation 

 

	 	•	 	 Lloyd’s of London 

 

	 	•	 	 Beazley Group 

  

	 	•	 	 AXIS Insurance Company 

 

	 	•	 	 Illinois National Insurance Company 

 

	 	•	 	 American International Group UK Limited 

 

	 	•	 	 Berkshire Hathaway Specialty Insurance 

 

	 	•	 	 Hiscox Insurance Company, Inc. 

 

	 	•	 	 Allied World Assurance Company 

 

	 	•	 	 The Hartford, Navigators Insurance Company 

 

	 	•	 	 Westchester Fire Insurance Company 

 

	 	•	 	 Enstar (US) Inc. as claims administrator for Aspen American Insurance Company 

 

	 	•	 	 Allianz Global Risks US Insurance Company 

 

	 	•	 	 Swiss Re Corporate Insurance Solutions America Insurance Corporation f/k/a North American Specialty Insurance
Company 

  

	 	•	 	 Enstar (UK) Inc. as claims administrator for Aspen Insurance UK Ltd. 

 

	 	•	 	 ACT 

  

	 	•	 	 Continental Casualty Company 

 

	 	•	 	 StartPoint, 

  

	 	•	 	 Argo Re Limited 

  

	 	•	 	 Validus Specialty (RT) 

 

	 	•	 	 Old Republic Insurance Company 

 EXHIBIT 3  

Sears Policies 
  

	1.	 XL Policy No. ELU139030-15 

 

	2.	 QBE Policy No. QPL0045025 

 

	3.	 Lloyd’s (Beazley) Policy No. FD1581481 

 

	4.	 AXIS Policy No. MCN738227/01/2015 

 

	5.	 Illinois National (AIG) Policy No. 01-309-63-06 

  

	6.	 Berkshire Hathaway Policy No. 47-XDA-301368-01 

  

	7.	 Lloyd’s (Hiscox) Policy No. FD1581601 

 

	8.	 Allied World Policy No. 0308-3251 

 

	9.	 Illinois National (AIG) Policy No. 01-310-13-60 

  

	10.	 The Hartford (Navigators) Policy No. CH15DOL586634IV 

 

	11.	 Westchester Policy No. G2759699A 001 

 

	12.	 Aspen American Insurance Company Policy No. MCAA1K415 

 

	13.	 XL Policy No. ELU149912-17 

 

	14.	 Lloyd’s (Beazley) Policy No. FSUSC1800413 

 

	15.	 Allianz Policy No. DOD2009095 

 

	16.	 NAS (Swiss Re) Policy No. DAX 2000102 00 

 

	17.	 Illinois National (AIG) Policy No. 01-423-10-78 

  

	18.	 Lloyd’s (Hiscox and ACT) Policy No. FSUSC1802479 

 

	19.	 CNA Policy No. 596686796 

 

	20.	 Certain Underwriters of Lloyds, London, Aspen Insurance UK Ltd., and ACT Policy 

 

	No.	 FSUSC1800410 

  

	21.	 Lloyd’s (Hiscox and ACT) and AIG UK Policy No. FSUSC1800971 

 

	22.	 AXIS Policy No. MCN738227/01/2017 

 

	23.	 Argo Policy No.
ARGO-ASIDE-17-001041.1 

  

	24.	 Lloyd’s (Beazley), Aspen Insurance UK Ltd., ACT, Certain Underwriters of Lloyds, 

London, and AIG UK Policy No. FSUSC1801088 
  

	25.	 AIG UK and ACT Policy No. FSUSC1801090 

 

	26.	 Validus Policy No. PDX0000018 

 

	27.	 Old Republic Policy No. ORPRO 39488 

 

	28.	 Illinois National (AIG) Policy No. 01-423-04-29 

 EXHIBIT 4 

 

			
	 Related Party
	  	 Original Action Defendant

		
	Andrew H. Tisch	  	Thomas J. Tisch
		
	Daniel R. Tisch	  	Thomas J. Tisch
		
	Trustee of the Andrew H. Tisch 10/10/2014 Annuity Trust	  	Thomas J. Tisch
		
	Trustee of the DRT 12/5/13 Annuity Trust	  	Thomas J. Tisch
		
	Trustee of the DRT 1/14/14 Annuity Trust	  	Thomas J. Tisch
		
	JHT 12/5/13 Annuity Trust	  	Thomas J. Tisch
		
	Trustee of the Thomas J. Tisch 1994 Issue Trust	  	Thomas J. Tisch
		
	Kenden Alfond*	  	Fairholme Capital Management
		
	Luma Capital S.A.-SPF*	  	Fairholme Capital Management
		
	Perceval Investment Partners, L.P.	  	Fairholme Capital Management
		
	SFM Capital Markets, L.P.	  	Fairholme Capital Management
		
	Timothy F. Palmer	  	Fairholme Capital Management

  

	*	 Related Party is contributing to Public Shareholder Payment per Exhibit 1 

 EXHIBIT 5 

Payment by wire: 
 Payee on the
wire instructions: Sears Holdings Corporation 
 Account Title: Sears Holdings Corporation 

Wind-Down Account 
 Address: 1700
Broadway, 19th Floor 
 New York, New York 10019 

Account Number: 4686303281 
 Wire
Domestic/Intl Routing: 041000124 
 SWIFT Code: PNCCUS33 (International Wires) 

Bank Address: PNC Bank 
 500
First Avenue 
 Pittsburgh, PA 15219 

Memo of the payment: Global Settlement and [name of payor in Settlement Agreement] 

In advance of making the wire payment, please call Antonio Concolino (212) 2022267 to verbally confirm the wire instructions.

 Payment by check:  

Make the check payable to: Sears Holdings Corporation 

Memo of the check: Global Settlement and [name of payor in Settlement Agreement] 

Mailing Address1:    M3 Advisory Partners, LP 

            c/o Mary Korycki 

            1700 Broadway,
19th Floor 

            New York, NY 10019 

 
  

	1	 M3 Advisory Partners, LP was formerly known as and retained in the case as
M-III Advisory Partners, LP [ECF 814]. 

 EXHIBIT 6 

 

									
	
PARTY1
	  	DOLLAR AMOUNT OF
SETTLEMENT
PAYMENT (EXCLUDING
ANY PAYMENT OF
DEFICIT) TO BE PAID	 	  	PERCENTAGE OF ANY
DEFICIT TO BE PAID	 
	 Sears Insurers
	  	 	125,625,000	 	  	 	75.00	 
	 Cushman & Wakefield, Inc.
	  	 	1,000,000	 	  	 	0.60	 
	 ESL Institutional Partners L.P., ESL Investments, Inc., ESL Investors, L.L.C., ESL Partners L.P.,
JPP LLC, and/ or JPP II, LLC
	  	 	3,000,000	 	  	 	1.80	 
	 Fairholme Capital Management, LLC
	  	 	1,750,000	 	  	 	1.04	 
	 Seritage Defendants
	  	 	34,375,000	 	  	 	20.52	 
	 Thomas J. Tisch
	  	 	1,750,000	 	  	 	1.04	 

  
  

	1	 Other than the portion of the Settlement Payment to be paid by the Sears Insurers on behalf of all the Original
Action Defendants that were directors and/or officers of the Debtors, no Original Action Defendants not listed on this Exhibit will be responsible for payment of any portion of the Settlement Payment. 

 EXHIBIT 7 

Formula for calculation of each Participating Public Shareholder Defendant’s Allocable Portion of the Public Shareholder Payment, based on the
information provided in each Participating Public Shareholder Defendant’s Certification: 
  

	 	•	 	 For every one (1) share of Lands’ End Inc. received by the applicable Participating Public Shareholder
Defendant in connection with the transfers alleged in the Public Shareholder Action, a settlement payment of $0.651810 shall be made. 

  

	 	•	 	 For every one (1) subscription right of Seritage Growth Properties received by the applicable Participating
Public Shareholder Defendant in connection with the transfers alleged in the Public Shareholder Action, a settlement payment of $0.083972 shall be made. 

 EXHIBIT 8 

FORM OF JOINDER TO SETTLEMENT AGREEMENT 

The undersigned hereby enter(s) into this Joinder to Settlement Agreement (“Joinder”), whereby it/they agree(s) to become a
Participating Public Shareholder Defendant party to the Settlement Agreement, dated as of (the “Agreement”), for all purposes thereunder. Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.
In consideration for the promises and agreements set forth in the Agreement, the undersigned agree(s) as follows: 
 Payment of Allocable
Portion. The undersigned shall pay its/their Allocable Portion of the Public Shareholder Payment, in the amount of AMOUNT ($    ), within five (5) days after the Settlement Approval Date, in accordance with Sections 3(d)
of the Agreement. 
 Certification. For purposes of determining its Allocable Portion (based on the formula set forth in Exhibit 7 to
the Agreement), the undersigned certify/certifies that it/they received the following securities in connection with the transfers that are alleged in the Public Shareholder Action to be avoidable: 

 

			
	 Lands’ End Shares
	 	 Seritage Growth Properties

Subscription Rights

Reservation of Rights. For the avoidance of doubt, this Joinder shall not take effect, and the undersigned shall not constitute a
Participating Public Shareholder Defendant, until it has paid its Allocable Portion of the Public Shareholder Payment. 

Reaffirmation. Except as provided herein, all other terms and provisions of the Agreement remain in full force and effect without
modification. 
 Dated: ____, 2022. 
  

			
	 [ENTITY NAME]

		
	 By:
	 	
		 	 Name:

		 	 Title:

 
			
	
	 on behalf of Public Shareholder Defendant(s):

		
	 [ENTITY NAME]
	 	
	 [ENTITY NAME]
	 	
	 [ENTITY NAME]
	 	

 EXHIBIT 9 

Notwithstanding anything to the contrary contained in the Agreement, and subject to and conditioned on the occurrence of the Final Approval
Date, the following matters at issue between Transform and its Related Parties, on the one hand, and the Debtors and the Estates, on the other hand, shall be settled and resolved on the following terms: 

 

	1.	 The appeal currently pending in the United States Court of Appeals for the Second Circuit captioned
Transform Holdco LLC v. Sears Holding Corporation, Case No. 22-1249, concerning approximately $6.3 million in escrowed funds shall be resolved as follows: Transform shall be entitled to
$1.0 million of the funds held by the Debtors in escrow, which shall be turned over to Transform no later than five (5) business days following the Final Approval Date, and the Debtors shall be entitled to the remaining funds in such
escrow account. Transform and the Debtors shall take all reasonably necessary actions to effect this division of the funds in escrow, to obtain extensions of any briefing deadlines in the appeal pending the occurrence of the Final Approval Date, and
to cause the withdrawal of the appeal as soon as reasonably practicable after the occurrence of the Final Approval Date. 

  

	2.	 The administrative expense claim asserted by Oracle Corporation (and/or one or more affiliates thereof)
(“Oracle”) against Transform and/or the Debtors in the approximate amount of $1.3 million (Claim No. 20588) shall be handled as follows: The parties have reached an agreement in principle to resolve this matter under which
Transform will pay Oracle $350,000 (in three installments) and the Debtors will pay Oracle $375,000. The Debtors will file a stipulation on notice of presentment with the Bankruptcy Court for approval of this resolution of Claim No. 20588.
Subject to final documentation and court approval, both Transform and the Debtors reserve all rights with respect to amounts claimed to be owed by Oracle against Transform and/or the Debtors. 

 

	3.	 The following vendors have asserted that they are owed money for goods or services provided post-petition in
the following approximate amounts: Colonial Properties, $30,000; Fox Run, $30,000; and Covington Gallery, $5,000. Transform reserves the right to dispute some or all of the charges, but acknowledges that to the extent these amounts are owed to these
vendors, Transform is responsible for the payments. 

  

	4.	 Any right to participate in (and to share in any recovery from) that certain class action captioned as In
re: Blue Cross Blue Shield Antitrust Litigation, MDL 2406, N.D. Ala. Master File No. 2:13-cv-20000-RDP, or in (and to share
in any recovery from) any related claims that have been or may be asserted by Transform or the Debtors against the defendant(s) to the extent that Transform or the Debtors opt out of the class, shall be allocated on a 50/50 basis between Transform
and the Debtors. Transform and the Debtors shall, in good faith, coordinate on any filings, any retention of counsel, and the strategy for the pursuit of their claims in the class action (or in any related potential litigation to the extent that
they elect, after consulting and coordinating with each other, to opt-out of the class). All reasonable out-of-pocket costs
incurred from and after the Final Approval Date in the pursuit of such claims, including any reasonable fees of counsel whose retention the Debtors and Transform agree upon, shall be allocated on a 50/50 basis between Transform

 and the Debtors; provided, however, such fees incurred from and after the Final
Approval Date to be so allocated on a 50/50 basis shall be limited to those of counsel retained by the Debtors and Transform for the specific purpose of pursuing these claims and shall not include the fees (or costs) of or incurred by counsel
representing Transform or the Debtors in the Bankruptcy Cases. For the avoidance of doubt, each of Transform and the Debtors shall be responsible for all fees and other costs as it may have incurred or may incur prior to the Final Approval Date with
respect to this action and all fees and costs relating to the action that it may incur from and after the Final Approval Date that are not expressly provided to be allocated on a 50/50 basis between them as specified in this paragraph. 

 

	5.	 The Debtors shall execute (and/or file) such documents as may be reasonably requested by Transform to transfer
to Transform all rights with respect to any software licenses granted to one or more of the Debtors by ASG Technologies Group, Inc. (and/or one or more affiliates thereof) (“ASG”), provided that ASG consents to such transfer.

  

	6.	 Transform shall have all rights with respect to the parcel of land located at 13 Beverly Road, Hoffman Estates,
(Property Index Number (PIN) 06-05-200-010-0000) (the “Hoffman Estates
Parcel”). To the extent reasonably requested by Transform, the Debtors shall execute and deliver (or file, as requested by Transform) such documents as may be necessary or appropriate to evidence the transfer of title to, and all such
rights, in the Hoffman Estates Parcel to Transform. Transform shall be responsible for the payment of all real estate taxes with respect to the Hoffman Estates Parcel for all periods from and after the closing of the Sale Transaction.

  

	7.	 Transform shall not bill the Debtors for the transition services it has provided to the Debtors for the period
from and including April 1, 2022, through and including the Execution Date under that certain Services Agreement, dated as of February 11, 2019, by and between Sears Holding Corporation, on the one hand, and Transform Holdco LLC and
Transform SR Holdings LLC, on the other hand (as it has been amended from time to time, the “TSA”). Transform shall also continue to provide transition services reasonably requested by the Debtors, in accordance with the TSA but
without charge to the Debtors, for the period after the Execution Date through and including December 31, 2022, up to a cap for the services of $10,000 per month (as calculated in accordance with the TSA, the Sale Order and that certain
Settlement Agreement by, between and among Transform and the Debtors dated September 17, 2020 (the “TSA Settlement Agreement”). To the extent that the Debtors (a) request that Transform provide transition services under
the TSA in excess of $10,000 per month for the period from the after the Execution Date through and including December 31, 2022, or (b) continue to request that Transform provide transition services under the TSA from and after
January 1, 2023, Transform shall be entitled to charge the Debtors for those services in accordance with the TSA, the Sale Order and the TSA Settlement Agreement. For the avoidance of doubt, to the extent that the TSA obligates the Debtors to
indemnify Transform in connection with services provided by Transform for the Debtors under the TSA, those indemnification obligations shall continue in effect. 

  
 2 

	8.	 The Asset Purchase Agreement, the Sale Order, and subsequent orders entered by the Bankruptcy Court1 provided for the Debtors’ assumption and assignment to Transform of the lease for store number 1722 located at 2000 N E Court, Bloomington, Minnesota (the “Mall of America
Lease”) and that the Mall of America Lease was an “Acquired Asset” under the APA. However, the lessor objected to that assumption and assignment, and appealed the Bankruptcy Court’s orders providing for that assumption and
assignment. The lessor’s challenges to the assumption and assignment are the subject of a petition for certiorari that the U.S. Supreme Court has granted. In light of this, the Debtors and Transform acknowledge and agree to the following:
Transform reserves all rights to obtain the assignment of the Mall of America Lease, including all such rights arising under or based on the Asset Purchase Agreement, the Sale Order, the Assumption and Assignment Order, the MOAC Assumption and
Assignment Order, the Bankruptcy Court’s Order (I) Confirming Modified Second Amended Joint Chapter 11 Plan of Sears Holdings Corporation and Its Affiliated Debtors and (II) Granting Related Relief
(ECF No. 5370) (the “Confirmation Order”), and the Debtors’ Modified Second Amended Joint Chapter 11 Plan of Sears Holding Corporation and Its Affiliated Debtors (ECF No. 5293) (as amended, supplemented, or
modified, the “Plan”), and any related orders, notices or other filings in the Bankruptcy Cases or in any related appellate proceedings. In the event, however, that as a result of a final,
non-appealable order entered by a court of competent jurisdiction Transform is unable to obtain the assignment of the Mall of America Lease (a “Denial Order”), Transform acknowledges and
agrees that it will not be entitled to an adjustment in (and the repayment by the Debtors of any of) the consideration Transform paid to the Debtors under the APA (or the consideration it is paying to the Debtors under this Settlement Agreement).
The Debtors agree to execute any documents and to take any actions that Transform may reasonably request to effect the assignment of the Mall of America Lease to Transform or its designee and/or to allow Transform to obtain the economic benefits
that the Debtors and Transform intended that Transform obtain from its acquisition of the Mall of America Lease. Transform shall be responsible for all reasonable fees and
out-of-pocket costs incurred by the Debtors in connection with the foregoing. Any economic consideration that the Debtors or Transform may be able to obtain for the Mall
of America Lease shall belong to and shall be turned over to Transform. 

  

 

	1	 Order (I) Authorizing Assumption and Assignment of Certain Executory Contracts and Leases and
(II) Granting Related Relief (ECF. No. 3008) (the “Assumption and Assignment Order”), and Order (I) Authorizing Assumption and Assignment of Lease with MOAC Mall Holdings LLC and
(II) Granting Related Relief entered in the Bankruptcy Cases (ECF No. 5074) (the “MOAC Assumption and Assignment Order”).  

  
 3Document

EXECUTION VERSION

COLLABORATION AND LICENSE AGREEMENT

This Collaboration and License Agreement (the “Agreement”) is entered into as of May 31, 2022 (the “Effective Date”), by and between vTv Therapeutics LLC, a Delaware limited liability company having an address at 3980 Premier Dr. Suite 310, High Point, North Carolina 27265 (“Company”) and Cogna Technology Solutions LLC, an Abu Dhabi limited liability company having an address at Abu Dhabi 624, Plot C18, E48 RG Building, Al Salam, Abu Dhabi, United Arab Emirates (“Partner”). Company and Partner may be referred to herein individually as a “Party” or collectively as the “Parties.”

RECITALS

WHEREAS, Company, a biopharmaceutical company, is developing a proprietary candidate known as TTP399 and owns or controls certain Patents, Know-How and other Intellectual Property relating to such candidate;

WHEREAS, Partner possesses substantial resources and expertise in clinical development and commercialization of pharmaceutical products; and

WHEREAS, Company and Partner desire to collaborate on certain Development of the Product and to grant Partner certain rights to Commercialize the Product within the Partner Territory, in each case, as further described in, and subject to, the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Partner hereby agree as follows:

Section 1.    Definitions.

Capitalized terms used in this Agreement shall have the meanings ascribed to such terms in this Agreement, including as specified in this Section 1. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement; provided that any use of the term “Purchaser” therein shall mean “Partner” for the purposes hereof.

“Affiliate” means, as to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act; provided that for purposes of this Agreement (a) Company, its Subsidiaries, MAF and its Subsidiaries will not be deemed an Affiliate of Partner or its Subsidiaries, (b) Partner and its Subsidiaries will not be deemed an Affiliate of Company, its Subsidiaries, MAF or its Subsidiaries and (c) notwithstanding the foregoing other than in the case of Section 12 and 13, “Affiliate,” as to Company, shall be deemed to mean Subsidiary.

“Anti-Corruption Laws” means, as applicable, the FCPA, the U.S. Travel Act, 18 U.S.C.
§ 1952, the U.K. Bribery Act 2010, any Law enacted to implement the OECD Convention on
1

Combating Bribery of Foreign Officials in International Business Transactions, and any other anti- corruption or anti-bribery Laws of similar effect in other countries or jurisdictions in which products, payments or services will be provided under this Agreement.

“Applicable Laws” means any and all applicable national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, and permits of or from any Regulatory Authority or other Governmental Authority having jurisdiction over or related to the subject item. For clarity, the Parties acknowledge and agree that, with respect to Partner’s and any Partner Member’s conduct of any Partner-Conducted Clinical Trials, and related activities hereunder, “compliance with Applicable Laws” shall be deemed to require compliance with the Laws of the applicable country or jurisdiction in which the Partner-Conducted Clinical Trial takes place or the IND is filed, as well as compliance with the FD&C Act, 21 CFR Parts 11, 50, 54, 56, 58 and 312 that are applicable as a result of Partner’s assumption of responsibilities as a CRO for a Sponsor with its principal place of business in the United States.

“Calendar Quarter” means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31, or the applicable part thereof during the first or last quarter of the Term.

“Calendar Year” means each respective period of twelve (12) consecutive months ending on December 31, or the applicable part thereof during the first or last year of the Term.

“cGCP” means the current clinical practice requirements set out in (a) ICH Harmonized Guidance on current Good Clinical Practice (CPMP/ICH/135/95), (b) U.S. Code of Federal Regulations, Title 21, Chapters 50, 54, 56, 58 and 312, (c) EU Directive 2001/20/EC and related guidelines, and (d) any foreign equivalents of any of the foregoing.

“cGLP” means current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58, and such other comparable regulatory standards in jurisdictions outside the U.S.

“cGMP” means the current minimum standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, distribution or holding of a drug as specified by Applicable Laws of the relevant jurisdictions at the time of manufacturing conducted in accordance with this Agreement, including (a) 21 C.F.R. Part 210 and 211, (b) Directive 2003/94/EC, (c) Volume 4, Rules Governing Medicinal Products in the EU, Part I and II, and (d) any foreign equivalents thereof.

“Clinical Hold” means that (a) the FDA has issued an order to a Party pursuant to 21 CFR
§ 312.42 to delay a proposed Clinical Trial or to suspend an ongoing Clinical Trial of the Compound or Product in the United States or (b) a Regulatory Authority other than the FDA has issued an equivalent order to that set forth in (a) in any other country or group of countries.

“Clinical Investigator” means an individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. “Subinvestigator” includes any other individual member of that team.

2

“Clinical Trial” means any clinical trial, which is any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects, including any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial or Phase 4 Clinical Trial.

“Collaboration Clinical Trial” means any Clinical Trial that is set forth in, and conducted under, the Global Development Plan.

“Commercialization” means with respect to a pharmaceutical product, any and all activities directed to the marketing, promotion, importation, distribution, pricing and reimbursement approval, offering for sale, and sale of such pharmaceutical product, and interacting with Regulatory Authorities regarding the foregoing, but excluding, Development and Manufacturing. “Commercialize” and “Commercializing” have a correlative meaning.

“Commercially Reasonable Efforts” means, with respect to a Party and its obligations to Develop, Manufacture or Commercialize (as applicable) the Product under this Agreement, those efforts and resources commonly used in the pharmaceutical industry (which shall be no less than those efforts used by the applicable Party) for the development and commercialization of a pharmaceutical product which is at a similar stage of development or commercialization, taking into account product profile, efficacy and safety, proprietary position, including patent and regulatory exclusivity, regulatory status, including anticipated or approved labeling and anticipated or approved post-approval requirements and present and future market and commercial potential, including competitive market conditions (but not taking into account any payment owed to the other Party under this Agreement). Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party: (a) establish a plan to achieve objectives and assign specific responsibilities for the achievement of that plan and (b) make and implement decisions and allocate resources designed to advance progress with respect to such objectives.

“Company Background IP” means any Intellectual Property, owned by or licensed to Company or any of its Affiliates that is: (a) (i) owned by or licensed to Company or any of its Affiliates as of the Effective Date or (ii) created or developed by a Company Member during the Term of this Agreement but outside of Company’s performance of activities contemplated under this Agreement, including improvements thereto, without using or referencing any Partner IP, and
(b) that is provided or otherwise made available to Partner under or in connection with this Agreement.

“Company IP” means the Company Know-How, Company Patents and Company Developed IP.

“Company Know-How” means any and all Know-How to the extent Controlled by Company or any of its Subsidiaries as of the Effective Date or any time during the Term that is incorporated into, or otherwise necessary for the Partner to Develop, Commercialize or Manufacture, the Product for use in the Partner Territory, excluding any Patents filed thereon or with respect thereto. Notwithstanding the foregoing, Company Know-How shall not include any Know-How to the extent related to any components, compounds or agents that are not the Compound, or products that are not the Product.

3

“Company Member” means Company, its Subsidiaries or its or their Sublicensees or subcontractors (including, for clarity, any of its CROs).

“Company Patents” means, to the extent Controlled by Company or any of its Subsidiaries as of the Effective Date or any time during the Term, any and all Patents (a) to the extent set forth on Schedule 1; (b) to the extent Covering any Company Know-How; (c) continuations, divisionals, renewals, continuations-in-part, and patents of addition claiming priority to any Patents described in the foregoing (a) or (b) and all foreign equivalents thereof; and (d) restorations, extensions, supplementary protection certificates, reissues and re-examinations of the Patents described in the foregoing (a), (b) or (c), each of the foregoing subsections (c) and (d), to the extent the claims of such Patents are fully supported by any Patent described in the foregoing subsections (a) or (b). Notwithstanding the foregoing, Company Patents shall not include any Patents to the extent related to any components, compounds or agents that are not the Compound, or products that are not the Product.

“Company Territory” means worldwide, other than the Partner Territory.

“Completion Date” means, as to a particular Clinical Trial, the earlier of (a) the date on which the last subject in such Clinical Trial completes the last visit as described in the protocol for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.
“Compound” means TTP399, an oral, small molecule liver selective glucokinase activator. “Confidential Information” means any and all Know-How and other information or data
that is generated or collected by or on behalf of a Party Member or which one Party Member provides or otherwise makes available to any other Party Member in connection with this Agreement, whether orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, Data, designs or formulae; provided that all confidential Company IP will be deemed Company’s Confidential Information and all confidential Partner IP will be deemed Partner’s Confidential Information.

“Controlled” means, with respect to any Intellectual Property, the legal authority or right (whether by ownership, license or otherwise, but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant the applicable access to, or license or sublicense under, such Intellectual Property to the other Party pursuant to this Agreement, without breaching the terms of any agreement or other arrangement with a Third Party, or violating any Applicable Laws.

“Co-Sponsor” means, with respect to any applicable Clinical Trial under this Agreement, such Clinical Trial is being “co-sponsored” by each of Partner and Company (each, a “Co- Sponsor”), which for purposes of this Agreement shall mean that (a) Company is the Sponsor (as defined below), and (b) subject to and in accordance with 21 CFR 312.52, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions, Company has transferred to Partner, and following such transfer Partner is responsible for, certain of Company’s responsibilities (and corresponding liabilities therefor) as the Sponsor of such Clinical Trial (i.e., Partner-Conducted Clinical Trials) in accordance with, and subject to, Section 4.2(e)(ii).

4

“Cover(ed)(ing)” means, with respect to any Patent and the subject matter at issue, that, but for a license granted under a Valid Claim of such Patent, the Development, Manufacture, use, sale, offer for sale, importation or other Commercialization of the subject matter at issue would infringe such Valid Claim, or, in the case of a Patent that is a patent application, would infringe a Valid Claim in such patent application if it were to issue as a patent.

“CRF” or “Case Report Form” means the collection of documents designed specifically for recording Data pursuant to the protocol for a Clinical Trial. For clarity, a CRF is completed for each subject and will be in electronic form, validated and in compliance with all Applicable Laws.

“CRO” means a contract research organization.

“CSR” means, with respect to a Clinical Trial, a clinical study report, or other equivalent document or series of materials, constituting a summary report of the clinical and medical data resulting from such Clinical Trial and prepared for incorporation into submissions seeking Regulatory Approval for the Product, and includes all statistical analyses of such data per the Statistical Analysis Plan.

“Data” means any and all scientific, technical, test, marketing or sales data pertaining to the Product that is generated by or on behalf of any Party Member, including research data, clinical pharmacology data, pre-clinical data and clinical data.

“Development” means any and all development activities with respect to a compound or product that are directed to obtaining Regulatory Approval, including all non-clinical, preclinical and clinical testing and studies; toxicology, pharmacokinetic and pharmacological studies; statistical analyses; assay development; protocol design and development; the preparation, filing and submission of any NDA therefor; and all regulatory affairs related to any of the foregoing. “Develop” and “Developing” have correlative meanings.

“EMA” means the European Medicines Agency or any successor thereof. “EU” means the European Economic Area and Switzerland.
“Executive Officers” means the Chief Executive Officer of Company (or any other executive officer as appointed by Company) and the Chief Executive Officer of Partner (or any other executive officer as appointed by Partner).

“Exploit(ation)” means to make, have made, import, export, use, sell or offer for sale, including to research, Develop, Manufacture, export, transport, and distribute, promote, market, or have sold or otherwise dispose of and otherwise Commercialize.

“Export Control Laws” means all Applicable Laws governing the export or re-export of commodities, software, technologies, or services, including the Export Control Reform Act of 2018, 50 U.S.C. §§ 4801-4852; the Export Administration Act of 1979, 24 U.S.C. §§ 4601 et seq.; the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701 et seq.; the Trading with the Enemy Act, 50 U.S.C. §§ 1 et seq.; sections 38 and 39 of the Arms Export Control Act, 22

5

U.S.C. §§ 2778 and 2779; and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended).

“FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et seq.). “FD&C Act” means the U.S. Federal Food, Drug and Cosmetic Act.
“FDA” means the U.S. Food and Drug Administration or any successor thereof.

“First Commercial Sale” means, on a country-by-country basis, the first sale by a Partner Member to a Third Party for end use in such country after Regulatory Approval has been granted for the Product in such country.

“Force Majeure Event” means external acts beyond the reasonable control of the affected Party, including acts of God, fires, floods, storms, wars, earthquakes, acts of terrorism, riots or civil commotions, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, legal or government restrictions or government acts or orders (even if caused by the Sars-Cov-2 pandemic), epidemics or pandemics (excluding the current Sars-Cov-2 pandemic in and of itself).

“GAAP” means generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity, as they exist from time to time, consistently applied.

“Government Official” means (a) any elected or appointed official of any Governmental Authority (e.g., a legislator or a member of a ministry of health), (b) any employee or other Person acting for or on behalf of a Governmental Authority, a Governmental Authority department or agency, an institution or entity owned or controlled by a Governmental Authority (e.g., an HCP employed by a Governmental Authority-owned or -controlled hospital, or a Person serving on a healthcare committee that advises a Governmental Authority), or an enterprise or instrumentality performing a governmental function, (c) any candidate for public office, or officer, employee, or other Person acting for or on behalf of a political party or candidate for public office, (d) an employee or other Person acting for or on behalf of a public international organization (e.g., the United Nations, the Red Cross, or the World Bank), (e) any member of a military or a royal or ruling family or (f) any Person otherwise categorized as an official of a Governmental Authority under Law.

“HCP” or “Healthcare Professional” includes any physician, nurse, pharmacist, or other person who may administer, prescribe, purchase, or recommend pharmaceutical products or other healthcare products.

“ICH” means the International Conference on Harmonization (of Technical Requirements for Pharmaceuticals for Human Use).

“IDMC” means the independent data monitoring committee, which shall be established pursuant to the terms hereof.

6

“IFRS” means International Financial Reporting Standards of the International Accounting Standards Board or any successor entity, as they exist from time to time, consistently applied.

“IND” means (a) an Investigational New Drug Application as defined in the FD&C Act or 21 C.F.R. Part 312, or any successor application or procedure required to initiate a Clinical Trial in the United States, (b) any counterpart in any country other than the United States and (c) all supplements and amendments to any of the foregoing.

“Initial Clinical Trials” means those Collaboration Clinical Trials for Development of the Initial Product.

“Initial Product” means that certain pharmaceutical product that is formulated as a tablet for oral administration and contains either four hundred (400) or eight hundred (800) milligrams of the Compound as the sole active pharmaceutical ingredient to the extent administered in a Clinical Trial, or approved, for treatment of Type 1 diabetes.

“Intellectual Property” means all Patents, Trademarks, Know-How, registered designs, design rights, copyrights (including rights in computer software), domain names, rights in databases and any and all other intellectual property and proprietary rights in any country or regulatory jurisdiction throughout the world, whether registered or not, together with all applications and registrations therefor.

“Investigator’s Brochure” means the written document containing a brief description of the drug substance and formulation of the Product, a summary of the pharmacological and toxicological effects of the Product in animals and human nonclinical models, a summary of the pharmacokinetics and biological disposition of the Product in animals and humans, a summary of information relating to safety and effectiveness of the Product in humans obtained from prior clinical studies, and a description of possible risks and side effects to be anticipated on the basis of prior experience with the Product under investigation or with related drugs.

“IPR Claim” means any Third Party Claim alleging Development or Commercialization of the Product by or on behalf of any Partner Member infringes, misappropriates or otherwise violates any Patent or Know-How owned by any Third Party.

“IRB” means institutional review board, or its equivalent.

“Know-How” means all technical, scientific, regulatory and other information, results, knowledge, techniques and data, in whatever form and whether or not confidential, patented or patentable, including inventions, invention disclosures, discoveries, plans, processes, practices, methods, knowledge, trade secrets, know-how, instructions, skill, experience, ideas, concepts, data (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, and preclinical and clinical data), formulae, formulations, compositions, specifications, marketing, pricing, distribution, cost, sales and manufacturing data or descriptions. Know-How does not include Patents claiming any of the foregoing.

“Knowledge” means the actual knowledge of the executive officers of Company or Partner, as applicable, as listed on Schedule 2.

7

“Losses” means liabilities, expenses and losses, including personal injury or death of any person, property damage, including reasonable legal expenses and attorneys’ fees.

“Manufacture” means all activities related to making, having made, production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of any compound or product, including process development, testing method development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. “Manufactured” and “Manufacturing” have correlative meanings.

“Material Safety Issue” means a Party’s good faith belief that there is an unacceptable risk for harm in humans based upon (a) preclinical safety data, including data from animal toxicology studies or (b) the observation of serious adverse effects in humans after dosing the Product.

“NDA” means a New Drug Application, as defined in the FD&C Act or 21 C.F.R. Part 314 or any foreign equivalent thereof.

“Net Sales” means the gross amounts billed or invoiced by any Partner Member for sale of the Product, less the following deductions, without duplication, to the extent allocable to the Product and invoiced or otherwise directly incurred in accordance with IFRS and Partner’s usual and customary accounting practices:

(a)trade discounts, returns, credits or allowances,

(b)credits or allowances additionally granted on account of rejections, returns, recalls (unless caused by its gross negligence or willful misconduct) or billing errors, commissions,

(c)import/export or other custom duties, reasonable prepaid outbound freight expenses, insurance and other transportation costs incurred in transporting the applicable Product,

(d)sale taxes, VAT, and other governmental charges (other than taxes on the income or capital of Partner),

(e)government mandated rebates,

(f)refunds and rebates for spoiled, damaged, outdated, rejected or returned Product or as otherwise required by Applicable Laws, and

(g)amounts that are actually written off as non-collectible for the sale of the Product after Partner Members’ commercially reasonable best efforts to collect such amounts.

In the case of any sale of the Product for non-cash consideration, Net Sales shall be calculated as the fair market price of the Product in the applicable country of sale or disposal. Sales of the Product between Partner and other Partner Members for resale shall be excluded from

8

the computation of Net Sales, but the subsequent resale of the Product to a Third Party shall be included within the computation of Net Sales.

The supply of the Product as samples, for use in nonclinical, preclinical, or clinical trials, or for use in any test or studies reasonably necessary to comply with any Applicable Laws, or as is otherwise normal and customary in the industry, shall not be included in the computation of Net Sales, so long as Partner Members do not receive consideration of monetary value for the Product.

“Novo Agreement” means that certain Agreement Concerning Glucokinase Activator Project, by and between Novo Nordisk A/S (“Novo”) and vTv Therapeutics, Inc. (f/k/a TransTech Pharma, Inc., “vTv Inc.”), dated as of February 20, 2007, as amended from time to time.

“Partner Background IP” means any Intellectual Property, owned by or licensed to any Partner Member that is: (a) (i) owned by or licensed to Partner or any Partner Member as of the Effective Date or (ii) created or developed by Partner or a Partner Member during the Term of this Agreement but outside of Partner’s performance of activities contemplated under this Agreement, in both cases including any improvements thereto, without using or referencing any Company IP, and (b) that is provided or otherwise made available to Company under or in connection with this Agreement.

“Partner-Conducted Clinical Trial” means any Collaboration Clinical Trial to be conducted by Partner pursuant to this Agreement.

“Partner-Conducted Initial Clinical Trial” means the Initial Clinical Trial to be conducted by Partner pursuant to this Agreement.

“Partner IP” means the Partner Know-How, Partner Patents and Partner Developed IP, including Partner Background IP.

“Partner Know-How” means any and all Know-How to the extent Controlled by Partner or any of its Affiliates as of the Effective Date or any time during the Term that is necessary or reasonably useful for the Development, Manufacture, or Commercialization of the Product.

“Partner Member” means Partner, its Affiliates or its or their Sublicensees or subcontractors (including, for clarity, any of its CROs).

“Partner Patents” means any and all Patents to the extent Controlled by Partner or any of its Affiliates as of the Effective Date or any time during the Term that is necessary or reasonably useful for the Development, Manufacture or Commercialization of the Product.

“Partner Territory” means those countries set forth on Schedule 3.

“Party Member” means, in the case of Partner, any Partner Party Member, and in the case of Company, any Company Member.

“Patents” means patents, patent applications, and all related continuations, continuations- in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof.

9

“Phase 1 Clinical Trial” means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR § 312.21(a).

“Phase 2 Clinical Trial” means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR § 312.21(b).

“Phase 3 Clinical Trial” means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR § 312.21(c).

“Phase 4 Clinical Trial” means any post-marketing approval clinical study, whether initiated by a Party or at the request of any Governmental Authority, to delineate additional information about the Product’s risks, benefits, and optimal use.

“Product” means any pharmaceutical product containing the Compound as an active ingredient, alone or in combination with other active ingredients, in any formulation or dosage form and for any mode of administration for treatment of any and all indications and uses in humans and animals.

“Purchase Agreement” means that certain Common Stock Purchase Agreement, dated as of the Effective Date, by and among vTv Inc., G42 Investments AI Holding RSC Ltd and, solely for purposes of Sections 5.3, 5.11 and Section 6 thereof, Group 42 Holding Limited.

“Regulatory Approval” means any and all approvals of any applicable Regulatory Authority required to commence commercial sale of the applicable product in the applicable country or regulatory jurisdiction, including approval of an NDA in the United States and pricing and reimbursement approval where required.

“Regulatory Authority” means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given country or regulatory jurisdiction, including the FDA and EMA.

“Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to the Product other than Patents, including rights similar to those conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity) and in the EU under Directive 2001/83/EC.

“Regulatory Filing” means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications and authorizations (or waivers) with respect to the testing, Development, Manufacture or Commercialization of a compound or product made to or received from any Regulatory Authority in a given country or regulatory jurisdiction, including any INDs, NDAs and labels.

“Right of Reference” shall have the meaning set forth in 21 C.F.R. § 314.3(b) or equivalents thereto under Applicable Laws in jurisdictions outside the United States.
10

“Sponsor” has the meaning set forth in Title 21 CFR Part 312, Subpart D, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions.

“Sublicensee” means any permitted sublicensee of Partner under Section 2.2 or Company under Section 2.6.

“Subsequent Clinical Trial” means any Collaboration Clinical Trial set forth in the Global Development Plan that is not an Initial Clinical Trial.

“Subsidiary” means, with respect to a specified Person, any corporation or other Person of which securities or other interests having the power to elect a majority of that corporation’s or other Person’s board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person (other than securities or other interests having such power only upon the happening of a contingency that has not occurred) are held by the specified Person or one or more of its Subsidiaries.

“Third Party” means any Person other than (a) in the case of Company, any Subsidiary of Company and (b) in the case of Partner, any Affiliate of a Party.

“Third Party Claim” means any claim, demand, action or other proceeding brought by any Third Party.

“Trademarks” means trade names, brand names, trade dress, logos, slogans, trademarks and service marks and all other indicia of origin (whether registered or unregistered), and registrations, applications for registration, renewals and extensions thereof, together with all translations, adaptations, combinations and derivations thereof and all goodwill associated therewith.

“U.S.” or “United States” means the United States of America, including its territories and possessions.

“Valid Claim” means (a) a claim of an issued and unexpired Patent that has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal or (b) a claim of a pending patent application that has not been revoked, cancelled, withdrawn, or abandoned or finally disallowed without the possibility of appeal or refiling of such application.

1.1Additional Definitions.    The following table identifies the location of definitions set forth in various Sections of the Agreement:

						
	Acquiror	Section 15.5(b)

	Acquisition Transaction
	Section 15.5(b)

	Agreement	Preamble
	Alliance Manager
	Section 3.1

	Annual Limitation
	Section 4.6(b)

	Arbitral Tribunal
	Section 15.11(d)

11

						
	Auditor	Section 9.4

	Clinical Investigator Meeting
	Section 4.3(c)(i)

	Clinical Trial Agreement
	Section 4.3(b)(i)

	Clinical Trials Database
	Section 4.5(c)(i)

	Clinical Trials Master File
	Section 4.5(d)

	CMO	Section 7.2(a)

	Collaboration Protocol
	Section 4.2(d)(ii)

	Commercial Supply Agreement
	Section 7.3(a)

	Company	Preamble
	Company Abandoned Patent
	Section 10.2(b)(iii)

	Company Developed IP
	Section 10.1(b)(i)(3)

	Company Indemnifiable IPR Claim
	Section 12.1(b)

	Company Indemnitee
	Section 12.2

	Company-Conducted Clinical Trials
	Section 4.2(e)(i)

	Compliance Policies
	Section 11.1(h)

	Data Management Plan
	Section 4.5(b)(i)

	Database Lock
	Section 4.10(a)

	Delivery	Section 7.2(c)

	Disclosing Party
	Section 13.1

	Dispute	Section 15.11(b)

	Effective Date
	Preamble
	Election Notice
	Section 10.2(b)(iii)

	Final Partner-Conducted Clinical Trial CSR
	Section 4.11(c)

	Financial Disclosure Form
	Section 4.3(b)(ii)

	Finished Product
	Section 7.2(a)

	FTO Analysis
	Section 10.4

	Global Development Plan
	Section 4.2(a)

	Global Trademarks
	Section 6.6(c)(i)

	IDMC Charter
	Section 4.8(c)(i)

	Indemnifying Party
	Section 12.3(a)

	Indemnitee	Section 12.3(a)

	Indemnity Notice
	Section 12.3(a)

	Informed Consent
	Section 4.3(e)(i)

	Insights	Section 2.2(b)

	JDC	Section 3.2

	LCIA	Section 15.11(b)

	Local Trademark
	Section 6.6(c)(ii)

	Manufacturing Agreement
	Section 7.3(c)

	Material Breach by Company
	Section 12.1(a)

	Material Breach by Partner
	Section 12.2

	Monitoring Plan
	Section 4.7

	New York Courts
	Section 15.11(j)

	Non-Conforming Product
	Section 7.2(d)(i)

	Parties	Preamble
	Partner	Preamble

12

						
	Partner Commercialization Plan
	Section 6.2

	Partner Developed IP
	Section 10.1(b)(ii)

	Partner Indemnitee
	Section 12.1(a)

	Partner Site
	Section 4.3(b)(i)

	Partner Territory Infringement
	Section 10.3(a)

	Party	Preamble
	Pharmacovigilance Agreement
	Section 5.8

	Prosecuting Party
	Section 10.2(a)

	Prosecution Activities
	Section 10.2(a)

	Quality Agreement
	Section 7.2(a)

	Recipient	Section 13.1

	Regulatory Meeting
	Section 5.2(a)

	Rejection Period
	Section 7.2(d)(i)

	Royalty Rate
	Section 8.1(a)

	Royalty Term
	Section 8.1(b)

	Site	Section 4.3(b)(i)

	Statistical Analysis Plan
	Section 4.5(f)

	Subject Recruitment Plan
	Section 4.3(d)

	Sunshine Reporting Laws
	Section 11.1(d)

	Term	Section 14.1(a)

	Third Party Infringement
	Section 10.3(b)

	Trademark Infringement Claim
	Section 10.6(a)(i)

	Trademark Searches
	Section 6.6(c)(i)

	Transfer of Responsibilities
	Section 4.2(e)(ii)

	UNCITRAL Rules
	Section 15.11(b)

1.2Construction. Any reference in this Agreement to a “Section,” “Exhibit” or “Schedule” refers to the corresponding Section, Exhibit or Schedule of or to this Agreement, unless the context indicates otherwise. The table of contents and the headings of Sections are provided for convenience only and are not intended to affect the construction or interpretation of this Agreement. All words used in this Agreement are to be construed to be of such gender or number as the circumstances require. The words “including,” “includes” or “include” are to be read as listing nonexclusive examples of the matters referred to, whether or not words such as “without limitation” or “but not limited to” are used in each instance. Where this Agreement states that a party “shall,” “will” or “must” perform in some manner or otherwise act or omit to act, it means that the party is legally obligated to do so in accordance with this Agreement. Any reference to a statute is deemed also to refer to any amendments or successor legislation as in effect at the relevant time. Any reference to a contract or other document as of a given date means the contract or other document as amended, supplemented and modified from time to time through such date. Any words (including capitalized terms defined herein) in the singular will be held to include the plural and vice versa and words (including capitalized terms defined herein) of one gender will be held to include the other gender as the context requires. The terms “hereof,” “herein” and “herewith” and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. All references to any period of days will be deemed to be to the relevant number of calendar days unless otherwise specified.  All references herein to “$” or dollars will refer to United States dollars, unless
13

otherwise specified. All accounting terms not otherwise defined herein have the meanings given to them in accordance with GAAP.

Section 2.    Grant of Licenses.

2.1Licenses Granted to Partner. Subject to the terms and conditions of this Agreement, during the Term, Company hereby grants to Partner:

(a)an exclusive (even as to Company, except to the extent expressly set forth herein), sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.2 and 4.17), non-assignable (except to the extent permitted in Section 15.5) license under the Company IP to use, promote, market, sell, offer for sale, import into, distribute and otherwise Commercialize (but not to Develop or Manufacture) the Product for use for those indications for which Partner is granted Regulatory Approval in the Partner Territory in accordance with the terms hereof, solely within the Partner Territory;

(b)a non-exclusive, sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.2 and 4.17), non-assignable (except to the extent permitted in Section 15.5) license under the Company IP to Develop (but not to Manufacture or Commercialize) the Product in the Company Territory solely in accordance with, and subject to, the Global Development Plan;

(c)an exclusive (even as to Company), sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.2 and 4.17), non-assignable (except to the extent permitted in Section 15.5) license under the Company IP to Develop (but not to Manufacture or Commercialize) the Product in the Partner Territory solely in accordance with, and subject to, the Global Development Plan; and

(d)an exclusive (even as to Company, except to the extent expressly set forth herein), sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.2 and 4.17), non-assignable (except to the extent permitted in Section 15.5) license under the Company IP to Manufacture (but not to Develop or Commercialize) the Product in the Partner Territory solely for commercial sale of such Product in the Partner Territory (such commercial sale, for clarity, solely in accordance with, and subject to, Section 2.1(a)).

2.2Sublicenses.

(a)Partner shall have the right to grant sublicenses under the licenses granted in Sections 2.1(a) and 2.1(d) to its Affiliates and Third Parties, in each case, without Company’s consent; provided that Partner shall not have the right to grant sublicenses to any Affiliate or Third Party, in each case, that is a Sanctioned Person or is owned or controlled (for purposes of this Section 2.2, as such term is used in and construed under Rule 405 under the Securities Act) by a Sanctioned Person.

14

(b)Partner shall have the right to grant sublicenses under the licenses granted in Sections 2.1(b) and 2.1(c) to its Affiliates and Third Parties, subject to prior written consent of the Company (such consent not to be unreasonably withheld, conditioned, or delayed and if Company fails to grant or deny such consent within seven (7) days of receipt of Partner’s request for such consent, such consent shall be deemed to be granted); provided that Partner shall not have the right to grant any sublicense to any Affiliate or Third Party that is a Sanctioned Person or owned or controlled by a Sanctioned Person. Notwithstanding the foregoing, Company hereby consents to Partner granting (i) its Affiliate, Insights Pharmaceutical Research LLC (“Insights”), a sublicense in the rights granted to Partner under Sections 2.1(b) and 2.1(c) to serve as a CRO for the purpose of the conduct of the Partner-Conducted Clinical Trials and (ii) to the extent necessary, the Sites and Clinical Investigators, appointed by either Partner or Insights, and in each case, selected in accordance with the terms of this Agreement, for the Partner-Conducted Clinical Trials; provided, in each case (in respect of the foregoing (i) and (ii)), that the sublicense agreement therefor is in writing.

(c)As soon as reasonably practicable following the Effective Date, Company shall, or shall cause vTv Inc. to, use commercially reasonable efforts to obtain a waiver from Novo with respect to the obligation set forth in Section 2.1(c) of the Novo Agreement to provide Novo with notice of sublicenses granted under the Novo Agreement; provided that, for clarity, in no event shall the foregoing require Company to agree to or make any payments or other concessions. Notwithstanding anything to the contrary herein, in the event Company is unable to obtain such waiver from Novo despite its use of commercially reasonable efforts in accordance with the foregoing, Partner must provide Company with forty-five (45) days advance written notice of each sublicense granted with respect to any licenses granted to Partner hereunder in order to ensure that Company complies with its obligations with respect thereto under the Novo Agreement.

(d)For clarity, granting a sublicense shall not relieve Partner of any obligations hereunder and Partner shall cause each of its Sublicensees to comply, and shall remain responsible for its Sublicensees’ compliance, with the terms of this Agreement that are applicable to Partner and all Applicable Laws. Sublicenses granted hereunder shall be subject to, and consistent with, the terms of this Agreement.

2.3Reserved Rights of Company.

(a)Company hereby expressly reserves: (i) rights under Company IP to exercise its rights and perform its obligations under this Agreement and (ii) all rights to practice, and to grant licenses under, the Company IP outside of the scope of the licenses granted in Section 2.1, including the right to Manufacture the Compound and Product anywhere in the world (except in the Partner Territory for commercial sale by or on behalf of Partner within the Partner Territory), Develop the Product outside the scope of the Global Development Plan in the Company Territory, and Exploit compounds and products (other than the Product within the scope of Partner’s exclusive licenses granted under Section 2.1).

(b)Partner acknowledges and agrees that nothing herein shall preclude Company from conducting research, or Development activities not set forth in the Global Development Plan, with respect to the Product in the Company Territory; provided that, during

15

the Term, Partner shall be granted rights to Data (if any) generated in connection with any such research or Development activities, solely for Partner to conduct Development in accordance with the Global Development Plan within the scope of the licenses granted in Sections 2.1(b) and 2.1(c), and Commercialize the Product for use in the Partner Territory within the scope of the license granted in Section 2.1(a).

2.4Licenses Granted to Company. Subject to the terms and conditions of this Agreement, Partner hereby grants to Company in partial consideration for the issue of certain shares in vTv Inc. to Sparkly Holdings SPV Ltd pursuant to the Purchase Agreement:

(a)an exclusive (even as to Partner), fully paid-up, royalty-free, sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.6 and 4.17), non-transferable (except to the extent permitted in Section 15.5) license under the Partner IP, to the extent necessary to use, promote, market, sell, offer for sale, import, distribute and otherwise Commercialize (but not Develop or Manufacture) the Product for use in the Company Territory;

(b)an exclusive (even as to Partner, except to the extent expressly set forth herein), fully paid-up, royalty-free, sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.6 and 4.17), non-transferable (except to the extent permitted in Section 15.5), license under the Partner IP, to the extent necessary to Develop the Product in the Company Territory; and

(c)an exclusive (even as to Partner, except to the extent expressly set forth herein), fully paid-up, royalty-free, sublicensable (provided that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under Sections 2.6 and 4.17), non-transferable (except to the extent permitted in Section 15.5), worldwide license under the Partner IP, to the extent necessary to Manufacture the Product; provided that Company may not Manufacture the Product in the Partner Territory for commercial sale in the Partner Territory.

2.5Reserved Rights of Partner. Partner hereby expressly reserves: (a) rights under Partner IP to exercise its rights and perform its obligations under this Agreement and (b) all rights to practice, and to grant licenses under, the Partner IP outside of the scope of the licenses granted in Section 2.4, including the right to develop, commercialize and/or manufacture any product other than the Product, anywhere in the world.

2.6Sublicenses. Company shall have the right to grant sublicenses under the licenses granted in Section 2.4 to its Affiliates and Third Parties, in each case, without Partner’s consent; provided that Company shall not have the right to grant sublicenses to any Affiliate or Third Party, in each case, that is a Sanctioned Person or is owned or controlled (for purposes of this Section 2.6, as such term is used in and construed under Rule 405 under the Securities Act) by a Sanctioned Person. For clarity, granting a sublicense shall not relieve Company of any obligations hereunder and Company shall cause each of its Sublicensees to comply, and shall remain responsible for its Sublicensees’ compliance, with the terms of this Agreement that are applicable to Company. Sublicenses granted hereunder shall be subject to, and consistent with, the terms of this Agreement.

16

2.7No Implied Licenses. Except to the extent expressly set forth in this Agreement, neither Party is granted any license or other right, title or interest, by implication or otherwise, in, to or under any Intellectual Property of the other Party. Each Party shall ensure that neither it, nor any of its Party Members, practices any Intellectual Property licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.

2.8Disclosure of Know-How. During the Term, Partner shall, and shall cause the Partner Members to, without additional compensation, disclose and make available to Company, in electronic form or such other form agreed upon by the Parties in writing, any Partner Know-How not previously provided to Company, promptly after the earlier of developing, making, conceiving or reducing to practice such Partner Know-How.

Section 3.    Governance.

3.1Alliance Managers. Promptly following the Effective Date, each Party shall appoint an employee with appropriate qualifications and experience to act as its alliance manager (each an “Alliance Manager”). Each Alliance Manager shall be responsible for facilitating communications between the Parties and shall act as a liaison between the Parties with respect to activities to be conducted pursuant to this Agreement. Each Alliance Manager shall be permitted to attend meetings of the JDC as a non-voting participant. Each Party may replace its Alliance Manager with another qualified employee at any time with prior notice to the other Party.

3.2Joint Development Committee. The Parties shall establish a joint development committee (the “JDC”), composed of three (3) members for each Party, to coordinate and oversee Development of the Product under the Global Development Plan and Commercialization of the Product for use throughout the Partner Territory. The JDC shall in particular:

(a)coordinate, monitor and oversee implementation of the Global 
Development Plan;
(b)provide a forum for and facilitate communications between the 
Parties with respect to the activities conducted hereunder;
(c)review and approve changes to the Global Development Plan and 
any Collaboration Protocols;
(d)monitor and coordinate the Parties’ regulatory activities, 
responsibilities and obligations hereunder, including with respect to pharmacovigilance and safety matters worldwide, as such activities, responsibilities and obligations are further set forth in the Pharmacovigilance Agreement;
(e)review and approve the Partner Commercialization Plan and any 
changes thereto;
(f)oversee the  exchange  of information  as  required  under the
Pharmacovigilance Agreement and all Applicable Laws;

17

(g)monitor and oversee Commercialization of the Product by the Partner
Members under this Agreement;
(h)provide a forum for dispute resolution as provided in Section 3.4; 
and 
(i)perform such other functions to the extent related to or in support of
this Agreement or otherwise agreed upon by the Parties in writing.

3.3JDC Membership and Meetings.

(a)JDC Members. Each JDC member shall have sufficient expertise and seniority within the applicable Party to fulfill the JDC’s responsibilities as set forth herein at the applicable time. The initial JDC members of each Party shall be appointed as soon as reasonably practicable following the Effective Date. Each Party may replace its JDC members upon written notice to the other Party; provided that each Party shall strive to maintain continuity in its JDC membership. Company shall appoint one of its JDC members to act as the JDC chairperson, which chairperson may be replaced with another Company JDC member or qualified employee in Company’s sole discretion upon written notice to Partner.

(b)Meetings. Prior to the First Commercial Sale of the Product in the Partner Territory, the JDC shall meet at least four (4) times per year (which meetings may be conducted via teleconference; provided that at least two (2) meetings per year shall be conducted by videoconference), spaced at regular intervals, unless the Parties agree otherwise. Following the First Commercial Sale of the Product in the Partner Territory, the JDC shall meet at least two (2) times per year, with such meetings spaced at regular intervals, unless the Parties agree otherwise. Either Party may call a special meeting of the JDC upon at least five (5) days’ prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting. Each Party may invite individuals who are not JDC members to participate in JDC meetings in a non-voting capacity; provided that (i) the other Party is given prior written notice thereof and in the case of any Third Party participants, grants written consent and (ii) such non-member is subject to written confidentiality and non-use obligations consistent with the terms of this Agreement. In accordance with the foregoing, Partner hereby grants Company consent for MAF representatives to participate in JDC meetings. The JDC chairperson shall prepare and circulate agendas to JDC members at least five (5) Business Days prior to each JDC meeting. The chairperson of the JDC shall circulate minutes to the JDC members within thirty (30) days from the date of the relevant meeting. Each Party shall have ten (10) Business Days from receipt to comment on and approve such minutes (such approval to be in writing and not to be unreasonably withheld, conditioned or delayed) and if such Party fails to respond within such time period, the minutes shall be deemed to have been approved by such Party.

3.4Decision-Making.

(a)All decisions of the JDC shall be made in good faith by unanimous vote, with each Party’s JDC members collectively having one (1) vote. If the JDC cannot reach an agreement as to such matter within thirty (30) days after such matter was referred to the JDC

18

for resolution, then either Party at any time may refer such issue to the Executive Officers for resolution.

(b)If the Executive Officers cannot resolve such matter within ten (10) Business Days of the date on which such matter was first referred to them by either Party’s JDC members, then:

(i)Company shall have the deciding vote on any matter that Company reasonably believes could detrimentally and materially impact in any way:

(1)the ability to obtain or maintain any Regulatory 
Approval for the Product; 
(2)the Commercialization of the Product in the 
Company Territory
(3)the Manufacture of the Compound or the Product 
by or on behalf of any Company Member;
(4)the research or Development (including any 
Collaboration Clinical Trials) of the Compound or the Product in the Company Territory or Partner Territory, including, for clarity, any revisions to the Global Development Plan and any decisions regarding (including with respect to any changes to) any Collaboration Protocol; and
(5)the scope, validity or enforceability of any 
Company IP;
(ii)Partner shall have the deciding vote on any and all matters 
solely related to the Development or Commercialization of the Product in the Partner Territory, or Manufacture by Partner of the Product for use in the Partner Territory to the extent permitted hereunder; provided in each case, that such matter does not fall under Company’s final decision-making authority pursuant to Section 3.4(b)(i); and
(iii)the status quo shall be maintained for all other matters.
(c)Notwithstanding the foregoing Section 3.4(b), neither Party shall 
have the deciding vote (as set forth in Sections 3.4(b)(i) and 3.4(b)(ii)) on, and the JDC shall not have decision-making authority regarding: (i) the imposition of any additional material obligations on the other Party (1) other than those for which it is expressly responsible hereunder, (2) that would violate any Applicable Laws or otherwise impose liability on a Party or any of its Affiliates; or (3) that would cause such Party to forgo any of its rights under this Agreement; (ii) any decision that is expressly stated to require the Parties’ mutual agreement; or (iii) any matters that would excuse the Party with the deciding vote from its obligations under this Agreement. For clarity, notwithstanding anything to the contrary herein, (x) in the event that the JDC fails to amend the Global Development Plan to include any Subsequent Clinical Trial, the Global Development Plan shall not be amended to include such Subsequent Clinical Trial and (y) in no event shall the JDC have decision-making authority with respect to the research, Development, or Commercialization

19

of the Compound or Product within the Company Territory (other than in respect of the Collaboration Clinical Trials as and to the extent expressly set forth herein) or the Manufacture of the Compound or Product in the Company Territory or Partner Territory (other than Manufacture of the Product by Partner for commercial sale in the Partner Territory).

3.5Limitations on Authority. The JDC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement. Without limiting the generality of the foregoing, the JDC shall not have the power to amend this Agreement, and no decision of the JDC may be in contravention of any terms and conditions of this Agreement.

Section 4.    Development.

4.1Overview. Subject to the terms and conditions of this Agreement, the Parties shall collaborate with respect to the Development of the Product as further described in this Section 4.

4.2Development Plan.

(a)General. Development of the Product under this Agreement shall be conducted pursuant to a comprehensive written global development plan (the “Global Development Plan”), which, when approved in writing by the JDC shall be incorporated by reference into this Agreement and shall set forth the activities to be undertaken by each Party under this Agreement to Develop the Product for use throughout the Partner Territory and Company Territory. Except as expressly stated herein, to the extent any terms or conditions of the Global Development Plan expressly conflict with the terms or conditions of this Agreement, the terms and provisions of this Agreement shall control. For clarity and notwithstanding anything to the contrary herein, in no event shall Partner or any Partner Member conduct any Development activities with respect to the Compound or the Product that are not expressly set forth in, or otherwise in compliance with, the Global Development Plan.

(b)Development Responsibilities. Subject to the terms hereof, the Global Development Plan shall allocate Development responsibilities under this Agreement for the Product between the Parties, including that Partner shall provide data management and services related to its genomic capabilities for the Partner-Conducted Clinical Trials.

(c)Initial Global Development Plan. The initial Global Development Plan shall be developed jointly by the Parties and shall set forth the Parties’ responsibilities for the Initial Clinical Trials. The JDC shall meet and agree upon such Global Development Plan as soon as reasonably practicable following the Effective Date. During the Term, any changes to the Global Development Plan, including any changes required by Applicable Laws and changes made in response to any communications with any Regulatory Authority, shall be developed jointly by the Parties and shall require the JDC’s written approval.

20

(d)Clinical Trial Protocols.

(i)Protocols. The Parties acknowledge and agree that the protocols for the Collaboration Clinical Trials shall require approval by the JDC and following such approval, shall be incorporated into the Global Development Plan.

(ii)Changes to the Protocols. Any changes to the protocol for any Collaboration Clinical Trial set forth in the then-current Global Development Plan (each, a “Collaboration Protocol”), including any country-specific appendices required by Applicable Laws and changes made in response to any communications with any Regulatory Authorities, shall require the JDC’s written approval.

(e)Sponsorship and Responsibilities.

(i)Company-Conducted Clinical Trials. As between the Parties, Company shall be the Sponsor of all Collaboration Clinical Trials that are not Partner- Conducted Clinical Trials (the “Company-Conducted Clinical Trials”). Except to the extent expressly set forth herein, as between the Parties, Company shall have sole discretion and control over the conduct of the Company-Conducted Clinical Trials.

(ii)Partner-Conducted Clinical Trials. As between the Parties, Company and Partner shall be Co-Sponsors of the Partner-Conducted Clinical Trials, and in furtherance of the foregoing, in accordance with 21 CFR 312.52, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions, Company hereby transfers the responsibilities (and all corresponding liabilities therefor) of a Sponsor to Partner for the Partner-Conducted Clinical Trials as set forth in Schedule 4 (such transfer, the “Transfer of Responsibilities”); provided, that, if designating Company as the Sponsor in furtherance of the foregoing would violate any Applicable Laws (including, by way of example, local Laws that require the Sponsor to have a presence in the applicable jurisdiction in order to be the Sponsor of a Clinical Trial with subjects in such jurisdiction), Partner shall notify Company and the Parties shall meet to discuss whether any amendments hereto are required (provided that any such amendments shall be subject to Section 15.4) to ensure that no such violation occurs. In the event required by any Regulatory Authority under 21 CFR 312.52, or any other corresponding Applicable Laws in any other countries or regulatory jurisdictions, the Parties shall prepare a separate written document documenting the Transfer of Responsibilities. In connection with the Partner- Conducted Clinical Trials, Partner shall provide Company with any information and assistance requested by Company to fulfill its obligations as a Co-Sponsor hereunder, and Partner agrees that time is of the essence with regard to the foregoing and shall take all steps necessary to comply with any such requests. Partner acknowledges and agrees that, in order to comply with its obligations as a Co-Sponsor hereunder, Company shall have the right to terminate or pause any Partner-Conducted Clinical Trial hereunder. Without limiting the foregoing, Partner shall ensure that any portion of any Partner-Conducted Clinical Trial that is conducted outside the United States complies with all Applicable Laws that are necessary or useful to obtain Regulatory Approval of the Product within the United States and the EU.

21

4.3Sites and Clinical Investigators.

(a)Selection. As between the Parties, each Party shall be responsible for selecting the study sites for the Collaboration Clinical Trials with respect to which it has responsibility under the Global Development Plan (which, for clarity, in the case of Partner, such Clinical Trials are the Partner-Conducted Clinical Trials, and in the case of Company, such Clinical Trials are Company-Conducted Clinical Trials), and will inform the JDC of each such study site; provided that, within seven (7) days of submission of such sites to the JDC, the JDC will have the right to reject any such sites proposed by Partner that the JDC determines in its reasonable judgment are not appropriate.

(b)Clinical Trial Agreement.

(i)For any Partner-Conducted Clinical Trials, Partner (or Partner Member, as applicable) shall enter into an agreement with each such study site, which agreement will be substantially in the form(s) provided by Company and consented to by Partner in writing (such consent not to be withheld except to the extent that such form violates any Applicable Laws) (the “Clinical Trial Agreement”). If a Partner Site requires any material changes to such form Clinical Trial Agreement, Partner shall provide Company with written notice thereof and such changes shall require the Company’s prior written approval. Upon execution of a Clinical Trial Agreement with any site for any Collaboration Clinical Trial, such study site shall be deemed a “Site” and any such Site for a Partner-Conducted Clinical Trial shall be deemed to be a “Partner Site.” For clarity, each Clinical Trial Agreement shall be on commercially reasonable and customary terms, consistent with industry standards for similar agreements and sufficient to enable Partner to comply with its obligations hereunder with respect to the applicable Collaboration Clinical Trial, including Sections 4.2(e), 4.6 and 5.3, the terms pertaining to ownership of Intellectual Property and publications, and treatment of Confidential Information and to enable Company to exercise its rights under Section 4.6.

(ii)The Clinical Trial Agreements for the Partner-Conducted Clinical Trials shall also require, to the extent required by Applicable Laws, that the Clinical Investigators, any Subinvestigators (including any research fellows, residents and associates) and any others required by Applicable Laws at each Partner Site, complete a financial disclosure document, which will be substantially in the form(s) provided by or on behalf of Company and consented to by Partner in writing (such consent not to be withheld except to the extent that such form violates any Applicable Laws) within seven (7) days following receipt of such form (the “Financial Disclosure Form”). For clarity, if any of the foregoing individuals that are required by Applicable Laws to complete such Financial Disclosure Form do not complete such Financial Disclosure Form, such individuals may not participate in, or do any work in connection with, the Partner-Conducted Clinical Trials.

(c)Meetings and Communications with Sites.

(i)Partner (or Partner Member, as applicable) shall conduct meetings with the Clinical Investigators of the Partner-Conducted Clinical Trials (each, a

22

“Clinical Investigator Meeting”), of which the JDC will be provided with reasonable advance written notice and to which Company (or, at Company’s option, any Company Members) shall have the right (but not the obligation) to attend and participate. Minutes of such Clinical Investigator Meetings shall promptly be made available to the JDC upon the JDC’s request.

(ii)Partner shall promptly provide the JDC with copies of all communications relevant to the Partner-Conducted Clinical Trials provided to Partner Sites and any other material communications between Partner and any individual Partner Sites.

(d)Subject Recruitment Plan. In recruiting subjects for any Partner- Conducted Clinical Trial, Partner shall comply with the subject recruitment plan for such Clinical Trial, which plan Partner shall prepare, and communicate to the JDC, for the JDC’s review and approval, within a reasonable period of time (which shall be no more than thirty (30) days) after the Effective Date (each, a “Subject Recruitment Plan”). For clarity, prior to engaging in any recruiting activities, Partner shall ensure that the applicable IRBs and/or other ethics committees approve any related materials and activities as required by the JDC and all Applicable Laws. Notwithstanding anything to the contrary herein, in the event that the JDC fails to approve such Subject Recruitment Plan in writing, the Global Development Plan shall automatically be amended to remove such Partner-Conducted Clinical Trial and for clarity, Company shall be permitted to conduct such Clinical Trial outside of the scope of this Agreement.

(e)Informed Consent.

(i)Company, with support from Partner, shall prepare the informed consent documents for use in any Collaboration Clinical Trial. Partner shall ensure that the informed consent of each subject participating in each Partner-Conducted Clinical Trial is obtained in accordance with all Applicable Laws (including, for clarity, all Applicable Laws required to obtain Regulatory Approval for the Product within the United States), including completion of such informed consent document. Such informed consent document for a Collaboration Clinical Trial shall be substantially in the form to be approved by the JDC within thirty (30) days of the Effective Date (collectively, “Informed Consent”). If a Partner Site or subject requires any material changes to such form Informed Consent, Partner shall provide Company with written notice thereof and such changes shall require the Company’s prior written approval. For clarity, the Informed Consent document that each subject executes shall expressly state that such subject understands that such Party is providing support for the Clinical Trial and shall authorize disclosure of Data and results related to such Clinical Trial to Company, Partner and each of their respective Party Members, as applicable, for any purpose, subject to all Applicable Laws; provided that (1) the Parties agree that neither Party shall provide the other Party any personally identifiable data of the subjects unless required for handling, investigating or reporting adverse events and in such case, such provision shall be subject to the terms of the Pharmacovigilance Agreement and (2) each Party’s use of any such data and results shall be subject to and in accordance with the terms hereof.

(ii)Partner shall ensure that the Informed Consent has been obtained from each subject participating in a Partner-Conducted Clinical Trial prior to

23

administration of the Product, or any placebo of the Product, to such subject in accordance with the applicable Collaboration Protocol.

(f)Inclusion and Exclusion Criteria. Partner shall not waive any exclusion or inclusion criteria specified in the Collaboration Protocol for any Partner-Conducted Clinical Trial without Company’s prior written consent.

4.4Investigator’s Brochure.

(a)As between the Parties, Company shall maintain the Investigator’s Brochure for the Product. Partner shall, promptly following receipt of written notice from Company of the need for an Investigator’s Brochure update, provide Company with all information regarding the Partner-Conducted Clinical Trials that is necessary to enable Company to update the Investigator’s Brochure.

(b)Promptly following the Effective Date, Company shall provide Partner with the most recent version of the Investigator’s Brochure for the Initial Product. Company shall also promptly provide Partner with any updated versions of such Investigator’s Brochure. Each Party shall ensure that each Site in such Party’s respective territory, and all applicable IRBs and other ethics committees, receive a copy of, and promptly receive any updates to, the Investigator’s Brochure for the applicable Product.

4.5Data Collection and Management.

(a)CRF. Partner, in consultation with Company, shall be responsible for preparing the form of CRF for the Partner-Conducted Clinical Trials in accordance with the Collaboration Protocols and Company’s CRF standards.

(b)Data Management Plan.

(i)Partner, in consultation with Company, shall be responsible for preparing the data management plan (the “Data Management Plan”) for the Partner- Conducted Clinical Trials, and the Data Management Plan for the Partner-Conducted Initial Clinical Trial shall be submitted to the JDC for its review and approval promptly following the Effective Date. Partner shall use Commercially Reasonable Efforts to comply with the Data Management Plan. For clarity, the applicable Data Management Plan must be agreed upon by the JDC prior to recruitment of subjects for the applicable Partner-Conducted Clinical Trials.

(ii)With respect to any data collected in connection with the Partner-Conducted Clinical Trials, Partner shall ensure that such data is held in one or more appropriate facilities with information security protections in accordance with all Applicable Laws, including (1) unique accounts for all operators; (2) cancellation of an account when an employee or other personnel terminates employment; (3) deactivation of an account when an employee or other personnel ceases working on the applicable Clinical Trials; (4) required password changes at frequent intervals; and (5) regular backups of electronic data.

24

(c)Clinical Trials Database.

(i)Partner, in consultation with Company, shall establish a Clinical Trials database for the purpose of hosting the data collected from each Partner Site for the Partner-Conducted Clinical Trials (the “Clinical Trials Database”). Such Clinical Trials Database shall be established by Partner for the Partner-Conducted Initial Clinical Trial promptly following the Effective Date (but, for clarity, will not be populated until the Partner-Conducted Initial Clinical Trial is conducted in accordance with the terms hereof) and Company shall be provided with access to such database (including the information therein) beginning on the date of such Clinical Trials Database’s establishment. Partner, in consultation with Company, shall promptly update the Clinical Trials Database upon any final amendments to the Collaboration Protocol, as necessary, and in accordance with this Section 4.5. Partner shall promptly update the Clinical Trials Database upon receiving data for the Partner-Conducted Clinical Trials from any Partner Site, and Partner shall use reasonable efforts to ensure that the Partner Sites, promptly following collection thereof at such Partner Site, provide data in connection with the Partner-Conducted Clinical Trials to Partner or its Affiliate, as applicable.

(ii)Partner shall provide the JDC with electronic copies of any data related to the Partner-Conducted Clinical Trials requested by the JDC at JDC meetings and in accordance with Applicable Laws.

(iii)Partner shall provide SAS datasets to Company in accordance with specifications as defined by Company (1) when fifty percent (50%) of subjects have been dosed for six (6) months (where the Collaboration Protocol provides for interim analysis); (2) when the data in the Clinical Trials Database is equivalent to one hundred percent (100%) of total data expected to be recorded in the Clinical Trials Database; (3) if a safety signal is identified; or (4) if a request is received from any applicable Regulatory Authorities, in relation to the Partner-Conducted Clinical Trials.

(iv)Partner shall maintain the Clinical Trials Database for the Partner-Conducted Clinical Trials, including ensuring that information included in the Clinical Trials Database is accurate and up-to-date.

(v)Company shall be responsible for registering, maintaining and updating any registries pertaining to the Initial Clinical Trials to the extent required by any Applicable Laws, including www.clinicaltrials.gov, www.clinicalstudyresults.org, and the PHRMA Website Synopsis.

(d)Clinical Trials Master File. Partner shall establish and maintain a Clinical Trials master file for each Partner-Conducted Clinical Trial in the format as agreed upon by the JDC (each, a “Clinical Trials Master File”), and the Clinical Trials Master File for the Partner-Conducted Initial Clinical Trial shall be established promptly following the Effective Date.

(e)Source Data Verification. Partner shall be responsible for source verification of data records with respect to the Partner-Conducted Clinical Trials, as set forth in the Monitoring Plan. At Company’s request, Partner shall provide Company with copies of any

25

reports relating to source data verification and other types of Partner-Conducted Clinical Trials audits.

(f)Statistical Analysis. The Parties shall collaborate to perform any statistical analysis required in accordance with the statistical analysis plan (“Statistical Analysis Plan”) for the Collaboration Clinical Trials. The Statistical Analysis Plan for the Collaboration Clinical Trials shall be developed by Company in consultation with the JDC. The Parties shall cooperate in good faith in carrying out the Statistical Analysis Plans.

4.6Audits; Inspection.

(a)During the term of a Partner-Conducted Clinical Trial, Company (on its own or through a Third Party) shall have the right, at its expense, to conduct quality oversight inspections and audits of the facilities (including Partner Sites) and services utilized, and activities performed, by or on behalf of Partner in connection with any Partner-Conducted Clinical Trial in accordance with its standard operating procedures and shall provide Partner with copies of such audit reports upon request, subject to Company giving to Partner no less than two (2) Business Days’ prior written notice of its intent to audit.

(b)Upon thirty (30) days’ prior written notice and during normal business hours, no more frequently than once per Calendar Year (the “Annual Limitation”), Company or any of its Affiliates, or a Third Party auditor appointed by Company and reasonably acceptable to Partner, may inspect and audit any and all records created by Partner Members in the conduct of the Partner-Conducted Clinical Trials solely for the purpose of confirming Partner’s compliance with this Agreement and Applicable Laws in the conduct of such Clinical Trials; provided that the scope of such audit is reasonable in its intended purpose. Partner agrees to make available employees of Partner and its Affiliates, and cause applicable Partner Members to make their employees available, as reasonably requested by Company, to answer Company’s reasonable questions in connection with such inspection or audit. Notwithstanding the foregoing, if Company has a reasonable, good faith belief that Partner has failed to materially comply with this Agreement or Applicable Laws in the conduct of the Partner-Conducted Clinical Trials and such reasonable, good faith belief is supported by reasonable evidence, Company shall have the right to conduct an audit and inspection described in this Section 4.6 upon thirty (30) days’ prior written notice and without regard to the Annual Limitation. All expenses of any inspection or audit requested by Company pursuant to this Section 4.6 (including the fees and expenses of any Third Party auditor engaged by Company for such purpose) shall be borne by Company. All information obtained by Company as a result of such inspection or audit shall be Confidential Information in accordance with the terms hereof. Any Third Party auditor appointed by Company pursuant to this Section 4.6 shall be subject to confidentiality obligations no less restrictive than those set forth in Section 13 with respect to such Confidential Information.

4.7Monitoring. (a) Partner shall monitor the Partner-Conducted Clinical Trials, and Company shall monitor the Collaboration Clinical Trials that it is conducting, in each case, in accordance with the monitoring plan (the “Monitoring Plan”) to ensure compliance with this Agreement and all Applicable Laws, and (b) each Party shall share information with the JDC pertaining to such monitoring, in each case (with respect the foregoing (a) and (b)) in accordance

26

with the Monitoring Plan for the Collaboration Clinical Trials (which shall be prepared by Company, in consultation with Partner, and submitted to the JDC for its review and approval).

4.8IRBs and Other Ethics Committees.

(a)Partner shall be responsible for obtaining the approval of the IRBs and other ethics committees required prior to commencing, and during, the Partner-Conducted Clinical Trials at every Partner Site. Partner shall ensure that such IRBs and such other relevant ethics committees have current registrations and accreditations as required by Applicable Laws and shall provide all ethics committees, including all IRBs, and Regulatory Authorities, with all necessary documentation prior to, and during the course of, the Partner-Conducted Clinical Trials as required by Applicable Laws.

(b)Partner shall be responsible for responding to all queries from the IRBs and other ethics committees in respect of the Partner-Conducted Clinical Trials; provided that (i) following Partner’s reasonable request, Company shall make itself reasonably available to assist with any such queries and (ii) if such query relates solely to the Company’s responsibilities or activities hereunder, Company shall prepare the applicable response and provide Partner with a copy thereof.

(c)IDMC.

(i)Company shall establish an IDMC, and the charter that governs such IDMC (the “IDMC Charter”), for the Collaboration Clinical Trials.

(ii)The Parties, via the JDC, shall ensure that the IDMC is provided with all required information and data in a timely manner as specified in the IDMC Charter.

4.9Environmental Health and Safety.

(d)In conducting the Partner-Conducted Clinical Trials, Partner shall comply with all Applicable Laws relating to environmental, health and safety matters and shall be solely responsible for establishing material and specimen handling guidelines and for ensuring use of controls, including appropriate personal protective equipment, that minimize potential worker exposure, obtaining the material safety data sheets and providing the appropriate training for workers who will be potentially exposed to the Product.

(e)Each Party shall promptly notify the JDC, in writing, of any worker claims of suspected occupational illnesses related to working with the Product, regardless of whether such claims are received during the Term or any time thereafter. After termination of this Agreement for whatever reasons, or expiration of this Agreement, each Party shall promptly notify the other Party in writing of any worker claims of suspected occupational illnesses related to working with the Product during the Term, of which it has Knowledge.

27

4.10Completion of Partner-Conducted Clinical Trials.

(a)With respect to each Partner-Conducted Clinical Trial, Partner shall use Commercially Reasonable Efforts to keep the Partner Sites operational, including continuing to dose subjects with the Product in accordance with the Collaboration Protocol, and conducting any follow-up work required, until the Completion Date for such Partner-Conducted Clinical Trial. On and following the Completion Date for each Partner-Conducted Clinical Trial, Partner shall close out such Clinical Trial in accordance with the Collaboration Protocol for such Clinical Trial, including performing any and all subject follow-up, providing Company with any and all data not provided as of such date and undertaking all activities required to lock the database (which shall occur no later than sixty (60) calendar days after the date on which the last subject in such Clinical Trial completes the last visit as described in the Collaboration Protocol for such Clinical Trial) (“Database Lock”). For clarity, copies of documents, including any CRFs and the Clinical Trials Master File, shall be transferred to Company within sixty (60) days of the Completion Date of each Partner-Conducted Clinical Trial or, at Company’s request, destroyed (provided that such destruction is in compliance with ICH guidelines and Applicable Laws). Notwithstanding the foregoing, neither Party shall provide the other Party (or its Party Members) with any personally identifiable information, unless as required under the Pharmacovigilance Agreement in relation to adverse events and as per Applicable Laws.

(b)Upon the Completion Date of a Partner-Conducted Clinical Trial, unless otherwise agreed upon by the Parties in writing, Partner, at its expense, shall return to the location specified by Company at such time, or, at Company’s option, destroy, any unused Product and placebo of Product from such Clinical Trial, and shall comply with all Applicable Laws in so returning or destroying such Product or placebo of Product.

4.11Data Results and CSRs.

(a)Within ninety (90) days of Database Lock, or any interim Database Lock, in each case, for a Partner-Conducted Clinical Trial, Partner shall promptly provide to Company (i) the analysis report, including the information, tables and value added data set, set forth in the Statistical Analysis Plan or otherwise agreed upon (including with respect to the format) by the JDC and (ii) all raw data collected for such Clinical Trial.

(b)Partner shall deliver to Company the top-line results from the Partner-Conducted Clinical Trials within ninety (90) days after Database Lock for such Clinical Trial. Such top-line results shall include the primary and secondary endpoints, as well as available safety and exposure data.

(c)The CSR, and any interim CSRs, for each Partner-Conducted Clinical Trial shall be prepared by Partner, with support from Company, in compliance with all Applicable Laws, including ICH E3 guidelines. The final, signed CSR for each Partner-Conducted Clinical Trial (the “Final Partner-Conducted Clinical Trial CSR”) shall be provided to Company promptly (but not more than ninety (90) days) following Database Lock of such Partner-Conducted Clinical Trial and any interim CSRs shall be provided to Company promptly (but no more than ninety (90) days) following the corresponding interim Database Lock for such Clinical Trial. In the event that there are any additional safety or efficacy data pertaining to a Partner-Conducted

28

Clinical Trial that come into the possession of a Partner Member after Partner has provided Company with the Final Partner-Conducted Clinical Trial CSR for such Partner-Conducted Clinical Trial, including as a result of any long-term safety monitoring which occurs or continues after the Database Lock, Partner shall promptly prepare and promptly provide Company with a supplement to such CSR.

4.12Development Reports.

(a)At each regularly scheduled JDC meeting, Partner shall provide the JDC with regular reports detailing its Development activities for the Product under the Global Development Plan, and a summary of the Data and results from such activities.

(b)In addition to the reports and notices described in Section 4.12(a), following Company’s reasonable request and subject to reasonable notice, Partner shall make its and its applicable Affiliates’ employees and any applicable Third Parties (to the extent permitted hereunder) available for an in-person, video or telephonic meeting with Company to discuss its progress with respect to its conduct of any Development activities under the Global Development Plan. Partner shall provide Company with access to the Data and results from the Partner- Conducted Clinical Trials upon Company’s reasonable request.

4.13Development Costs. Except to the extent otherwise expressly set forth herein, each Party shall bear its own costs and expenses incurred in performing Development activities under this Agreement.

4.14Diligence. Partner shall use Commercially Reasonable Efforts to conduct those Development activities that it is assigned under the Global Development Plan and, seek Regulatory Approval for the Product in one or more countries or regulatory jurisdictions in the Partner Territory.

4.15Compliance. Each Party shall Develop the Product under this Agreement in compliance with the applicable Collaboration Protocol and all Applicable Laws, including good scientific and clinical practices, cGCP, cGLP, and cGMP. For the avoidance of doubt, Partner shall ensure that the Partner-Conducted Clinical Trials are conducted in accordance with (a) 21 CFR 312.120 and 21 CFR 314.106 and shall provide Company with any and all supporting documentation required under such regulations in accordance with Section 4.16 and (b) all Applicable Laws with respect to privacy and data protections.

4.16Development Records. Partner shall maintain complete, current and accurate records of all Development activities conducted by it under this Agreement, including all Data and other information arising or otherwise resulting from such activities, including all records required under all Applicable Laws. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory (including, in the case of records maintained by Partner, as required to obtain and maintain Regulatory Approval in the Company Territory) and patent purposes and shall be made available to Company upon reasonable request.

29

4.17Use of Subcontractors.

(a)Each Party may perform its activities under the Global Development Plan through one or more subcontractors; provided that each Party complies with Section 2.2 (in the case of subcontractors engaged by Partner) or 2.6 (in the case of subcontractors engaged by Company) as if such subcontractor was a Sublicensee hereunder; provided that (i) such Party will remain responsible for performance of the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself, (ii) each subcontractor is subject to confidentiality and non-use obligations consistent with the terms of this Agreement and (iii) each subcontractor agrees in writing to assign all Intellectual Property developed in the course of performing any such work to such Party.

(b)Without limiting any other obligations of Partner hereunder, in the event that Partner is permitted to engage a Third Party in accordance with Section 2.2 to conduct any Partner-Conducted Clinical Trial (or portion thereof) or Manufacture or Commercialization of the Product pursuant to the terms hereof, Partner shall conduct due diligence and ongoing oversight with respect to such Third Party to ensure compliance with this Agreement, including that such Third Party can comply with all applicable terms and obligations of this Agreement (including the applicable Collaboration Protocol) and Applicable Laws.

Section 5.    Regulatory Activities.

5.1Regulatory Filings.

(a)General. The Global Development Plan shall set forth the regulatory strategy for seeking Regulatory Approval for the Product following completion of specified Development activities under the Global Development Plan in the Partner Territory and Company Territory. Under the oversight of the JDC and subject to Section 4 and this Section 5, each Party shall be responsible for implementing such regulatory strategy in its respective territory.

(b)INDs. As between the Parties, Partner shall use Commercially Reasonable Efforts to prepare and submit any INDs and amendments thereto for each Partner- Conducted Clinical Trial as required by Applicable Laws in the countries where Partner Sites have been selected at its sole cost and expense; provided that, if fulfilling such obligations with respect to the Partner-Conducted Clinical Trials would violate any Applicable Laws (including, by way of example, local Laws that require the submitting Person to have a presence in the applicable jurisdiction in order to submit an IND for a Clinical Trial with subjects in such jurisdiction or the Sponsor to submit the applicable IND), Partner shall notify Company and the Parties shall meet to discuss and determine whether any amendments hereto are required (provided that any such amendments shall be subject to Section 15.4). Following Partner’s reasonable request and at Partner’s expense, Company shall provide Partner with reasonable assistance with respect to preparation of the INDs for each Partner-Conducted Clinical Trial. At least thirty (30) days prior to the contemplated submission date of any such IND with respect to a Partner-Conducted Clinical Trial, Partner shall submit to Company a completed draft thereof, confer with Company thereon, and incorporate all comments provided by Company prior to submission to the applicable Regulatory Authorities. For clarity, except to the extent otherwise agreed upon by the Parties in writing, Partner shall not have the right to submit any INDs to any Regulatory Authorities with

30

respect to the Compound or the Product for any Clinical Trials that are not Partner-Conducted Clinical Trials. Partner shall reimburse Company for costs and expenses incurred by or on behalf of Company and Company Members in connection with fulfilling its obligations under this Section 5.1(b) for the Partner-Conducted Clinical Trials. For clarity, Company shall have the sole right and discretion to prepare and submit any INDs and amendments thereto for all Company- Conducted Clinical Trials and following Company’s reasonable request and at Company’s expense, Partner shall provide Company with assistance in connection therewith.

(c)Regulatory Approvals and Other Licenses. Partner will be responsible for obtaining, under its name and at its cost, any import licenses or permits for the entry of the Product into the Partner Territory. Partner shall be responsible for preparing, filing and otherwise seeking Regulatory Approval for the Product in the Partner Territory, subject to the guidance of the JDC. For clarity, Company shall retain all rights to prepare, file and otherwise seek Regulatory Approval for the Product in the Company Territory. In no event shall Company file any applications for Regulatory Approval for use of the Product outside the Company Territory, and in no event shall Partner file any applications for Regulatory Approval for use of the Product outside the Partner Territory. Without limiting Section 5.1(d), upon the written request of either Party, the other Party shall, at the requesting Party’s cost and expense, reasonably assist and cooperate with the other Party in the exercise of its rights and obligations set forth in this Section 5.1(c).

(d)Review Rights. Prior to its submission of any applications for Regulatory Approval for which it has responsibility pursuant to Section 5.1(c), Partner shall provide Company with an opportunity to review and comment on such Regulatory Filings and Company shall provide its comments thereon (if any) within sixty (60) days, or such other period of time agreed upon by the Parties in writing. In the event that a Regulatory Authority establishes a response deadline for any Regulatory Filing or material action shorter than such period, the Parties shall cooperate to ensure Company has a reasonable opportunity for review and comment within such deadlines. Without limiting Partner’s obligations under Section 11.1, the JDC shall discuss, and Partner shall incorporate, any such comments from Company (including with respect to the Product label), except to the extent in violation of any Applicable Laws. At Company’s request, Partner shall provide the Company with an English translation of the Regulatory Approval along with the original document.

5.2Meetings with Regulatory Authorities.

(a)No later than thirty (30) days before commencement of each Calendar Quarter (or as soon as reasonably practicable if Partner becomes aware following such time), Partner shall provide Company with a schedule of any meetings or teleconferences with any Regulatory Authority (or related advisory committees) planned for the next Calendar Quarter in the Partner Territory that are related to the Product (each, a “Regulatory Meeting”).

(i)In the case of any Regulatory Approval granted to Partner, and following the grant of such approval, Partner shall be responsible for any communications with the Regulatory Authorities occurring or required in connection with its regulatory responsibilities set forth in this Section 5 with respect to the Product for use in the Partner Territory, and without limiting Partner’s obligations hereunder, Company shall have the

31

right to provide input in preparation for such Regulatory Meetings and to the extent permitted by Applicable Laws, to have its representatives attend the Regulatory Meetings. Without limiting Partner’s obligations hereunder, Partner shall implement any such input from Company, except to the extent in violation of any Applicable Laws.

(ii)In the case of any IND or meetings with respect to any research or Development activities hereunder, as between the Parties, Company shall be responsible for such communications with the Regulatory Authorities occurring or required with respect to the Product, and without limiting Company’s obligations hereunder, Partner shall provide Company with any input in preparation for, or that is otherwise required for, such Regulatory Meetings and in the case of any Partner-Conducted Clinical Trials, to the extent permitted by Applicable Laws, to have its representatives attend the Regulatory Meetings.

(b)Partner further acknowledges that Company may be required to communicate with Regulatory Authorities in the Partner Territory as a result of any of its or the Company Members’ Manufacturing in or for such territory. To the extent permitted by Applicable Laws and related to Partner’s rights under this Agreement, Company shall keep Partner reasonably informed of such discussions and without limiting Company’s obligations hereunder, Partner shall have the right to provide input in preparation for such discussions or communications and to the extent permitted by Applicable Laws, to have its representatives attend any such discussions with Regulatory Authorities in the Partner Territory.

5.3Regulatory Inspections. Partner shall permit, and shall cause the other Partner Members to permit, Regulatory Authorities to conduct inspections of any Partner Member (including Partner Sites) relating to its Development, Manufacture or Commercialization of the Product upon request of any such Regulatory Authority. Partner shall promptly notify Company of any such inspection, shall supply Company with all information and correspondence related thereto and, without limiting Partner’s obligations hereunder, Company shall have the right to provide input in preparation for, and in response to, such inspection and to the extent permitted by Applicable Laws, to have its representatives attend any such inspections in the Partner Territory. Following Partner’s reasonable request, Company agrees to provide support to Partner in any such inspection and shall supply all necessary information pertinent thereto.

5.4Notification of Threatened Action. Each Party shall notify the other Party in writing within twenty-four (24) hours of any information it receives regarding any threatened or pending action, inspection or communication by any Person or Regulatory Authority with respect to the Product, including any such threatened or pending actions, inspections or communications which may affect the safety or efficacy claims of the Product or its continued Development or Commercialization under this Agreement. Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at an acceptable procedure for taking appropriate action; provided that, in the event that the Parties fail to agree, Company shall have final decision making authority.

5.5Right of Reference to Regulatory Filings.

(a)Subject to the terms and conditions of this Agreement, Company hereby grants Partner a non-exclusive, sublicensable (solely in accordance with Sections 2.2 and

32

4.17) Right of Reference, to any Regulatory Filings to the extent Controlled by Company in connection with Company’s Development activities under the Global Development Plan, solely to the extent necessary for Partner to Develop, Manufacture or Commercialize the Product for use throughout the Partner Territory, in each case, to the extent permitted hereunder.

(b)Subject to the terms and conditions of this Agreement, Partner hereby grants Company a non-exclusive, sublicensable (solely in accordance with Section 2.6 and 4.17), worldwide Right of Reference, to Regulatory Filings to the extent Controlled by Partner in connection with Partner’s Development activities under the Global Development Plan, solely to the extent necessary for Company to Develop, Manufacture and Commercialize the Product, in each case, to the extent permitted hereunder.

5.6Complaints. During the Term, each Party shall promptly forward to the other Party any complaints that it receives related to the Product. Company in the Company Territory, and Partner in the Partner Territory, shall respond to any complaints of which such Party becomes aware relating to the Product; provided that, following such Party’s reasonable written request, the other Party shall provide reasonable cooperation in connection therewith. Notwithstanding the foregoing, as between the Parties, if a complaint pertains to the Manufacturing, appearance or general physical characteristics of the Product or other processes at the manufacturing facility, the Party responsible for Manufacturing the applicable batch(es) shall be solely responsible for responding to such complaint.

5.7Recalls. Each Party shall notify the other Party in writing promptly following its determination that any event, incident or circumstance has occurred that would reasonably be expected to result in the need for a recall, market suspension or market withdrawal of the Product and shall include in such notice the reasoning behind such determination and any supporting facts. As between the Parties, Partner shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal in the Partner Territory; provided that prior to any implementation of such a recall, market suspension or market withdrawal, Partner shall consult with Company and shall reasonably consider Company’s comments in good faith. If a recall, market suspension or market withdrawal is mandated by a Regulatory Authority in the Partner Territory, as between the Parties, Partner shall initiate such a recall, market suspension or market withdrawal in compliance with Applicable Laws. For clarity, as between the Parties, Company shall have sole discretion with respect to all recalls in the Company Territory. To the extent a recall, market suspension or market withdrawal undertaken pursuant to this Section 5.7 arises due to Manufacture of a Product supplied by or on behalf of one Party to the other Party, the Party responsible for Manufacturing the applicable batch(es) shall be solely responsible for all costs and expenses related thereto. The Party with responsibility for conducting the applicable recall, market suspension or market withdrawal under this Section 5.7 shall otherwise be responsible for such costs and expenses.

5.8Pharmacovigilance Agreement. As soon as reasonably practicable following the Effective Date, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Product, including safety data sharing, adverse events reporting and safety signal and risk management (the “Pharmacovigilance Agreement”), which agreement shall be amended by the Parties from time to time to the extent necessary to comply with any changes in Applicable Laws or guidance received

33

from Regulatory Authorities. Each Party agrees not to enter into any clinical activity implicating pharmacovigilance obligations for the Product with respect to its respective Development activities under the Global Development Plan prior to execution of the Pharmacovigilance Agreement. Each Party agrees to comply, and shall cause its Party Members to comply, with its obligations under the Pharmacovigilance Agreement. In the event of any conflict or inconsistency between this Agreement and the Pharmacovigilance Agreement with respect to (a) safety-related matters, the Pharmacovigilance Agreement shall prevail and (b) any other matter, this Agreement shall prevail. Company shall maintain the global safety database for the Initial Product for so long as the Initial Product is under Development, Manufacture or Commercialization by the Parties.

Section 6.    Commercialization.

6.1General. Subject to the oversight of the JDC and the terms and conditions of this Agreement (including this Section 6), Partner shall have the sole and exclusive responsibility, for Commercializing the Product for use throughout the Partner Territory, including
(a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Product, (c) marketing and promotion, (d) booking sales and distribution and performance of related services, (e) handling all aspects of order processing, invoicing and collection, inventory and receivables, (f) providing customer support, including handling medical queries (with the Company’s technical support as reasonably requested by the Partner, and in compliance with the regulator’s requirements in the Partner Territory), and performing other related functions and (g) conforming its practices and procedures to Applicable Laws relating to the promotion, sales and marketing, access, and distribution of the Product.

6.2Commercialization Plan. Reasonably in advance of (but in no event less than sixty (60) days prior to) the anticipated First Commercial Sale of the Product for use in a country or regulatory jurisdiction in the Partner Territory, Partner shall provide the JDC with a Commercialization plan that sets forth its anticipated Commercialization activities for the Product throughout the Partner Territory, for the JDC’s review and approval (the “Partner Commercialization Plan”). On an annual basis (or more frequently if material changes are made to such plan), Partner shall update the Partner Commercialization Plan and will provide each such updated Partner Commercialization Plan to the JDC for its review and approval.

6.3Diligence. During the Term, Partner shall use Commercially Reasonable Efforts to Commercialize the Product for all indications for which Regulatory Approval is granted in the Partner Territory.

6.4Commercial Updates. Partner shall update the JDC at each regularly scheduled JDC meeting regarding its Commercialization activities with respect to the Product in the Partner Territory. Each such update shall be in a form to be agreed by the JDC and shall summarize Partner Members’ significant Commercialization activities with respect to the Product in the Partner Territory, and shall contain at least such information at such level of detail reasonably required by Company to determine Partner’s compliance with its diligence obligations set forth herein. Such updates shall include, on a country-by-county basis, Partner Members’ sales and marketing activities.

34

6.5Standards of Conduct. Partner shall, and shall cause applicable Partner Members to, perform all Commercialization activities with respect to the Product throughout the Partner Territory in a professional and ethical business manner and in compliance in all material respects with Applicable Laws.

6.6Coordination of Commercialization Activities.

(a)Generally. The Parties recognize that their collaboration may benefit from the coordination of certain activities in support of the Commercialization of the Product in both the Partner Territory and the Company Territory. As such, the Parties, through the JDC, may coordinate Commercialization strategies for the Product (e.g., for branding and messaging, international congresses, advisory boards), and without limiting its obligations hereunder (including as set forth in this Section 6 and Section 11.1), Partner shall conduct Commercialization activities for the Product in the Partner Territory in a manner consistent with such global strategy.

(b)Promotional Materials. Company may provide promotional materials for use by the applicable Partner Members in performing Partner’s obligations hereunder. Partner shall, and shall cause applicable Partner Members to, share their promotional materials for the Product with the JDC on a regular basis (for any materials not yet shared, no less frequently than each meeting of the JDC), and without limiting Partner’s obligations under Section 6.5, the JDC shall have the right to review and comment on any of the Partner Members’ promotional materials prior to their use in the Partner Territory, which comments shall be considered in good faith by Partner. If any such promotional materials are originally created in a language other than the English language, then at Company’s request and at Company’s expense, Partner shall provide an English translation along with the original materials to the JDC. Partner shall, and shall ensure that all applicable Partner Members, comply with Applicable Laws with respect to the use of promotional materials for the Product in the Partner Territory. Insofar as claims are allowed or authorized for the Product in Partner’s Territory that are not so authorized where Company sells the Product, Partner agrees to work with Company in good faith and to take such reasonable action as is necessary to help ensure the claims made in Partner’s Territory are not imputed to other jurisdictions.

(c)Branding.

(i)Global Trademarks. It is the Parties’ intent to maintain consistent global branding for the Product to the extent permitted by Applicable Laws. To the extent such consistent global branding is permitted under Applicable Laws, Company shall own all Trademarks related to the Product and associated domain names in and outside the Partner Territory (collectively, the “Global Trademarks”). Subject to Section 10.6(a)(i), as between the Parties, Company, shall be responsible for conducting Trademark searches (“Trademark Searches”), selecting, registering, prosecuting, defending and maintaining the Global Trademarks worldwide at its sole cost and expense; provided, that any costs or expenses incurred in connection with conducting Trademark Searches shall be borne equally between the Parties. As between the Parties, Company or its Subsidiary shall own all right, title, and interest in and to the Global Trademarks, all corresponding Trademark applications and registrations thereof, and all common law rights

35

thereto. All goodwill of the business associated with or symbolized by the Global Trademarks shall inure to the benefit of Company or its Subsidiary (as applicable). Partner acknowledges Company’s (or its Subsidiary’s, as applicable) exclusive ownership of the Global Trademarks in accordance with the foregoing and agrees not to take any action inconsistent with such ownership.

(ii)Local Trademarks. If Company provides Partner with written notice that it is not obtaining a Global Trademark for the Product in any country or regulatory jurisdiction in the Partner Territory, or otherwise grants Partner prior written consent, Partner shall have the right to select an alternate Trademark (and associated domain names) for use with the Product in the Partner Territory (each, a “Local Trademark”) in consultation with, and subject to the prior written approval (not to be unreasonably withheld, conditioned or delayed) of, Company. Partner shall be responsible, at its sole cost and expense, for developing, searching, filing, registering, maintaining, defending and enforcing the Local Trademarks. As between the Parties, Partner shall own all right, title and interest in and to the Local Trademarks, all corresponding Trademark applications and registrations thereof, and all common law rights thereto. All goodwill of the business associated with or symbolized by the Local Trademarks shall inure to the benefit of Partner. Company acknowledges Partner’s exclusive ownership of the Local Trademarks in accordance with the foregoing and agrees not to take any action inconsistent with such ownership.

(d)Use of Trademarks. Partner shall only promote, market, sell, offer for sale, import, distribute and otherwise Commercialize the Product in the Partner Territory under the applicable Global Trademark or Local Trademark, alone or in combination with Partner’s G42 logo.

(e)Commercialization in Company Territory. For clarity, as between the Parties, Company shall have the exclusive right to Commercialize the Product in the Company Territory at its own cost and expense, with or without Third Party(ies).

(f)Ex-Territory Sales. Subject to Applicable Laws, neither Party shall engage in any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product located outside of its territory or accept orders for the Product from or sell the Product into such other Party’s territory for its own account, and, if a Party receives any order for the Product in the other Party’s territory, it shall refer such orders to the other Party, to the extent it is not prohibited from doing so under Applicable Laws.

(g)Export Monitoring. Each Party shall use commercially reasonable efforts to monitor and prevent exports of the Product from its own territory for Commercialization in the other Party’s territory using methods permitted under Applicable Laws that are commonly used in the industry for such purpose (if any), and shall promptly inform the other Party in writing of any such exports of the Product from its territory, and any actions taken to prevent such exports. Each Party agrees to use commercially reasonable efforts as permitted by Applicable Laws to take reasonable actions requested in writing by the other Party to prevent exports of the Product from its territory for Commercialization in the other Party’s territory.

36

Section 7.    Manufacture and Supply.

7.1Supply, Generally. The Parties acknowledge and agree that, as between the Parties, Company shall have the sole right to Manufacture the Product for Development.

7.2Clinical Supply.

(a)Obligations. Solely for purposes of use in the Development activities hereunder, Company shall, itself or through any of its Subsidiaries or a Third Party (any such Third Party, a “CMO”), use Commercially Reasonable Efforts to supply Partner the Product for dosing subjects in the Partner-Conducted Clinical Trials as set forth in the Global Development Plan and placebo of such Product, in finished form (“Finished Product”) in the quantities, and subject to the timeline, set forth in the Global Development Plan and in accordance with an applicable quality agreement to be entered into by the Parties prior to supply of the Finished Product (the “Quality Agreement”). To the extent Company is unable to meet the quantities or timeline set forth in the Global Development Plan, as between the Parties, Company shall endeavor to supply Finished Product on a pro rata basis such that each Party shall receive a percentage of Finished Product equal to the percentage of dosage units of Finished Product administered by such Party or its Party Members, as applicable, during the previous Calendar Quarter as compared to the aggregate dosage units of Finished Product administered by both Parties and their applicable Party Members during such Calendar Quarter; provided that in the event Company’s inability to meet the quantities or timeline set forth in the Global Development Plan occurs during the first Calendar Quarter following the Effective Date, Finished Product shall be allocated between the Parties in a manner which would reasonably cause the least disruption to the Parties’ Development activities hereunder, as determined by Company using its reasonable business judgment, on a good faith basis. Partner shall use, and shall cause all applicable Partner Members to use, all Finished Product supplied by Company under this Section 7.2 solely to conduct Development in the Partner Territory in accordance with the terms of this Agreement and the Global Development Plan.

(b)Price. Finished Product supplied by Company for Development use in the Partner-Conducted Initial Clinical Trial will be supplied at a total cost of two thousand five hundred dollars ($2,500) per subject (including any VAT, if applicable), regardless of whether such subject is dosed with the Initial Product or placebo. Along with each shipment of Finished Product, Company will invoice Partner, and Partner shall pay each such invoice within thirty (30) days after receipt thereof. Price of supply of the Finished Product for any other Partner-Conducted Clinical Trials or Development activities conducted hereunder shall be agreed upon by the Parties in writing prior to commencement of such Partner-Conducted Clinical Trial.

(c)Product Delivery. Subject to Section 5.1(c), risk of loss and damage for, and title to, Finished Product supplied under this Section 7.2 shall pass to Partner on Delivery of the Finished Product. Company (itself or through any of its Subsidiaries or CMO) shall deliver the Finished Product DDP Abu Dhabi, or any other location that the Parties mutually agree upon in writing, (Delivery Duty Paid) INCOTERMS 2020 at the delivery location (as designated by the Partner) (the “Delivery”).

37

(d)Acceptance and Non-Conforming Finished Product.

(i)In the event that any Finished Product supplied by Company to Partner under this Section 7.2, at the time of Delivery by Company pursuant to Section 7.2(c), is damaged, or shipment documentation including certificates of origin as required by applicable Governmental Authorities is missing or incomplete, or such Finished Product does not otherwise conform to the specifications therefor (as set forth in the Quality Agreement) (“Non-Conforming Product”), as soon as reasonably practicable following Partner’s request, Company shall, at its cost, replace such Non-Conforming Product, and Partner shall, at Company’s option and expense, return to Company or dispose of such Non-Conforming Product; provided, however, that Partner shall have notified Company in writing of the Non-Conforming Product before the earliest of (1) thirty (30) days after Delivery of such Finished Product, (2) five (5) days before the applicable Company Member is obligated to notify the CMO that manufactured such Finished Product of any non-conformity (provided that Partner has reasonable prior notice of such time periods), or (3) Partner’s use of such Finished Product for any purpose (such period, the “Rejection Period”). If Partner does not notify Company in writing within the Rejection Period of such Non-Conforming Product, then Partner shall be deemed to have accepted the applicable Finished Product. Such replacement of Non-Conforming Product shall be Partner’s sole remedy and Company’s sole liability for Company’s supply of Non- Conforming Product.

(ii)If Partner notifies Company of any Non-Conforming Product in writing within the Rejection Period therefor, and Company disagrees that the applicable Finished Product is Non-Conforming Product and the Parties fail to resolve such disagreement within thirty (30) days after Company’s receipt of Partner’s written notice (or any applicable shorter period), then Company shall have the right to have a qualified independent third party laboratory test such Product to determine whether or not it so conforms. The determination of such tests shall be binding upon the Parties for all purposes hereunder; provided that if such tests are unable to determine whether or not such rejected Finished Product is Non-Conforming Product, such Finished Product shall be deemed to not be Non-Conforming Product. The expenses of the analysis or testing will be borne by the Party against which the laboratory rules.

(e)Use of the Product.

(i)Partner shall (1) only use Finished Product supplied by or on behalf of Company for the sole purpose of conducting the Partner-Conducted Clinical Trials in accordance with the respective Collaboration Protocols and (2) ensure subject dosing compliance per the respective Collaboration Protocols for such Clinical Trials.

(ii)For each dose administered to a subject in a Partner-Conducted Clinical Trial, Partner shall implement procedures and ensure that records are maintained specifying the date and time that such dose of the Finished Product is administered, the amount of the Finished Product administered to such subject, the lot number of the Finished Product from which such dosage came, and the number of the subject to which such dosage

38

was administered.    Partner shall provide copies of such records to Company upon Company’s reasonable request.

7.3Commercial Supply and Manufacturing.

(a)Commercial Supply By Company. As soon as reasonably practicable after completion of the Initial Clinical Trials, Partner shall notify Company in writing if it would like Company to supply Partner Members with Initial Product for commercial sale in the Partner Territory and, in the event such notice has been provided, the Parties shall meet to negotiate in good faith the terms of a supply agreement (the “Commercial Supply Agreement”) and related quality agreement, pursuant to which a Company Member (which may be its CMO) shall supply Partner with the Initial Product for Commercialization in accordance with the terms hereof. The Parties acknowledge and agree that such Commercial Supply Agreement shall specify that the Initial Product shall be supplied to Partner at a price equal to Company’s cost of goods as set forth in such Commercial Supply Agreement.

(b)Commercial Supply By Partner. Partner shall promptly notify Company in the event that a Partner Member plans to Manufacture the Product in accordance with the rights expressly granted to Partner hereunder and, at Company’s option, the Parties shall meet to negotiate in good faith the terms of a Commercial Supply Agreement and related quality agreement, pursuant to which a Partner Member (which may be its CMO) shall supply Company with the Product for Commercialization outside of the Partner Territory in accordance with the terms hereof. The Parties acknowledge and agree that such Commercial Supply Agreement shall specify that the Product shall be supplied to Company or any Company Member, as applicable, on terms at least as favorable to Company as those under which Partner supplies the Product to a Third Party that is not an Affiliate.

(c)Manufacturing by Partner. As soon as reasonably practicable following Partner notifying Company in writing of its intention to Manufacture the Products as per Section 7.3(b), the Parties shall meet to negotiate in good faith the terms of a manufacturing agreement and related quality agreement (the “Manufacturing Agreement”), pursuant to which Company shall use Commercially Reasonable Efforts to provide Partner with the Compound and eCTD for the Product in accordance with the terms thereof.

Section 8.    Financial Provisions.

8.1Royalty Payments.

(a)Royalty Rate. Subject to this Section 8.1, during the Royalty Term, Partner shall make non-creditable royalty payments to Company on the Net Sales of the Product sold in the Partner Territory at a royalty rate of eight percent (8%) (the “Royalty Rate”).

(b)Royalty Term. Royalties shall be paid on a country-by-country basis in the Partner Territory from the First Commercial Sale of the Product in such country by or on behalf of a Partner Member until the latest of (i) expiration of the last-to-expire Valid Claim of the Company Patents Covering the Product in such country, (ii) the expiration of any Regulatory Exclusivity covering the Product in such country or (iii) ten (10) years after the First Commercial Sale of the Product in such country (the “Royalty Term”).

39

(c)Royalty Reductions. If the Applicable Laws in a particular country or regulatory jurisdiction require a royalty reduction after the expiration of the relevant Patents in such country or regulatory jurisdiction, and the Royalty Term for a particular Product in such country or jurisdiction remains in effect pursuant to Section 8.1(b), then the Royalty Rate shall be reduced by twenty percent (20%) for the Product in such country (e.g., a reduction from eight percent (8%) to six percent (6%)) during the remainder of the Royalty Term that extends beyond expiration of the relevant Patents.

8.2Company Payments to Third Party. Company shall be solely responsible for all payments, including royalties and milestone payments, due with respect to the Novo Agreement; provided that, notwithstanding anything to the contrary herein, Partner shall cooperate with Company to provide Company (at Company’s cost and expense) with any information and documentation that Company reasonably requests to fulfill its obligations under the Novo Agreement, subject to the obligations of confidentiality and non-use set forth in the Novo Agreement. For clarity, Partner shall be responsible for all other amounts owed by Partner to Third Parties with respect to its exercise of any rights granted hereunder.

Section 9.    Payment; Records; Audits.

9.1Payment; Reports. Royalty payments payable under Section 8.1 shall be calculated and reported for each Calendar Quarter. All royalty payments due under Section 8.1 shall be paid net sixty (60) days after the end of each Calendar Quarter and shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Product in the Partner Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including the number of Products sold, the gross sales and Net Sales of Products (including the deductions from gross sales to arrive at Net Sales), the royalties payable, the exchange rates used and any adjustments to royalties in accordance with Section 8.1.

9.2Exchange Rate; Methods of Payment. All payments hereunder shall be payable in U.S. Dollars. Wherever it is necessary to convert currencies for Net Sales invoiced in a currency other than the U.S. Dollar, such conversion shall be made into U.S. Dollars at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last Business Day of the applicable Calendar Quarter or, if such rate is unavailable, a substitute therefor reasonably selected by the Parties. All payments owed under this Agreement shall be made by wire transfer to a bank and account designated in writing by the Party entitled to receive such payment, unless otherwise specified in writing by such Party.

9.3Taxes.

(a)Taxes on Income. Each Party shall be solely responsible for the payment of (and all liabilities with respect to) all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.

(b)Tax Cooperation. Each Party and its Affiliates shall be entitled to deduct and withhold from any amounts payable pursuant to this Agreement such amounts that are required to be deducted and withheld under any provision of Applicable Laws. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or

40

similar obligations in respect of any payments made by Partner to Company under this Agreement. To the extent Partner is required by Applicable Laws to deduct and withhold taxes on any payment to Company, Partner shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Company an official tax certificate or other evidence of payment of such taxes that is reasonably satisfactory to Company. Company shall provide Partner any tax forms that may be reasonably necessary in order for Partner to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty or Applicable Laws. Company shall use reasonable efforts to provide any such tax forms to Partner in advance of the due date.

(c)Taxes Resulting from Partner’s Action. Partner represents and warrants that, as of the Effective Date, Partner is not required by Applicable Laws to deduct or withhold taxes on any amounts payable to Company under this Agreement. If, pursuant to Applicable Laws, Partner is required to withhold taxes on any payment made to Company under this Agreement, then the sum payable by Partner (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Company receives a sum equal to the sum which it would have received if no taxes were required to be deducted and withheld under Applicable Laws. The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty or similar agreement that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement.

9.4Records; Audit. Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of royalty and other payments payable under this Agreement. Each Party shall keep such books and records for at least five (5) years following the Calendar Year to which they pertain or such longer period required by Applicable Laws. Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the “Auditor”) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of confirming Net Sales and the corresponding payments made, or required to be made, by or to the audited Party pursuant to this Agreement. Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit. Such audits may occur no more often than once each Calendar Year and not more frequently than once with respect to records covering any specific period of time. Each Party shall only be entitled to audit the books and records from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. The Auditor shall not disclose the audited Party’s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement. In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within thirty (30) days after the Auditor’s report. The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment or overpayment was more than seven and one half percent (7.5%) of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.

41

9.5Late Payments. In the event that any payment due under this Agreement is not paid within fifteen (15) days of when due in accordance with the applicable provisions of this Agreement, without limiting any rights or remedies hereunder, the payment shall accrue interest from the date due at the lesser of six percent (6%) per annum or the maximum rate under Applicable Laws.

Section 10.  Intellectual Property.

10.1Ownership.

(a)Background IP. Subject to the rights and licenses expressly granted under this Agreement, as between the Parties, Company shall retain all rights, title and interest in, to and under any and all Company Background IP and Partner shall retain all rights, title and interest in, to and under any and all Partner Background IP.

(b)Developed IP.

(i)As between the Parties, Company shall own any and all:

(1)Patents and Know-How discovered, invented or otherwise created solely by or on behalf of a Company Member in the course of exercising Company’s rights or performing its obligations hereunder;

(2)Patents and Know-How discovered, invented or otherwise created by or on behalf of either Party, its Affiliates, its licensees or its Sublicensees (to the extent applicable) solely or jointly together with the other Party, its Affiliates, its licensees or its Sublicensees (to the extent applicable), to the extent related to the Compound or Product; and

(3)Patents and Know-How discovered, invented or otherwise created jointly by or on behalf of Partner or any of its Affiliates, its licensees or its Sublicensees, on the one hand, and Company or any of its Affiliates, licensees or Sublicensees, on the other hand, in the course of exercising its rights or performing its obligations hereunder (such Intellectual Property described in the foregoing (1) through (3), explicitly excluding the Partner Background IP, being referred to as the “Company Developed IP”).

(ii)As between the Parties, Partner shall own any and all Patents and Know-How discovered, invented or otherwise created solely by or on behalf of a Partner Member (to the extent applicable) in the course of exercising the rights that it is granted hereunder or that it retains as specified herein or otherwise; provided that such Intellectual Property is not Company Developed IP (“Partner Developed IP”).

(iii)For clarity, for purposes of this Agreement, inventorship will be determined in accordance with United States patent Laws (regardless of where the applicable activities occurred).

42

(c)Assignment. To the extent that a Party Member is assigned or otherwise obtains ownership of any right, title, or interest in or to any Intellectual Property in contravention of the foregoing (i) or (ii), such Party hereby assigns, and shall cause its Party Member to assign, to the other Party all such right, title and interest.

10.2Patent Prosecution and Maintenance.

(a)Subject to Section 10.2(b), as between the Parties, Company, in the case of the Company IP, and Partner, in the case of the Partner IP (each, a “Prosecuting Party”), shall have the exclusive right to (i) prosecute and maintain, at its expense, all pending and new Patent applications included within such Intellectual Property and (ii) respond to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties against the issuance of such Patents (“Prosecution Activities”).

(b)Patents Exclusively Licensed to Partner.

(i)Existing Patent Applications. With respect to any Patents that have been filed, but have not issued, as of the Effective Date and are exclusively licensed to Partner hereunder in any country or regulatory jurisdiction in the Partner Territory, the Company shall remain responsible for all costs of prosecuting such Patent application following the Effective Date, subject to Section 10.2(b)(iii).

(ii)New Patent Applications. If, at any time during the Term, Company decides to file any Patent applications that have not been filed as of the Effective Date and, upon filing, would be exclusively licensed by Company to Partner hereunder in any country or regulatory jurisdiction in the Partner Territory, Company shall notify the JDC at the next scheduled JDC meeting and the JDC members shall discuss in good faith the countries and regulatory jurisdictions in the Partner Territory in which such application will be filed.

(1)In the event that, for any such Patent application, the JDC members (or the Executive Officers) agree on any countries or regulatory jurisdictions (without either Party exercising its final decision making authority under Section 3.4(b)(i) or Section 3.4(b)(ii) if and to the extent applicable), then Company shall have the sole right to file such Patent applications in such countries and jurisdictions and the Parties shall share equally (on a 50-50 basis) the costs of filing and prosecuting such Patent applications, subject to Section 10.2(b)(iii).

(2)In the event that, for any such Patent application, the JDC members and Executive Officers do not agree on any such countries or regulatory jurisdictions (without either Party exercising its final decision making authority under Section 3.4(b)(i) or Section 3.4(b)(ii) if and to the extent applicable), then Partner shall have the right to notify the Company in writing that, notwithstanding such failure to agree, Partner would like Company to file such Patent application in one or more of such countries or regulatory jurisdictions. If Partner provides such written notice within ten (10) Business Days of the JDC meeting when such matter is first discussed, then Company shall file such Patent

43

application, in Company’s name, in such countries and regulatory jurisdictions identified in Partner’s notice at Partner’s sole cost and expense, subject to Section 10.2(b)(iii).

(iii)Issued Patents. In the event that Company elects, in any country or regulatory jurisdiction in the Partner Territory, not to continue to maintain an issued Patent exclusively licensed to Partner hereunder with respect to a country or regulatory jurisdiction in the Partner Territory (such Patent, a “Company Abandoned Patent”) without the intent to pursue substantially similar subject matter in a continuation or divisional filing or an equivalent thereof, it shall notify Partner of such election in writing at least forty-five (45) days prior to any filing or payment due date, or any other due date that requires action (“Election Notice”). Following receipt of an Election Notice, and if requested by Partner, (1) Company shall and hereby does assign to Partner its right, title and interest in and to such Company Abandoned Patent in such country or regulatory jurisdiction (as applicable), and (2) upon the effective date of such assignment (A) Partner may continue maintenance of such Company Abandoned Patent in such country or regulatory jurisdiction at its sole cost and expense, in which case (B) Partner hereby grants Company a nonexclusive license to such Company Abandoned Patent for all uses other than those within the scope of the exclusive licenses granted to Partner with respect to such Patent under Sections 2.1(a), (c) and (d). For clarity, any such Company Abandoned Patent shall not constitute a Company Patent hereunder, except with respect to Section 8.1(b).

(c)Cooperation. With respect to any Patents exclusively licensed to a Party that is not the Prosecuting Party, such Party will provide reasonable assistance to the Prosecuting Party, at the Prosecuting Party’s expense, in connection with the Prosecution Activities, where such assistance shall include providing reasonable access to relevant Persons and executing all documentation reasonably requested by the Prosecuting Party.

10.3Third Party Infringement.

(a)Notice. Partner will promptly notify Company in writing of (i) any actual or threatened infringement, misappropriation, other violation, or challenge to the validity, scope or enforceability by a Third Party of any Company IP in the Partner Territory of which it becomes aware (“Partner Territory Infringement”) and (ii) any allegation by a Third Party that any of such Third Party’s Intellectual Property is infringed, misappropriated, or otherwise violated by the Development, Commercialization, or other Exploitation of the Product in the Partner Territory of which it becomes aware.

(b)Company Control. Company shall have the first right (but not the obligation), at its own expense and by counsel of its own choice, to control enforcement of the Company IP against any actual or threatened infringement, misappropriation or other violation, or challenge to the validity, scope or enforceability by a Third Party, including any Partner Territory Infringement (“Third Party Infringement”). Prior to commencing any suit, action or proceeding with respect to a Partner Territory Infringement to the extent reasonably practicable, Company shall reasonably consult with Partner and shall consider Partner’s timely recommendations regarding the proposed suit, action or proceeding, except to the extent delay may reasonably result in the loss of rights by or otherwise adversely impact Company.

44

(c)Partner Control. Partner shall have the right (but not the obligation) to control, at its own expense and by counsel of its own choice, enforcement of the Company IP against any Partner Territory Infringement (i) if Company provides Partner with written notice that it is not exercising its right to control such enforcement, or (ii) if Company fails to initiate, or file the relevant response to, (as applicable) a suit, action or proceeding with respect to such Partner Territory Infringement prior to or upon the earlier of (1) expiration of the ninety (90)-day period following first receipt by Company of written notice from Partner of such Partner Territory Infringement or (2) thirty (30) days prior to the deadline for filing, or filing the applicable response to (as applicable), such suit, action or proceeding (including suits, actions or proceedings based on a Third Party’s filing of a Paragraph IV Certification under 21 CFR §314.94(a)(12)(i)(A)(4)).

(d)Rights of Non-Controlling Party. Notwithstanding anything to the contrary herein, the Party that is not controlling the suit, action or proceeding pertaining to enforcement of the Company IP against Third Party Infringement as described in this Section 10.3 shall cooperate fully, including if required to bring such action, the provision of a power of attorney, and agrees to be joined as a party plaintiff to such suit, action or proceeding, upon the reasonable request and expense of the Party controlling such action if necessary for standing purposes. The Party that is not controlling such a suit, action or proceeding shall have the right to be represented by counsel (which shall act in an advisory capacity only, except for matters solely directed to such Party) of its own choice and at its own expense (subject to the immediately preceding sentence in this Section 10.3(d)) in any such suit, action or proceeding. To the extent reasonably practicable, the Party that is controlling such suit, action or proceeding shall give the other Party timely written notice of any proposed settlement and shall not settle, stipulate to any facts or make any admission with respect to any such Partner Territory Infringement without such other Party’s prior written consent (not to be unreasonably withheld, conditioned or delayed) if such settlement, stipulation or admission would (i) give rise to liability of such other Party or any its Affiliates, (ii) grant to a Third Party a license or covenant not to sue under any Intellectual Property that such Party or any of its Affiliates owns or has rights or (iii) otherwise impair such Party’s or any of its Affiliates’ rights under this Agreement.

(e)Recoveries. Any and all recoveries resulting from a suit, action or proceeding relating to a claim of Third Party Infringement shall first be applied to reimburse each Party’s costs and expenses in connection with such suit, action or proceeding, with any remaining recoveries allocated to the Party that controls such action, suit or proceeding in accordance with the terms hereof.

10.4Defense Actions. Prior to Commercialization of the Product by or on behalf of Partner (including by any Partner Member to the extent permitted hereunder) in each country or regulatory jurisdiction in the Partner Territory, the Parties shall cooperate in good faith to have a patent attorney that is reasonably acceptable to both Parties conduct a freedom to operate analysis (“FTO Analysis”) to determine whether Commercialization of the Product in such country or regulatory jurisdiction would be reasonably likely to become the subject of an IPR Claim (the cost and expense of any such FTO Analysis to be shared equally by the Parties) and, if based on such FTO Analysis, an IPR Claim is reasonably likely, the Parties shall promptly meet to consider the appropriate course of action. If the Product becomes the subject of an IPR Claim in a country or regulatory jurisdiction within the Partner Territory, Partner shall promptly (a) notify Company in writing and the Parties shall promptly meet to consider the IPR Claim and the appropriate course

45

of action and (b) take reasonable steps to mitigate any resulting Losses. If, in Company’s reasonable discretion, it is not commercially reasonable to procure sufficient rights to one or more Patents that are the subject of the IPR Claim, or modify the Product, to ensure that such IPR Claim is not pursued by the applicable Third Party, Partner shall, and shall cause the Partner Members, to promptly cease Exploiting the Product in such country or regulatory jurisdiction (as applicable). Notwithstanding the foregoing, following receipt of the FTO Analysis, Partner shall have the right to commence or continue Commercialization of the Product in the applicable countries or regulatory jurisdictions in the Partner Territory its sole discretion; provided that Company’s indemnification obligations under Section 12.1(b) shall not apply if the FTO Analysis identifies one or more Patents in the Partner Territory (nor shall they apply if Partner fails to comply with its obligations under the second sentence in this Section 10.4) and in each such case, Partner shall be obligated to indemnify Company in accordance with Section 12.2.

10.5Patent Term Extensions. Subject to Section 10.2(b)(iii), Company shall have the sole authority to select the appropriate Company Patents for patent term extensions, including supplementary protection certificates and any other extensions that are now available or become available in the future, for the Product in the Company Territory and Partner Territory, and shall consult with Partner with respect to such decisions for the Partner Territory and shall consider the comments and concerns of Partner in good faith. Partner shall cooperate with Company in obtaining such patent term extensions, including by signing all necessary papers.

10.6Trademarks. Partner shall comply with reasonable policies provided by Company from time to time to maintain the goodwill and value of the Global Trademarks. Partner shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in the Partner Territory to any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Global Trademarks or Local Trademarks or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Global Trademarks or Local Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Global Trademarks or Local Trademarks.

(a)Enforcement of Trademarks.

(i)Company shall have the first right, but not the obligation, at Company’s expense and by counsel of its own choice, to (1) subject to Sections 12.1(b) and 12.3, defend the Global Trademarks, including defending against any alleged, threatened or actual claim by a Third Party that the use of any Global Trademark infringes, dilutes or misappropriates any Trademark of that Third Party or constitutes unfair trade practices, or any other claims that may be brought by a Third Party against a Party in connection with the use of or relating to any Global Trademark (a “Trademark Infringement Claim”) and (2) to enforce the Global Trademarks, including taking such action as Company deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution or misappropriation of, or unfair trade practices or any other like offense relating to, any Global Trademark, it being agreed that the provisions of Sections 10.3(b), (d) and (e) shall apply; provided that, for the purpose of this

46

Section 10.6(a)(i), use of “Company IP” in Sections 10.3(b) and (d) shall be deemed to mean “Global Trademarks”.

(ii)Partner shall have the first right, but not the obligation, at Partner’s expense and by counsel of its own choice, to enforce and defend the Local Trademarks in the Partner Territory, including (1) defending against any alleged, threatened or actual claim by a Third Party that the use of any Local Trademark in the Partner Territory infringes, dilutes or misappropriates any Trademark of that Third Party or constitutes unfair trade practices, or any other claims that may be brought by a Third Party against a Party in connection with the use of or relating to any Local Trademark in the Territory with respect to the Product and (2) taking such action as Partner deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution or misappropriation of, or unfair trade practices or any other like offense relating to, any Local Trademark in the Partner Territory by a Third Party.

(iii)Each Party shall provide to the other Party all reasonable assistance requested by such Party in connection with any such action, claim or suit under this Section 10.6(a), including allowing such Party access to such other Party’s documents and to such other Party’s personnel who may have possession of relevant information.

10.7Trademark License. Subject to the terms and conditions of this Agreement, Company hereby grants to Partner an exclusive, royalty-free, limited license under the Global Trademarks solely to promote, market, sell, offer for sale, import, distribute and otherwise Commercialize the Product in the Partner Territory in accordance with the terms of this Agreement. Unless terminated in accordance with Section 14.2, such license shall be in effect, on a country-by-country basis, as long as the sale of the Product under a Global Trademark is not discontinued by Partner.

Section 11. Representations, Warranties and Covenants.

11.1Mutual Representations, Warranties and Covenants.

(a)Each Party represents and warrants to the other as of the Effective Date, and covenants, that:

(i)it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof,

(ii)it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual or individuals executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate or partnership action,

(iii)this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor 

47

violate any material law or regulation of any court or other Governmental Authority having jurisdiction over it, 
(iv)it has the right to grant the licenses granted by it under this Agreement; and 
(v)it has not, and will not during the term of such license, grant
any right to any Third Party that would conflict with the rights granted to the other Party hereunder.

(b)Each Party covenants to the other that in the performance of its obligations under this Agreement, such Party shall comply with, and shall cause its Party Members and its respective Indemnitees to comply, with all Applicable Laws. Neither Party shall, nor shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith after consultation with counsel, may violate, any Applicable Laws.

(c)Each Party hereby represents, warrants and covenants to the other Party that it is not debarred or disqualified under the FD&C Act, or any other comparable Applicable Laws in any country or jurisdiction, and it does not, and will not during the Term, employ or use the services of any Person who is debarred or disqualified, in connection with activities relating to the Product. In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to such Party, including any Party Member, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such Person to perform any such services.

(d)Each Party acknowledges that the other Party may be subject to federal, state, local and international Laws related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities (collectively, “Sunshine Reporting Laws”), and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Laws.

(e)Neither Party shall, and each Party shall ensure its respective Indemnitees and Party Members do not, directly or indirectly, including through Third Parties, (i) pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Government Official, Governmental Authority, or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, or (ii) request or accept any such improper payment or (iii) cause a violation of any Anti-Corruption Laws. For example, this includes knowingly providing any inducement for such Government Official or Person (i) to approve, reimburse, prescribe, or purchase a product, to influence the outcome of a Clinical Trial, or otherwise to benefit the Company’s business activities improperly or (ii) with the intent to influence or reward, or the effect of influencing or rewarding any Person for acting in breach of an expectation of good faith, impartiality or trust, or which it was otherwise improper for the recipient to accept. Each Party
48

represents and warrants that as of the Effective Date, none of its respective Indemnitees or Party Members have, directly or indirectly, (i) promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a Government Official, Governmental Authority or any other Person in connection with the performance of Partner’s obligations under this Agreement, (ii) requested or accepted any such improper payment or (iii) caused a violation of any Anti-Corruption Laws, and each Party covenants that its respective Indemnitees and Party Members and others acting on its or their behalf or for its or their benefit shall not, directly or indirectly, engage in any of the foregoing.

(f)Each Party shall take reasonable steps to ensure, so far as they lawfully can, that its execution and performance of this Agreement is conducted in compliance with all Applicable Laws, including Anti-Corruption Laws, Export Control Laws and Sanctions. In connection with this Agreement, neither Party shall, and each Party shall cause its respective Indemnitees and other Party Members not to, (i) violate Anti-Corruption Laws, Export Control Laws, Sanctions, or any other Applicable Laws or otherwise cause any reputational harm to the other Party or (ii) engage, directly or indirectly, in any activities or business, including any activities or business with or involving any Sanctioned Person or any Sanctioned Jurisdiction, to the extent such activities or business would be prohibited by Sanctions, Anti-Corruption or Export Control Laws if conducted by an entity formed in the United States, in a country that is a European Union member state, or in the United Kingdom.

(g)Each Party shall promptly notify the other Party in writing if it has any information or reason to believe that there may be a material actual or potential violation, or any activities or business that may cause any of its respective Indemnitees or other Party Members to be in violation, of (i) Anti-Corruption Laws, Sanctions, Export Control Laws, or any other Applicable Laws, rules or regulations in the performance of this Agreement or the Development, Manufacture or Commercialization of the Product or (ii) any of its policies and procedures relating to the foregoing.

(h)In connection with the performance of its obligations under this Agreement, each Party shall comply, and shall cause its respective Indemnitees and other Party Members to comply, with its own anti-corruption and anti-bribery policy, economic sanctions policy, export controls policy, and code of ethics (“Compliance Policies”). The Parties shall cooperate in good faith to ensure that each Party implements (to the extent necessary) and complies with a compliance program (which program shall include compliance with Compliance Policies and periodic training and shall be updated from time to time as necessary or otherwise appropriate), that is designed to ensure that such Party, its Indemnitees and Party Members comply with Section 11.1(f). Prior to commencing Commercialization of the Product in the Partner Territory or any other activities in connection with this Agreement that, if conducted improperly, could result in a breach of Section 11.1(f), Partner shall certify in writing that it has fully implemented such a compliance program (including Compliance Policies) and such program (including such Compliance Policies) is operating effectively. Each Party shall comply, and shall cause its respective Indemnitees and other Party Members to comply, with its own Compliance Policies. In connection with the performance of its obligations under this Agreement, each Party shall immediately notify the other Party in writing if it has any information or reason to believe that there may be a failure by any of its Indemnitees or other Party Members to comply with any of its

49

Compliance Policies. Partner shall maintain adequate policies, controls and systems to ensure compliance with its Compliance Policies and the requirements of this Section 11.1.

(i)Each Party agrees to maintain and enforce, at all times during the Term, (i) a system of internal accounting controls designed to ensure the making and keeping of fair and accurate books, records, and accounts with respect to any products, payments, or services provided under this Agreement (and each Party agrees, during the Term, to regularly monitor and audit its and its Party Members’ business activities to ensure compliance with its policies, the Compliance Policies, the terms of this Agreement, and the adequacy of internal controls, and implements remediation in response to identified issues) and (ii) a compliance and ethics program containing adequate systems, policies, and procedures for the detection, investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Laws, including Anti-Corruption Law, with respect to the products, payments and services under this Agreement (such policies and procedures should set out rules governing interactions with HCPs and Government Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Laws). Each Party will have the right, upon reasonable prior written notice and during regular business hours, to conduct at its own cost and expense, inspections and audits of the other Party’s books and records in the event of a suspected violation of, or to ensure compliance with the representations, warranties or covenants of this Section 11.1; provided, however, that in the absence of good cause for such inspections and audits, each Party shall exercise this right no more than once annually. Each Party acknowledges and agrees that the access rights provided in the foregoing sentence do not create or imply any obligation on the part of a Party to inspect or audit the other Party’s books, records or accounts or otherwise limit the other Party’s rights or remedies hereunder. Each Party agrees to permit, during the term of this Agreement and for five (5) years after final payment has been made under this Agreement, the other Party’s external auditors access to any of its relevant books, documents, papers, and records involving transactions related to the products, payments or services provided under this Agreement, and the audited Party agrees to cooperate fully in any audit or in connection with any investigation regarding any potential violations of Applicable Laws, including all Anti-Corruption Laws, applicable in connection with the products, payments, or services provided under this Agreement.

(j)Each Party agrees, at all times during the Term, to: (i) maintain truthful and complete documentation supporting, in reasonable detail, the work and services performed and any expenses incurred in connection with this Agreement and (ii) maintain financial books and records that timely, fairly, accurately, and completely reflect all financial transactions, in accordance with all Applicable Laws, including Anti-Corruption Laws (for example, invoices, reports, statements, books, and other records), and shall maintain such books and records during the Term and for five (5) years after final payment has been made under this Agreement.

(k)In the event either Party, its Indemnitees or other Party Members engages in, is reported to have engaged in, or there is a reasonable basis to believe may have engaged in conduct that may constitute a violation of any Anti-Corruption Laws, Sanctions, Export Control Laws and its Compliance Policies, such Party shall perform a diligent investigation of the facts of the alleged or possible violation, appropriate disciplinary and remedial action by such Party up to and including termination of employment or relationship with any Person involved in

50

the violation or any relationship obtained through improper means, and confirmation to the other Party that it has taken appropriate remedial action.

(l)Each Party shall cause its respective Indemnitees and Party Members working under its direction or control in connection with the performance of its obligations under this Agreement to submit to periodic training on compliance with Anti- Corruption, Laws, Sanctions, Export Control Laws and its Compliance Policies.

(m)Each Party shall annually certify to the other Party in writing its compliance, in connection with the performance of its obligations under this Agreement, with the representations, warranties, or covenants in this Section 11.1 in the form set forth in Exhibit A, which certification shall be issued by Party’s Executive Officer.

(n)Each Party shall have the right to immediately suspend or terminate this Agreement in its entirety, and without any further liability or obligation, in the event it has reason to believe that the other Party or any Indemnitee or Party Member of the other Party or others acting on its or their behalf or for its or their benefit has violated, is violating, or is reasonably likely to violate Anti-Corruption Laws, Sanctions, Export Control Laws, or any portion of this Section 11.1 in connection with performance of such Party’s obligations under this Agreement. In the event a Party terminates this Agreement as set forth in the foregoing sentence, the terminating Party shall not pay for, and the breaching Party shall not be entitled to receive payment on account of, any services that have been completed and not previously paid for that involved any conduct of the breaching Party that the terminating Party reasonably suspects breaches this Section 11.1, or that causes, or is reasonably likely to cause, any of the representations, warranties or covenants in this Section 11.1 not to be true and correct or to otherwise be breached, as applicable. Further, breaching Party shall be liable for damages or remedies as provided by law, and the provisions of Section 12 shall apply as applicable.

11.2Additional Representations and Warranties by Company. Company hereby represents and warrants to Partner as of the Effective Date:

(a)Company is the sole owner of the Company Patents set forth on Schedule 1 and all such Patents are subsisting, and to its Knowledge, valid and enforceable. Schedule 1 sets forth a true a complete list of the Company Patents Controlled by the Company which are related to the Compound and to the development of the Product;

(b)to its Knowledge, no Third Party is infringing, misappropriating or otherwise violating the Company IP within the Partner Territory;

(c)no claim or litigation is or has been, in the past three (3) years, pending, or to its Knowledge, threatened in writing, by any Person against Company or its Subsidiaries alleging that the Company Patents are invalid or unenforceable or that the Development of the Product in the Partner Territory infringes, misappropriates or otherwise violates any Intellectual Property of any Person;

(d)Company has used reasonable measures to protect the confidentiality of material Confidential Information included in the Company Know-How; and

51

(e)Company and its Subsidiaries have conducted any and all preclinical studies and Clinical Trials for the Initial Product in material compliance with all Applicable Laws.

11.3Additional Representations, Warranties and Covenants by the Partner. Partner hereby represents, warrants and covenants, as applicable, to Company:

(a)Partner, on behalf of itself and all Partner Members, covenants that it has obtained or will obtain written agreements from each of its and their employees, consultants and contractors who perform Development activities pursuant to this Agreement, which agreements shall obligate such Persons to obligations of confidentiality and non-use that are no less restrictive than, and to assign Intellectual Property in a manner consistent with, the provisions of this Agreement; and

(b)at all times during the Term, Partner will maintain its licenses, consents, authorizations and registrations to do business and continue to make any notifications as may be necessary or required by all Applicable Laws (including local laws, regulations, policies or administrative requirements) in order to provide the products or services encompassed within this Agreement.

11.4Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS SECTION 11, IN THE COMMERCIAL SUPPLY AGREEMENT, THE MANUFACTURING AGREEMENT OR THE PURCHASE AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, VALIDITY, ENFORCEABILITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT TO THE EXTENT EXPRESSLY SET FORTH HEREIN, AND IN RESPECT OF THE DEVELOPMENT OF THE PRODUCT, ANY ITEMS PROVIDED BY COMPANY OR ITS SUBSIDIARIES HEREUNDER ARE MADE AVAILABLE ON AN “AS IS” BASIS, WITHOUT WARRANTY WITH RESPECT TO COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED, AND EACH PARTY HEREBY ACKNOWLEDGES AND AGREES THAT SUCH ITEMS ARE EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN CHARACTERISTICS.

Section 12.  Indemnification.

12.1Indemnification by Company.

(a)Company hereby agrees to defend, indemnify and hold harmless Partner, its Affiliates and its and their respective directors, officers, employees, consultants and agents (each, a “Partner Indemnitee”) from and against any and all Losses incurred in connection with any Third Party Claims to the extent arising from or relating to: (a) the gross negligence, fraud or willful misconduct of any Company Indemnitee or other Company Member in connection with this Agreement (including in connection with the exercise any of Company’s rights or performance of any of its obligations hereunder), (b) the Material Breach by Company of this Agreement, (c) the Development, Manufacturing, use, handling, storage, Commercialization or other disposition of the Product by any Company Indemnitee or other Company Member or (d)

52

death of or personal injury to any subject of the Initial Clinical Trial (or any other Collaboration Clinical Trial for which the related Collaboration Protocol is being developed by Company, and provided to Partner) arising out of such subject’s use of the Product under any such Clinical Trial unless such death or personal injury is caused by a failure of any Partner Indemnitee or other Partner Member to comply with (i) the Collaboration Protocol, (ii) the applicable requirements in the Federal Food, Drug, and Cosmetic Act and its implementing regulations (including 21 CFR Parts 50, 54, 56, 58 and 312) and publicly-available FDA guidelines, (iii) cGCP, or (iv) any other Laws in the jurisdictions where such Collaboration Clinical Trial is being conducted, in each case, and to the extent such death or personal injury does not arise from Partner failing to comply with the terms of this Agreement; except to the extent that any of the foregoing (a) through (d) was caused by (x) the gross negligence or willful misconduct of any Partner Indemnitee or other Partner Member or (ii) material breach of this Agreement by Partner. Solely as used in this Section 12.1, “Material Breach by Company” means a material breach by Company of (1) Section 2.4(a) as a result of Company Commercializing the Product Developed under this Agreement and in accordance with the Global Development Plan outside of the Company Territory or (2) Sections 4.2 through 4.12, 4.15, 4.17, 5, 7.2, 7.3, 10.1(c), 11.1, 11.2, or 13, which in each case has not been cured within sixty (60) days of Partner providing written notice to Company of such material breach (provided that, in the case of any such breach that is cured in accordance with the foregoing, Losses that are indemnifiable hereunder shall include those Losses that arise as a result of such breach (whether such Losses arise prior to or after the date on which such breach is cured)).

(b)Subject to Partner’s obligations under Section 12.2(d), Company hereby agrees to defend, indemnify and hold harmless the Partner Indemnitees from and against fifty percent (50%) of all Losses incurred in connection with any IPR Claim or Trademark Infringement Claim; provided that (i) such Patents that are the subject of the IPR Claim were not identified by the FTO Analysis or such Trademarks that are the subject of the Trademark Infringement Claim were not identified or flagged by the intellectual property counsel or other intellectual property specialist in connection with the Trademark Search in the Partner Territory, as applicable and in the case of any IPR Claim, Partner complies with the second sentence of Section 10.4 and (ii) such infringement, misappropriation or other violation is not caused by, nor did it arise out of, Partner’s or any Partner Member’s failure to comply with the terms hereof or in the case of misappropriation of trade secrets, any action or omission by any Partner Member (subject to the remainder of this Section 12.1(b), each, a “Company Indemnifiable IPR Claim”). Notwithstanding the foregoing, Company shall not be obligated to indemnify the Partner Indemnitees as described in this Section 12.1(b) (i) to the extent the foregoing was caused by (x) the gross negligence or willful misconduct of any Partner Indemnitee or other Partner Member or
(y) material breach of this Agreement by Partner or (ii) if Partner fails to comply with its obligations in Section 10.4. For clarity, (i) Partner shall be responsible for the remaining fifty percent (50%) of Losses incurred in connection with any Company Indemnifiable IPR Claim, for which Partner shall reimburse Company on a quarterly basis within sixty (60) days of Company providing Partner with an invoice for Losses incurred during the applicable Calendar Quarter and
(ii) for purposes of Section 12.3, Company shall be the Indemnifying Party for any IPR Claim in respect of which Company has indemnification obligations under this Section 12.1(b).

12.2Indemnification by Partner. In addition to, and not in lieu of, Partner’s indemnification obligations under Section 10.4, Partner hereby agrees to defend, indemnify and hold harmless Company, its Affiliates and its and their respective directors, officers, employees,

53

consultants and agents (each, a “Company Indemnitee”) from and against any and all Losses incurred in connection with any Third Party Claims to the extent arising from or relating to: (a) the gross negligence, fraud or willful misconduct of any Partner Indemnitee or other Partner Member in connection with this Agreement (including in connection with the exercise any of Partner’s rights or performance of any of its obligations hereunder), (b) the Material Breach by Partner of this Agreement, (c) subject to Company’s obligations under Section 12.1(a)(d), death of or personal injury to any subject of any Partner-Conducted Clinical Trials caused by a failure of any Partner Indemnitee or other Partner Member to comply with (i) the Collaboration Protocol,
(ii) the applicable requirements in the Federal Food, Drug, and Cosmetic Act and its implementing regulations (including 21 CFR Parts 50, 54, 56, 58 and 312) and publicly-available FDA guidelines, (iii) cGCP, (iv) use, handle, store, distribute or dispose of the Finished Product provided for use in any Clinical Trials hereunder according to the specifications for the Product, cGMP and current good distribution practices or (iv) any other Applicable Laws in the jurisdictions where such Partner-Conducted Clinical Trials are being conducted, (d) any IPR Claim or Trademark Infringement Claim to the extent not a Company Indemnifiable IPR Claim or (e) any Partner Indemnitee’s or other Partner Member’s use of any (1) Intellectual Property in material breach of this Agreement or (2) Local Trademark; except to the extent that any of the foregoing
(a) through (e) was caused by (x) the gross negligence or willful misconduct of any Company Indemnitee or other Company Member or (y) material breach of this Agreement by Company. Solely as used in this Section 12.2. “Material Breach by Partner” means (1) a material breach by any Partner Indemnitee or other Partner Member of (i) Sections 2.1(a) or 2.1(d) as a result of Commercializing or Manufacturing the Product outside of the Partner Territory, (ii) Sections 2.1(b) or 2.1(c) as a result of Developing the Product outside the scope of the Global Development Plan or (iii) Sections 2.2, 2.8, 4.2, 4.3, 4.5 through 4.12, 4.15, 4.16, 4.17, 5, 6.2, 6.4, 6.5, 6.6, 7.2(e), 10.1(c), 11.1, 11.3, or 13, which in each case has not been cured within sixty (60) days of Company providing written notice to Partner of such material breach (provided that, in the case of any such breach that is cured in accordance with the foregoing, Losses that are indemnifiable hereunder shall include those Losses that arise as a result of such breach (whether such Losses arise prior to or after the date on which such breach is cured)) or (2) a failure of Partner to pay all amounts due and payable under Section 8.1 at the time such amounts have become due and payable.

12.3Indemnification Procedures.

(a)If a Company Indemnitee or Partner Indemnitee (“Indemnitee”); provided that, solely for purposes of Section 11, “Indemnitee” shall mean (i) Company, its Subsidiaries and its and their respective directors, officers, employees, consultants and agents and
(ii) Partner Indemnitees) learns of any Third Party Claim that a Party (“Indemnifying Party”) may be obligated to indemnify hereunder, such Indemnitee shall notify (“Indemnity Notice”) such Indemnifying Party in writing, describing such claim in reasonable detail as promptly as practicable (and in any event within fifteen (15) calendar days) after becoming aware of such claim. Failure to give an Indemnity Notice shall not relieve the Indemnifying Party of its indemnification obligations hereunder, except to the extent that such Indemnifying Party is materially prejudiced by such failure.

(b)An Indemnifying Party has the right to elect to assume direction and control of the defense (including the right to settle claims for monetary compensation), at its own

54

cost and by its own counsel (which shall be reasonably satisfactory to the Indemnitee), any Third Party Claim; provided that the Indemnifying Party shall not be entitled to defend such claim, and shall pay the reasonable fees and expenses of one separate counsel for all Indemnitees, if such claim for indemnification relates to or arises in connection with any criminal action, indictment or allegation. Within thirty (30) calendar days after the Indemnity Notice (or sooner, if the claim requires), the Indemnifying Party shall notify the Indemnitee in writing if it is elects to assume direction and control of the defense and, in such event, the Indemnitee shall entrust its defense to the Indemnifying Party in the context of the Third Party Claim and may employ separate counsel to take advice from (but not control) such claim at its sole cost and following the Indemnifying Party’s reasonable request and at the Indemnifying Party’s cost, shall reasonably cooperate with the Indemnifying Party in the prosecution or defense thereof. If the Indemnifying Party fails to provide an election notice in accordance with the foregoing, or the Indemnifying Party is not permitted to defend the claim in accordance with the first sentence of this Section 12.3(b), the Indemnitee may defend such claim at the Indemnifying Party’s cost and for clarity, it shall not be a defense to such obligation to pay such costs that the Indemnifying Party was not consulted in the defense thereof, that such Indemnifying Party’s views or opinions as to the conduct of such defense were not accepted or adopted, that such Indemnifying Party does not approve of the quality or manner of the defense thereof or that such Third Party Claim was resolved by reason of a settlement rather than by a judgment or other determination of liability.

(c)Unless the Indemnifying Party fails to assume defense of a Third Party Claim, or the Indemnifying Party is not permitted to defend the claim in accordance with the first sentence of Section 12.3(b), the Indemnitees may not settle or compromise any Third Party Claim without the Indemnifying Party’s prior written consent. No Indemnifying Party shall settle any Third Party Claim without the Indemnitee’s prior written consent if such settlement will (i) permit any injunction, declaratory judgment, other order or other non-monetary relief to be entered, directly or indirectly, against any Indemnitee or (ii) ascribe any fault on any Indemnitee. Without limiting the foregoing, the Indemnifying Party shall not, without prior written consent of the Indemnitee, settle any Third Party Claim or consent to the entry of any judgment which does not include as an unconditional term thereof the delivery by the claimant or plaintiff to the Indemnitee of a written release from all Losses in respect of such Third Party Claim.

12.4Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF SECTION 13, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; PROVIDED, HOWEVER, THAT THIS SECTION 12.4 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS SECTION 12.

Section 13.  Confidentiality.

13.1Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that each Party (the “Recipient”) receiving any Confidential Information of the other Party (the “Disclosing Party”) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of Disclosing

55

Party, and both Parties shall keep confidential and, subject to Sections 13.2 through 13.5, shall not publish or otherwise disclose the terms of this Agreement. Recipient may use Disclosing Party’s Confidential Information only to the extent required to exercise its rights or fulfill its obligations under this Agreement, and subject to Section 13.3, or, where Company is Recipient, the Novo Agreement, subject to compliance with the terms of Section 13.3(d). Recipient shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors and other representatives do not disclose, or use in violation of the terms hereof, the Confidential Information of the Disclosing Party. Recipient shall promptly notify Disclosing Party in writing upon discovery of any unauthorized use or disclosure of the Confidential Information of Disclosing Party. Each Party shall be responsible for any breach of this Section 13 by its Party Members and their respective Affiliates and its and their respective employees, directors and officers, and such other Persons to which a Recipient provides Confidential Information of the Disclosing Party as if such Persons were a party to this Agreement.

13.2Exceptions. The obligations of confidentiality and restriction on use under Section 13.1 shall not apply to any information that Recipient can prove by competent written evidence (a) is now, or hereafter becomes, through no act or failure to act on the part of Recipient, generally known or available to the public, (b) is known by Recipient at the time of receiving such information, as evidenced by its records, other than by previous disclosure of Disclosing Party, or its Party Members, Affiliates or its or their employees, agents, consultants, or contractors, (c) is hereafter furnished to Recipient without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right or (d) is independently discovered or developed by Recipient without the use of, or access to, Confidential Information of Disclosing Party.

13.3Authorized Disclosure. Recipient may disclose Confidential Information of Disclosing Party to the extent expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:

(a)submission of Regulatory Filings to Develop, Manufacture and Commercialize the Product and obtain Regulatory Approval for the Product to the extent expressly permitted hereunder;
(b)prosecuting or defending litigation to the extent permitted by this Agreement;
(c)complying with applicable orders of courts or other Governmental  Authorities;
(d)in the case of Company as the Disclosing Party, disclosures under and in accordance with the Novo Agreement; provided that Novo is under written obligations of confidentiality and non-use as set forth in the Novo Agreement;

(e)disclosure to its Party Members, Affiliates and its and their employees, consultants, contractors and agents, in each case on a need-to-know basis in connection with the Development, Manufacture or Commercialization of the Product in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; and
(f)disclosure to potential and actual investors, acquirors, licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; provided that such Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition or collaboration.

56

Notwithstanding the foregoing, in the event Recipient is required to make a disclosure of Disclosing Party’s Confidential Information pursuant to Section 13.3(b) or Section 13.3(c), it shall, except where impracticable, give reasonable advance written notice to Disclosing Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as Recipient would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. Any information disclosed pursuant to Section 13.3(b) or Section 13.3(c) shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Section 13.

13.4Publicity; Public Disclosures. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of any press releases or announcements relating to this Agreement, which shall be agreed in advance by the Parties prior to the issuance thereof; provided that a Party may not unreasonably withhold, condition or delay consent to such releases by more than five (5) Business Days and that either Party may issue press releases or disclosures to the SEC or other applicable Governmental Authorities as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or the rules and regulations of any applicable stock exchange. Each Party shall provide the other Party with advance written notice of legally required disclosures to the extent practicable and the Parties shall consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws; provided that each Party shall have the right to make such filings as it reasonably determines necessary under Applicable Laws.

13.5Publications. Partner may not publish or otherwise disclose any results or other Data related to this Agreement unless it obtains prior written consent from Company as per the provisions of this Section 13.5, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, written consent of Company shall not be required to publish any information that does not constitute Confidential Information. If Partner wishes to publish research papers or research reports related to the Collaboration Clinical Trials, Partner shall give Company at least forty-five (45) calendar days to review the draft contents of any publication, abstract, poster or slide deck related to such Clinical Trial before it is presented at the conferences and the draft contents of any journal article before it is submitted for publication, shall consult with the Company with respect thereto, so that the Company can review each proposed submission to identify patentable subject matter and/or any inadvertent disclosure of Confidential Information (including Confidential Information contained in any unpublished Patent application in relation to the Product) and Partner shall comply with Company’s request to delete references to its Confidential Information in any such paper or other materials. Absent any response from

57

Company within such forty-five (45) calendar day period, Partner shall be free to assume that Company has no objection to the proposed publication and shall have the right to proceed.

13.6Prior Confidentiality Agreement. As of the Effective Date, the terms of this Section 13 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the Confidentiality Agreement; provided, however, that this Section 13 shall be in addition to, and not in limitation of, the confidentiality provisions of the Purchase Agreement. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement.

13.7Equitable Relief. Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Section 13. In addition to all other remedies, a Party shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Section 13.

13.8Survival. The obligations and prohibitions contained in this Section 13 shall survive the expiration or termination of this Agreement for a period of seven (7) years; provided that, with respect to any Confidential Information that qualifies as a trade secret under Applicable Laws, such obligations and prohibitions shall survive for so long as such Confidential Information qualifies as a trade secret under Applicable Laws.

Section 14.  Term and Termination.

14.1Term.

(a)This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Section 14, shall expire upon expiration of the last Royalty Term in the Partner Territory (the “Term”).

(b)Notwithstanding anything to the contrary herein, on a country-by- country basis, upon the expiration of the Agreement in accordance with Section 14.1(a),

(i)the licenses granted to Company under Sections 2.4(a) and 2.4(c) shall be deemed to be perpetual, fully paid-up and royalty-free (except to the extent expressly set forth herein) solely with respect to the Product Commercialized by the Company in such country as of the expiration date, but shall be on a non-exclusive basis. The Parties understand and agree that such licenses exclude any license in the Local Trademarks; and

(ii)the licenses granted to Partner under Sections 2.1(a) and 2.1(d) shall be deemed to be perpetual, non-exclusive, fully paid up and royalty-free solely with respect to Products Commercialized by Partner in the Partner Territory as of the date of expiration.

58

14.2Termination for Cause.

(a)Material Breach. Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement or the Closing Note and has not cured such breach within sixty (60) days (thirty (30) days with respect to any payment breach) after written notice of such breach from the non-breaching Party.

(b)Bankruptcy. Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the Laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within sixty (60) days after the commencement thereof.

(c)Material Safety Issue. Company shall have the right to terminate this Agreement immediately upon written notice if it reasonably deems it necessary to protect the safety, health or welfare of subjects enrolled in any Collaboration Clinical Trial on the basis of a Material Safety Issue.

(d)Clinical Hold. In the event a Clinical Hold is imposed on any Collaboration Clinical Trial, the Parties shall meet to discuss the basis for the Clinical Hold, how long the Clinical Hold is expected to last, and how they might address the issue that caused the Clinical Hold. If such Clinical Hold has not been lifted ninety (90) days after such Clinical Hold has been imposed, Company shall have the right (in its sole discretion) to immediately terminate this Agreement.

(e)Sanctioned Person Termination. In the event that either Party becomes a Sanctioned Person (whether due to a Change of Control or otherwise), such Party shall immediately notify the other Party in writing and the notified Party shall have the right to terminate this Agreement upon written notice. In the event that a Sublicensee becomes a Sanctioned Person (whether due to Change of Control or otherwise), such Sublicensee shall be immediately terminated by Partner and Partner shall immediately notify Company. Either Party shall have the right to immediately suspend or terminate this Agreement in its entirety in the event a Sublicensee of the other Party becomes a Sanctioned Person and such Sublicensee is not terminated by such Party immediately after written notice received from the other Party.

14.3Effects of Termination. In the event of termination of this Agreement:

(a)Licenses.

(i)Licenses Granted to Partner.

(1)Termination    by    Company. Subject to Sections 14.3(c) and 14.3(d), in the event this Agreement is terminated by

59

Company as set forth herein, all licenses granted by Company to Partner hereunder, and sublicenses granted by Partner to any Company IP, shall automatically terminate.

(2)Termination by Partner.    Subject to Sections 14.3(c) and 14.3(d), in the event this Agreement is terminated by Partner as set forth herein, (1) the licenses granted by Company to Partner pursuant to Sections 2.1(b) and (c), and sublicenses granted by Partner under and in accordance with Sections 2.1(b) and (c), shall automatically terminate and (2) the licenses granted by Company to Partner pursuant to Sections 2.1(a) and 2.1(d), and sublicenses granted by Partner under and in accordance with Sections 2.1(a) and 2.1(d), shall be deemed perpetual solely with respect to Products Commercialized by Partner in the Partner Territory as of the effective date of termination; provided that on a country-by-country and Product-by-Product basis, upon the expiration of the Royalty Term, such licenses shall be deemed to be nonexclusive, fully paid-up and royalty-free.

(ii)Licenses Granted to Company. All licenses granted by Partner to Company under Section 2.4(b), and sublicenses granted by Company, to any Partner IP shall automatically terminate upon termination of the Agreement. All licenses granted by Partner to Company under Sections 2.4(a) and (c), and sublicenses granted by Company, to any Partner IP shall automatically terminate upon termination of the Agreement (i) by Partner in accordance with Section 14.2 or (ii) by Company on the basis of Sections 14.2(c) (Material Safety Issue) or 14.2(d) (Clinical Hold); provided that such Clinical Hold is not imposed as a result of the acts or omissions of Partner. Except as expressly set forth in the preceding sentence, upon termination of this Agreement, all licenses to Partner IP (excluding Partner Background IP) granted by Partner to Company under Sections 2.4(a) and 2.4(c) shall continue solely with respect to the Products Commercialized by the Company as of the termination date and shall be deemed to be nonexclusive, fully paid-up and royalty-free. The Parties understand and agree that such licenses set forth in the preceding sentence exclude any license to the Local Trademarks. In the event of termination of this Agreement by the Company pursuant to Sections 14.2(a), 14.2(b) or 14.2(e), Partner shall grant to Company an exclusive and royalty free license to use the Local Trademarks in the Partner Territory, solely to the extent necessary to use, promote, market, sell, offer for sale, import into, distribute and otherwise Commercialize (but not to Develop or Manufacture) the Product for a transitional period of twelve (12) months following the effective date of termination, except to the extent a longer period of time is required for approval from Regulatory Authorities for Commercialization.

(b)Transfers. In the event this Agreement is terminated by Company as set forth herein or by the Parties by mutual written agreement, Partner shall, at Company’s written request, to the extent permitted under Applicable Laws, promptly following the effective date of termination: (i) assign and transfer to Company (or its designee) all of Partner’s right, title, and interest in and to any and all Regulatory Filings (including Regulatory Approvals), and materials, in each case, to the extent related to Development or Commercialization of the Product and (ii) disclose to Company all documents embodying the foregoing that are in any Partner Member’s possession or control or that any Partner Member is able to obtain using reasonable

60

efforts. In the event of termination of this Agreement by the Company pursuant to Section 14.2(a), 14.2(b) or 14.2(e) Partner shall, at Company’s request and to the extent permissible under Applicable Laws, transfer to the Company clinical and commercial agreements (to the extent assignable and not cancelled). If any such contracts described in the foregoing sentence are not assignable to Company or its designee, but are reasonably necessary for Company to continue Development or Commercialization of the Product in the Partner Territory, then Partner shall reasonably cooperate with Company to negotiate for the continuation of such services for Company from such entity, for a reasonable period (not to exceed twelve (12) months) after termination at Company’s cost until Company establishes an alternate, validated source of such services.

(c)Development Wind-Down. The Parties shall promptly meet to prepare a close-out schedule, and Partner shall cease performing all work not necessary for the orderly close-out of its activities or obligations hereunder or required by Applicable Laws. Partner shall either, as directed by Company: (i) wind-down any ongoing Development activities (including Clinical Trials) of the Product conducted by any Partner Member in an orderly fashion or (ii) promptly transfer such Development activities to Company or its designee, in compliance with all Applicable Laws; provided that, (1) in the event of termination by Company in accordance with Section 14.2(c) or 14.2(d), Partner shall proceed as specified in clause (i) above and (2) in the event of termination by Company in accordance with Section 11.1(n) or 14.2(e), Partner shall proceed as specified in clause (ii) above. Company shall remain responsible for the costs of the activities for which it was responsible under the Global Development Plan from the effective date of termination until completion of such Clinical Trial (or early termination of such Clinical Trial by Company).

(d)Commercial Wind-Down. Except to the extent this Agreement is terminated by Company in accordance with Section 11.1(n), 14.2(c), 14.2(d) or 14.2(e) or terminated by the Partner in accordance with Section 11.1(n), 14.2(a), 14.2(b) or 14.2(e), Partner shall, as directed by Company, (i) continue certain ongoing Manufacturing (if any) and Commercialization activities of Partner Members with respect to the Product in the Partner Territory for a period of up to six (6) months as determined by Company and (ii) handoff such Manufacturing (if any) and Commercialization activities to Company or its designee, on a timetable to be set by Company, not to exceed six (6) months, and in compliance with all Applicable Laws. During such commercial wind-down period, Partner shall continue to book sales and pay royalties to Company. Except as necessary to conduct the foregoing activities as directed by Company, Partner shall immediately discontinue its (and shall ensure that Partner Members immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and use of all Global Trademarks and Local Trademarks. In addition, Partner shall immediately deliver to Company (at Company’s expense) all samples, demonstration equipment, sales and marketing materials, catalogs, and literature related to the Product in Partner’s possession or control.

(e)Transition Assistance. Partner shall use commercially reasonable efforts to seek an orderly transition of the Development, and in the event of termination of this Agreement by Company, the Manufacture (if any) and Commercialization, of the Product to Company or its designee. Except to the extent this Agreement is terminated by Partner for Company’s material breach of this Agreement in accordance with Section 14.2(a) or pursuant to

61

Section 14.2(e), without limiting any other rights of Company hereunder, (i) Company may, in its sole discretion, postpone the effective date of such termination for up to six (6) months and (ii) Partner shall, at no cost to Company, provide reasonable consultation and assistance for a period of no more than ninety (90) days after the effective date of such termination (and in any case not to exceed a total of two hundred (200) hours of working time) to transfer or transition Development, and in the event of termination of this Agreement by Company pursuant to Sections 14.2(a), (b) or (e), Manufacture (if any) and Commercialization, of the Product to Company hereunder (including the transfer of all Company Developed IP not already in Company’s possession). Such assistance does not include sharing Partner’s Background IP.

(f)Remaining Inventories. Company shall have the right, at its discretion, to purchase from Partner any or all of the inventory of the Product held by Partner as of the date of termination at a price equal to the transfer price paid by Partner to acquire such inventory from Company. Company shall notify Partner in writing within sixty (60) days after the date of termination whether Company elects to exercise such right.

(g)Confidential Information. Upon Disclosing Party’s request, Recipient shall promptly return to Disclosing Party or, at Disclosing Party’s option, destroy, all copies of the Confidential Information in Recipient’s or its Party Members’ possession and shall certify in writing as to such destruction. Notwithstanding the foregoing, Recipient (a) may retain a single copy of the Confidential Information in its legal files for the sole purpose of ascertaining its ongoing rights and responsibilities respecting such information and (b) shall not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by Recipient. Recipient shall continue to be bound by the terms and conditions of this Agreement with respect to such retained Confidential Information in accordance with Section 13.

14.4Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: Sections 2.1(a) and (d) (solely in accordance with Section 14.3(a)(i)), 2.3, 2.4 (solely in accordance with Sections 14.1(b) and 14.3(a)(ii)), Sections 4.5(b)(ii), 4.13, 4.16, 5.4 through 5.7,
8, 9, 10.1, 12, 13 (as set forth in Section 13.8), 14.1(b), 14.3 and 15.

Section 15.  General Provisions.

15.1Fees and Expenses. Except as set forth in the Transaction Documents, each Party will pay its own direct and indirect expenses incurred by it in connection with the preparation and negotiation of this Agreement and the consummation of the transactions contemplated by this Agreement, including all fees and expenses of its advisors and representatives.

15.2Notices. All notices, requests, consents and other communications under this Agreement to either Party must be in writing and are deemed duly delivered when (a) delivered if delivered personally or by nationally recognized overnight courier service (costs prepaid), (b) transmitted via e-mail (including via attached .pdf document) to the e-mail address set out below or (c) received or rejected by the addressee, if sent by United States of America certified or registered mail, return receipt requested; in each case to the following addresses or email of the

62

individual (by name or title) designated below (or to such other address, email or individual as a Party may designate by notice to the other Party):

If to Company:

vTv Therapeutics, LLC 
 Richard Nelson
3980 Premier Dr., Suite 310 High Point, NC 27265
Email:    rnelson@vtvtherapeutics.com Attention:    Chief Executive Officer

With a copy (which will not constitute notice) to:

Skadden, Arps, Slate, Meagher & Flom LLP One Manhattan West
New York, New York 10001
Email:    peter.serating@skadden.com
michael.zeidel@skadden.com Attention:    Peter D. Serating
Michael J. Zeidel

If to Partner:

G42 Healthcare
Dr. Fahed Al Marzooqi, COO
MBA UAI Campus, Madasar City, Building 1B Masdar, Abu Dhabi, United Arab Emirates 
 Email:    fahed.almarzooqi@g42.ai
G42.Legal@g42.ai 
Attention:    Dr. Fahed Al Mazooqi, COO

15.3Entire Agreement. The Transaction Documents and the Confidentiality Agreement (together with the exhibits and schedules thereto) and the other written agreements entered into between the Parties as of the date hereof, contain the entire understanding of the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the Parties acknowledge have been merged into such documents, exhibits and schedules.

15.4Amendments and Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Parties or, in the case of a waiver, by the Party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement will be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor will any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

63

15.5Successors and Permitted Assigns.

(a)Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party’s consent to (i) a wholly owned Subsidiary; provided that such Party shall remain primarily liable for any acts or omissions of such Subsidiary or (ii) to any Third Party who acquires all or substantially all of the business or assets of the assigning Party by merger, sale of assets or otherwise; provided that in no event may either Party assign or transfer this Agreement or any rights or obligations hereunder to a Sanctioned Person. Any permitted assignee shall, in writing to the non-assigning Party, expressly assume performance of such assigning Party’s rights and obligations. Any permitted assignment is binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.5 is null, void and of no legal effect.

(b)Notwithstanding anything in this Agreement to the contrary, in no event shall the Intellectual Property licensed to Partner by Company or any of its Affiliates include any Intellectual Property to the extent Controlled by any Third Party (the “Acquiror”) or any of its Affiliates that acquires all or any part of, or otherwise undergoes a Change of Control with, Company or any Affiliate of Company (any such transaction, an “Acquisition Transaction”), which Intellectual Property (i) is Controlled, immediately prior to the effective date of the applicable Acquisition Transaction, by the Acquiror or any of its Affiliates (other than, for clarity, Company or any of its Affiliates immediately prior to the effective date of the acquisition) or (ii) is Controlled by the Acquiror or any of its Affiliates (other than, for clarity, Company or any of its Affiliates immediately prior to the effective date of the acquisition) on or after the effective date of such Acquisition Transaction, but was not created using any Intellectual Property licensed from Partner pursuant to the terms hereof.

15.6No Third-Party Beneficiaries. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

15.7Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction will not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. In the event that any provision hereof would, under Applicable Laws, be invalid or unenforceable in any respect, each of the Parties intend that such provision will be construed by modifying or limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, Applicable Laws.

15.8Remedies. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement are not performed by either Party in accordance with their specific terms or were otherwise breached by such Party. Without prejudice to the dispute resolution provisions of Section 15.11, the Parties accordingly agree that, in addition to any other remedy to which the Parties are entitled at law or in equity, each Party is entitled to injunctive relief to prevent breaches of this Agreement by the other Party and otherwise to enforce specifically the provisions of this Agreement against the other Party. Each Party expressly waives

64

any requirement that the other Party obtain any bond or provide any indemnity in connection with any action seeking injunctive relief or specific enforcement of the provisions of this Agreement.

15.9Business Days. If the last or appointed day for the taking of any action or the expiration of any right required or granted in this Agreement or any other Transaction Document is not a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

15.10Construction. The Parties agree that each of them and their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting Party will not be employed in the interpretation of this Agreement or any amendments hereto.

15.11Governing Law; Venue and Dispute Resolution.

(a)All questions concerning the construction, validity, enforcement and interpretation of this Agreement will be governed by and construed and enforced in accordance with the internal procedural and substantive laws of the laws of England and Wales, without regard to the principles of conflicts of law thereof.

(b)Except for any matters to be determined in accordance with Section 3.4, any dispute, controversy, or claim arising out of or relating to this Agreement (and any subsequent amendments thereof), or the breach, termination, or validity thereof, and any question of the arbitral tribunal’s jurisdiction or the existence, scope or validity of this arbitration agreement or the arbitrability of any claim (each a “Dispute”), shall be resolved by final and binding arbitration administered by the London Court of International Arbitration (the “LCIA”), in accordance with the Arbitration Rules of United Nations Commission on International Trade Law then in effect (the “UNCITRAL Rules”), except as modified herein, with the LCIA being the appointing authority for purposes of the UNCITRAL Rules.

(c)The seat of arbitration shall be New York, New York, and the arbitration shall be conducted in the English language. The arbitration, and any decisions and awards arising thereunder, will be subject to the Federal Arbitration Act (9 U.S.C. § 1 et seq.).

(d)The arbitral tribunal shall consist of one arbitrator (the “Arbitral Tribunal”) mutually agreed by the Parties. If the Parties cannot mutually agree upon the selection of the Arbitral Tribunal within thirty (30) days of the notice of arbitration, the arbitrator shall be appointed by the LCIA.

(e)Any arbitration hereunder shall be confidential, and the Parties and their representatives agree not to disclose to any Third Party the existence or status of the arbitration or any information related thereto, except and to the extent that disclosure is required by Applicable Laws or is required to protect or pursue a legal right.

(f)In addition to monetary damages, the Arbitral Tribunal shall be empowered to award equitable relief, including an injunction and specific performance of any obligation under this Agreement.

65

(g)The award of the Arbitral Tribunal shall be final and binding upon the Parties thereto, and shall be the sole and exclusive remedy between the Parties regarding any Dispute presented to the Arbitral Tribunal. Judgment upon any award may be entered in any court having jurisdiction over any party or any of its assets.

(h)The Arbitral Tribunal shall have the power to award attorneys’ fees, costs and related expenses, as well as the costs of the arbitration, to such extent and to such Parties as it sees fit, in accordance with the UNCITRAL Rules.

(i)Nothing in this Section 15.11, shall preclude either Party from seeking interim or provisional relief from a court of competent jurisdiction including a temporary restraining order, preliminary injunction or other interim relief concerning a Dispute either prior to or during any arbitration if necessary to protect the interest of such Party or to preserve the status quo pending the arbitration proceeding.

(j)The Parties submit to the non-exclusive jurisdiction of the federal and state courts located in the Borough of Manhattan, New York County in the State of New York (the “New York Courts”), for the enforcement of any arbitral award rendered hereunder and to compel arbitration or for interim or provisional remedies in aid of arbitration. The Parties hereby unconditionally and irrevocably waive any right to stay or dismiss any such proceeding brought before the New York Courts on the basis of inappropriate or improper venue. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service will constitute good and sufficient service of process and notice thereof. Nothing contained herein will be deemed to limit in any way any right to serve process in any other manner permitted by law. Furthermore, nothing herein shall affect the Parties’ right to bring legal action or proceedings to enforce an arbitral award in any other court of competent jurisdiction.

15.12Force Majeure. Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any Force Majeure Event. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Written notice of a Party’s failure or delay in performance due to Force Majeure Event must be given to the other Party within ten
(10) days after its occurrence. All delivery dates under this Agreement that have been affected by Force Majeure Event shall be tolled for the duration of such force majeure.

15.13Interpretation. Except as expressly set forth herein, in the event of a conflict between this Agreement and the Schedules, this Agreement shall control.

15.14Counterparts and Execution. This Agreement may be executed in two or more counterparts, all of which when taken together will be considered one and the same agreement and will become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that both Parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email

66

delivery of a “.pdf” format data file, such signature will create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

(Signature Page Follows)
67

IN WITNESS WHEREOF, the Parties hereto have caused this Collaboration and License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.

vTv THERAPEUTICS LLC

By: vTv Therapeutics Inc., its managing member

By:       /s/ Richard S. Nelson                
Name: Richard S. Nelson
Title:    Interim Chief Executive Officer

[Signature Page to Collaboration and License Agreement]

IN WI1NESS WHEREOF, the Parties hereto have caused this Collaboration and License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.

vTv Therapeutics, LLC

By:            /s/                                                
Name:  Richard Nelson
Title:    Interim Chief Executive Officer Cogna Technology Solutions LLC
                  By:                /s/ Peng Xiao                               
Name:  Peng Xiao
Title:    Authorised Signatory

[Signature Page to Collaboration and License Agreement]
[

Schedule 1

Company Patents

For the avoidance of doubt, the licenses granted to Partner with respect to Company Patents under Section 2.1 are limited to the Partner Territory and expressly exclude any Patents with respect to other countries or regulatory jurisdictions unless expressly set forth in the Global Development Plan.

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS
	OWNER
	

US
	

11/453,330
	

6/14/2006
	

7,598,391
	

10/6/2009
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Issued
	vTv Therapeutics
LLC

	

US
	

12/757,217
	

4/9/2010
	

7,851,636
	

12/14/2010
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Issued
	vTv Therapeutics
LLC

	

US
	

12/942,297
	

11/9/2010
	

8,263,634
	

9/11/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Issued
	vTv Therapeutics
LLC

	

DE
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

FR
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

GB
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

AT
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

BE
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

CH
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

CZ
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

DK
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

ES
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

FI
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

GR
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

HU
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

IE
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

IT
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

NL
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

PT
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

SE
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

TR
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

AU
	

2005203930
	

1/6/2005
	

2005203930
	

2/16/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

BR
	

PI0506662-0
	

1/6/2005
	

PI0506662-0
	

5/25/2021
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

CA
	

2551324
	

1/6/2005
	

2551324
	

11/27/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

CN
	

200580002021.6
	

1/6/2005
	

ZL200580002021.6
	

1/4/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

IL
	

176257
	

1/6/2005
	

176257
	

7/31/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

IN
	

3624/DELNP/2006
	

1/6/2005
	

252466
	

5/16/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

JP
	

2006-548114
	

1/6/2005
	

4834840
	

10/7/2011
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

KR
	

10-2006-7013454
	

1/6/2005
	

10-1196313
	

10/25/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

MX
	

PA/a/2006/007667
	

1/6/2005
	

297252
	

3/21/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

RU
	

2006122209
	

1/6/2005
	

2386622
	

4/20/2010
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

ZA
	

2006/05467
	

1/6/2005
	

2006/05467
	

5/28/2008
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

HK
	

07107531.4
	

1/6/2005
	

1103074
	

8/17/2012
	HETEROARYL-UREAS AND
THEIR USE AS GLUCOKINASE ACTIVATORS
	

Granted
	vTv
Therapeutics LLC

	

NO
	

20063351
	

1/6/2005
	

337003
	

12/21/2015
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

PL
	

05700554.8
	

1/6/2005
	

1723128
	

11/7/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

JP
	

2011-103784
	

1/6/2005
	

5415477
	

11/22/2013
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

	

KR
	

10-2012-7000490
	

1/6/2005
	

10-1126225
	

3/6/2012
	HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE
ACTIVATORS
	

Granted
	vTv Therapeutics
LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS
	OWNER
	

US
	

14/071,976
	

1/5/2013
	

10,004,782
	

6/26/2018
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Issued
	vTv Therapeutics
LLC

	

US
	

15/983,249
	

5/18/2018
	

10,588,943
	

3/17/2020
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Issued
	vTv Therapeutics
LLC

	

US
	

16/744,956
	

1/16/2020
	

10,980,861
	

4/20/2021
	GLUCOKINASE ACTIVATOR
COMPOSITIONS FOR THE TREATMENT OF DIABETES
	

Issued
	vTv
Therapeutics LLC

	

EP
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

DE
	

13726933.8
	

5/15/2013
	

602013077007.7
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

FR
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR
COMPOSITIONS FOR THE TREATMENT OF DIABETES
	

Granted
	vTv
Therapeutics LLC

	

GB
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

BE
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

CH
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

ES
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

IE
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

IT
	

13726933.8
	

5/15/2013
	

2849776
	

4/21/2021
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

CA
	

2,872,021
	

5/15/2013
			GLUCOKINASE ACTIVATOR
COMPOSITIONS FOR THE TREATMENT OF DIABETES
	

Published
	vTv
Therapeutics LLC

	

CN
	

201380024802.X
	

5/15/2013
			GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Published
	vTv Therapeutics
LLC

	

JP
	

2015-512779
	

5/15/2013
	

6234443
	

11/2/2017
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

MX
	

MX/a/2014/013105
	

5/15/2013
	

360304
	

10/29/2018
	GLUCOKINASE ACTIVATOR
COMPOSITIONS FOR THE TREATMENT OF DIABETES
	

Granted
	vTv
Therapeutics LLC

	

HK
	

15103235.2
	

5/15/2013
			GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Published
	vTv Therapeutics
LLC

	

AU
	

2017203835
	

5/15/2013
	

2017203835
	

3/7/2019
	GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Granted
	vTv Therapeutics
LLC

	

KR
	

10-2021-7006420
	

5/15/2013
			GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE
TREATMENT OF DIABETES
	

Pending
	vTv Therapeutics
LLC

	

US
	

17/480,856
	

9/21/2021
			SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Pending
	vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

EP
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

DE
	

14710738.7
	

2/28/2014
	

602014062792.7
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

FR
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

GB
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

CH
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE
ACTIVATOR AND METHODS OF MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

ES
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

IE
	

14710738.7
	

2/28/2014
	

2964197
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

IT
	

14710738.7
	

2/28/2014
	

502020000058210
	

3/25/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

AU
	

2014226292
	

2/28/2014
	

2014226292
	

1/17/2019
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

CA
	

2,903,440
	

2/28/2014
	

2,903,440
	

4/13/2021
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

JP
	

2015-561469
	

2/28/2014
	

6441829
	

11/30/2018
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

MX
	

MX/a/2015/011110
	

2/28/2014
	

372548
	

3/23/2020
	SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Granted
	vTv Therapeutics LLC

	

HK
	

42021034616.9
	

2/28/2014
			SOLID COMPOSITIONS COMPRISING A GLUCOKINASE
ACTIVATOR AND METHODS OF MAKING AND USING THE SAME
	

Published
	vTv Therapeutics LLC

	

CN
	

202011088593.3
	

2/28/2014
			SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF
MAKING AND USING THE SAME
	

Published
	vTv Therapeutics LLC

	

US
	

16/741,224
	

1/13/2020
	

10,952,993
	

3/23/2021
	THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Issued
	vTv Therapeutics LLC

	

US
	

17/178,402
	

2/18/2021
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS
	OWNER
	

US
	

17/178,404
	

2/18/2021
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

EP
	

19740096.3
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

AU
	

2019287437
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

CA
	

3,093,025
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

CN
	

201980028636.8
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN
COMBINATION WITH INSULIN OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

JP
	

2020-563743
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

KR
	

10-2020-7029851
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

MX
	

MX/a/2020/008905
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS
	OWNER
	

HK
	

62021031811.4
	

6/10/2019
			THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN
OR INSULIN ANALOGS
	

Published
	vTv Therapeutics LLC

	

WO
	

PCT/US2021/017743
	

2/12/2021
			SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE
THEREOF
	

Published
	vTv Therapeutics LLC

	

WO
	

PCT/US2021/036082
	

6/7/2021
			CRYSTALLINE FORMS OF {2-[3- CYCLOHEXYL-3-(TRANS-4- PROPOXY-CYCLOHEXYL)- UREIDO]-THIAZOL-5- YLSULFANYL}-ACETIC ACID AND
AND USES THEREOF
	

Published
	

vTv Therapeutics LLC

	

WO
	

PCT/US2021/036084
	

6/7/2021
			SALTS OR CO-CRYSTALS OF {2- [3-CYCLOHEXYL-3-(TRANS-4- PROPOXY-CYCLOHEXYL)- UREIDO]-THIAZOL-5- YLSULFANYL}-ACETIC ACID AND
USES THEREOF
	

Published
	

vTv Therapeutics LLC

	

US
	

13/114,964
	

5/24/2011
	

9,359,313
	

6/7/2016
	Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase
Activator
	

Issued
	

vTv Therapeutics LLC

	

US
	

14/988,143
	

2/11/2016
	

9,855,251
	

1/2/2018
	Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase
Activator
	

Issued
	

vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS
	OWNER
	

US
	

15/687,824
	

8/28/2017
	

10,064,846
	

9/4/2018
	Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase
Activator
	

Issued
	

vTv Therapeutics LLC

	

US
	

16/058,512
	

8/8/2018
	

10,363,244
	

7/30/2019
	Compositions Comprising Metformin and A Glucokinase
Activator
	

Issued
	vTv Therapeutics
LLC

	

DE
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising
Metformin and a Glucokinase Activator
	

Granted
	

vTv Therapeutics LLC

	

FR
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

GB
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

ES
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a
Glucokinase Activator and Compositions Comprising
	

Granted
	vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
						Metformin and a Glucokinase
Activator
		
	

IE
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

IT
	

11787250.7
	

5/24/2011
	

2576524
	

10/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

AU
	

2011258460
	

5/24/2011
	

2011258460
	

6/4/2015
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

CA
	

2,799,591
	

5/24/2011
	

2,799,591
	

6/11/2019
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

CN
	

201180025744.3
	

5/24/2011
	

ZL201180025744.3
	

3/4/2015
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

JP
	

2013-512164
	

5/24/2011
	

5902676
	

3/18/2016
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

KR
	

10-2012-7033687
	

5/24/2011
	

10-1860120
	

5/15/2018
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

MX
	

MX/a/2012/013617
	

5/24/2011
	

347372
	

4/25/2017
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

TW
	

100118368
	

5/25/2011
	

I508723
	

11/21/2015
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

	

HK
	

13108290.5
	

5/24/2011
	

1181044
	

3/4/2015
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

			
	[Schedule 1]

																								
	CNTRY
	APPLICATION NO.
	DATE
FILED
	PATENT NO.
	GRANT
DATE
	TITLE
	STATUS	OWNER
	

KR
	

10-2018-7006115
	

5/24/2011
	

10-1878252
	

7/9/2018
	Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase
Activator
	

Granted
	

vTv Therapeutics LLC

			
	[Schedule 1]

Schedule 2

Knowledge Individuals

For Company: 
Richard Nelson 
Carmen Valcarce 
Jennifer Freeman

For Partner:
Dr. Fahed Al Marzooqi 
Divyesh Mahajan 
Joanne Norman

			
	[Schedule 2]

Schedule 3

Partner Territory

Cyprus, Lebanon, Syria, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Iran, Iraq, Oman, Yemen, Nigeria, Ethiopia, Egypt, Democratic Republic of the Congo, Tanzania, South Africa, Kenya, Uganda, Algeria, Sudan, Morocco, Angola, Mozambique, Ghana, Madagascar, Cameroon, Cote d’Ivoire, Niger, Burkina Faso, Mali, Malawi, Zambia, Senegal, Chad, Somalia, Zimbabwe, Guinea, Rwanda, Benin, Burundi, Tunisia, South Sudan, Togo, Sierra Leone, Libya, Congo, Liberia, Central African Republic, Mauritania, Eritrea, Namibia, Gambia, Botswana, Gabon, Lesotho, Guinea-Bissau, Equatorial Guinea, Mauritius, Eswatini, Djibouti, Comoros, Cabo Verde, Sao Tome & Principe, Seychelles, Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Afghanistan, Ukraine, Uzbekistan, India, Pakistan, Turkey, Malaysia and Indonesia
			
	[Schedule 3]

Schedule 4

Transfer of Responsibilities

Responsibilities for Partner-Conducted Clinical Trial

												
	

I.
	TASK
	

Company
	

Partner

	PROTOCOL
	1.	Preparing drafts and final versions of the Collaboration Protocol (subject to JDC approval)
	

X
	
	2	Distributing copies of the Collaboration Protocol to the Partner Sites
		

X

	3.	Preparing drafts and final versions of country-specific appendices (subject to JDC approval)
		

X

	4.	Preparing translations of the Collaboration Protocol and distributing copies of such translations to the Partner Sites
		

X

	5.	Preparing drafts and final versions of amendments to the Collaboration Protocols (subject to JDC approval)
	

X
	
	6.	Distributing copies of the amendments/country-specific appendices of the Collaboration Protocol
		

X

	7.	Tracking Partner Site acceptance and approval of the Collaboration Protocol, any amendments thereto and country-specific appendices thereof
		

X

	8.	Obtaining ethics committees’, including IRBs, approval of Collaboration Protocol / amendments
		

X

	II.	DATA CAPTURES
		
	1.	Initial CRF Draft Preparation
		X
	2.	Provisions of the CRF to the Partner Sites
		X
	3.	Technical support for eCRFs
		X
	4.	Clinical Trial Master File creation and maintenance
		X
	5.	Clinical Trial Database creation and maintenance, including obtaining and inputting data from Clinical Investigators
		

X

	6.	Provide SAS datasets to Company to the defined specifications (1) when fifty percent (50%) of subjects have been dosed for six (6) months (where the Collaboration Protocol provides for interim analysis); (2) when the data in the Clinical Trials Database is equivalent to one hundred percent (100%) of total data expected to
be recorded in the Clinical Trials Database; (3) if a safety signal is
		

X

			
	[Schedule 4]

												
		TASK
	

Company
	

Partner

		identified; or (4) if a request is received from any applicable Regulatory Authorities
		
	III.	SUBJECTS		
	1.	Preparing (subject to JDC approval), implementing and complying with the Subject Recruitment Plan
		

X

	2.	Preparing the form of Informed Consent documents (and any amendments thereto) for use in the Collaboration Clinical Trial
	

X
	
	3.	Preparing translation of the form of Informed Consent, including authorization to share private information with Company consistent with all Applicable Laws
		

X

	4.	Ensuring that subjects are given proper informed consent and make informed and knowing signatures
		

X

	5.	Distribution of the Informed Consent to the Partner Sites/approved CROs
		

X

	6.	Obtaining ethics committees’, including IRBs, approval of the Informed Consent and authorization
		

X

	IV.	CLINICAL SUPPLY

	1.	Supply and labelling of Finished Product for the Partner Sites
	X
	
	2.	Providing relevant instructions to Company with respect to labelling of Finished Product, in accordance with Applicable Laws
		

X

	3.	Maintain records that document shipment, receipt, disposition, return and destruction of the Finished Product supplied for the Clinical Trial
		

X

	4.	Assure the return/destruction of all unused Finished Product from Partner Sites and maintain records of such returns/destruction
		

X

	V.	PHARMACOVIGILANCE		
	1.	Compliance with the Pharmacovigilance Agreement
	X
	X

	VI.	ETHICS ACTIVITIES
		
	1.	Ensure that a copy of, and updates to, the Investigator’s Brochure are promptly provided to the Partner Sites
		

X

	2.	Tracking proof of submission of safety reports to the Regulatory Authorities, ethics committees, including IRBs, and Clinical Investigators, in accordance with Applicable Laws
		

X

	3.	Ensuring that ethics committees, including IRBs, have all necessary qualifications and remain in good standing throughout the Clinical Trial
		

X

	4.	Responding to queries from ethics committees, including IRBs,
		X

			
	[Schedule 4]

												
		TASK
	

Company
	

Partner

	5.	Complying with Applicable Laws relating to disclosure and approval from ethics committees, including IRBs
		

X

	6.	Paying any fees associated with ethics committees, including IRBs,
		X

	7.	Establishing and maintaining material and specimen handling guidelines
		

X

	VII.	SELECTION OF INVESTIGATORS
		
	1.	Selection of Clinical Investigators/Partner Sites (subject to JDC approval) and ensuring that such Clinical Investigators and/or Partner Sites are appropriately qualified and eligible to conduct the Clinical Trial under the Collaboration Protocol
		

X

	2.	Communication of termination to the Partner Sites
		X

	3.	Ensuring that the Partner Sites comply with all Applicable Laws (including GCP)
		

X

	4.	Entering into the Clinical Study Agreement with the Partner Sites
		X

	5.	Paying all expenses associated with the Partner-Conducted Clinical Trial and ensuring that such payments are in compliance with Applicable Laws, and Regulatory Authority and ethics committee, including IRBs, requirements
		

X

	6.	Obtaining executed Financial Disclosure Forms from the relevant Persons
		

X

	7.	Conduct of initiation/opening visit for the Clinical Trial at each Partner Site
		

X

	8.	Confirming all documentation and approvals are in place for activation of the Partner Sites
		

X

	9.	Formally activating a Partner Site
		X

	VIII.	AUDITING AND MONITORING
		
	1.	Complying with the Monitoring Plan with respect to the Clinical Trial
		

X

	2.	Complying with the audit requirement
		X

	IX.	INVESTIGATOR MEETINGS
		
	1.	Planning and conducting the Investigator Meetings
		X

	2.	Cost of Investigator Meetings
		X

	X.	DATA MANAGEMENT
		
	1.	Preparing (subject to JDC approval) and complying with the Data Management Plan
		

X

			
	[Schedule 4]

												
		TASK
	

Company
	

Partner

	2.	Source verification of data records, as set forth in the Monitoring Plan
		

X

	3.	Subject randomization, per the Collaboration Protocol
		X

	4.	Ensuring timely data completion and review
		X

	5.	Updating Clinical Trials Database
		X

	XI.	TRIAL CLOSEOUT
		
	1.	Decision on appropriate time for closure of each Site subject to and in accordance with the Collaboration Protocol
		

X

	2.	Partner Site closure on a timely basis as data is completed and subjects off study
		

X

	XII.	SAFETY MONITORING
		
	1.	Conducting safety monitoring and ensuring all appropriate informed consent documents (and any required updates) are obtained
		

X

	XIII.	COMMUNICATION		
	1.	Obtaining and managing copies of all correspondence with the Partner Sites and providing such to JDC at the JDC’s request
		

X

	2.	Providing the JDC with pertinent information regarding the Partner- Conducted Clinical Trial as agreed upon by the JDC, including all correspondence with Regulatory Authorities and ethics committees, including IRBs
		

X

	XIV.	STATISTICAL ANALYSIS AND TRIAL REPORT
		
	1.	Statistical analysis of any data pursuant to the Statistical Analysis Plan and providing such analysis to Company
	

X
	
	2.	Preparation of final report and providing such report to Company
		X

	XV.	CROs		
	1.	Selection of CRO (subject to Company’s approval).
		X

	2.	Enter into the written CRO agreement with the approved CRO
		X

	XVI.	REGULATORY AFFAIRS
		
	1.	Initial development of Investigator’s Brochure
	X
	
	2.	Updates to Investigator’s Brochure
	X
	
	3.	Compilation of IND and any amendments
		X

	4.	Submission of IND to applicable Regulatory Authorities (to the extent permitted by Applicable Laws) and any amendments
		

X

			
	[Schedule 4]

												
		TASK
	

Company
	

Partner

	5.	Submission of Partner Site Information to the Regulatory Authorities
		

X

	6.	End of Clinical Trial notice.
		X

	7.	CofA, CofC, TSE/BSE Certification, GMP Compliance Statement
	X
	
	8.	Translations of any documents for submission to the Regulatory Authorities
		

X

	9.	Authorization of first CTS shipment to Partner Sites
	X
	
	10.	Collection of Regulatory Documents from Partner Sites
		X

	11.	End of Study Declaration to ethics committees, including IRBs
		X

			
	[Schedule 4]

Exhibit A

Anti-Corruption Compliance Certification

Pursuant to Section 11.1(m) of the Collaboration and License Agreement between vTv Therapeutics LLC (“Company”) and Cogna Technology Solutions LLC (“Partner”) dated May
    , 2022 (the “Agreement”), I, [Name], on behalf of [Party], hereby certify that to my knowledge:

1.[Party] has provided a copy of the Compliance Policies and communicated regarding such documents to all persons acting on its behalf in connection with work und this Agreement, including any employees, agents, contractors or subcontractors.

2.With respect to any products, payments or services provided under this Agreement, [Party] has not taken any action directly or indirectly to knowingly (i) offer, promise, provide, or authorize the offer or provision of money or anything of value, in order to improperly or corruptly seek to influence any Government Official or any other Person in order to obtain or retain business or any other improper business advantage; (ii) request or accept any such improper payment; or (iii) cause a violation of any Anti-Corruption Law. For example, this includes knowingly providing any inducement for such Government Official or person to approve, reimburse, prescribe, or purchase a product, to influence the outcome of a clinical trial, or otherwise to benefit Company’s business activities improperly;

3.[Party] has ensured that it and every agent, contractor, or subcontractor performing services in connection with the Agreement has agreed to comply with and be bound by the provisions of the Agreement that address compliance with Anti-Corruption Laws;

4.[Party] has met all relevant disclosure obligations required under the Agreement;

5.[Party] has informed [Other Party] in good faith of any significant changes in information provided during pre-contractual due diligence; and

6.To the extent required by the Agreement, [Party] has provided training on its policies and Anti-Corruption Laws to its officers, directors, employees, and appropriate third parties.

7.Capitalized terms used but not defined herein shall have the meaning assigned to such term in the Agreement.

COMPANY NAME:          NAME:     
TITLE:       DATE:     

[Exhibit A]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]